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Muscle specific RING-Finger ubiquitin E3 ligases MuRF1, MuRF2 and MuRF3 have been 
implicated in several cellular functions. MuRF1 and MuRF3 have been shown to bind and 
degrade muscle contractile and structural proteins via the ubiquitin proteasome system (UPS), 
thus playing an important role in the maintenance of skeletal and cardiac muscle structure and 
function. MuRF1 is considered an atrophy marker since its expression increases during 
muscle atrophy. MuRF2 and MuRF3 are involved in myocyte differentiation. In addition, 
both proteins bind to and stabilize microtubules. Nevertheless, many aspects of the functions 
of the MuRF-family are unknown. The domain structure of the MuRF family implicates 
several highly conserved domains involved in protein-protein interaction. Accordingly, one 
way to better understand the role of MuRF proteins in myocyte function and protein 
homeostasis is to identify and characterize their interactome. Therefore, quantitative mass 
spectrometric analysis was used to identify novel interaction partners and target proteins of 
MuRF1, MuRF2 and MuRF3. 
In this study, the mammalian retromer subunit sorting nexin 5 (SNX5), which plays an 
important role in subcellular trafficking pathways, was identified as a novel interaction 
partner of MuRF3. SNX5 interacted via its Bin/Amphiphysin/Rvs (BAR)-domain with 
MuRF3. SNX5 and MuRF3 co-localized and associated with early endosomes, connecting the 
microtubule-binding MuRF3 to structures of subcellular trafficking pathway. SNX5 was also 
identified as a substrate of MuRF2, which interacted with and ubiquitinated SNX5 in vivo, 
mediating its degradation in a UPS-dependent manner. Interestingly, this MuRF2-mediated 
degradation was inhibited by MuRF3, which stabilized SNX5.  
The role of MuRF2 and MuRF3 in stabilizing microtubules has been reported only in relation 
to muscle differentiation and contraction. In this study, MuRF2 and MuRF3 were linked for 
the first time with a subcellular trafficking protein, SNX5, which is directly associated with 
microtubules and functionally dependent on a stable microtubule network. Therefore, results 
may suggest a possible regulatory role of MuRF2 and MuRF3 in microtubule-dependent 
subcellular trafficking pathways.  
 
Keywords: MuRF, UPS, SNX5, microtubules





Die muskelspezifischen RING-Finger Ubiquitin E3 Ligasen MuRF1, MuRF2 und MuRF3 
wurden mit verschiedenen zellulären Prozessen in Verbindung gebracht. MuRF1 und MuRF3 
beteiligen sich zum Beispiel am Abbau mehrerer Muskelstrukturproteine über das Ubiquitin 
Proteasom System (UPS) und spielen somit eine wichtige Rolle bei der Aufrechterhaltung der 
Skelett- und Herzmuskelstruktur und -funktion. MuRF1 wurde als Atrophie-Marker 
identifiziert, da seine Expression während der Muskelatrophie ansteigt. Darüber hinaus 
wirken MuRF2 und MuRF3 bei der Stabilisierung von Mikrotubuli und Differenzierung von 
Myozyten mit. Dennoch sind bisher viele Aspekte der Funktion von MuRF-Proteinen 
ungeklärt. Die Domänenstruktur der MuRF-Proteinfamilie zeigt mehrere hochkonservierte 
Domänen, die sich an Protein-Protein Interaktionen beteiligen. Die Identifizierung und 
Charakterisierung ihres Interaktoms ermöglicht ein besseres Verständnis ihrer Funktionen. 
Aus diesem Grund wurden quantitative massenspektrometrische Analysen durchgeführt, um 
neue Interaktionspartner und Substrate für MuRF1, MuRF2 und MuRF3 zu identifizieren. 
In der vorliegenden Arbeit wurde sorting nexin 5 (SNX5), eine Untereinheit des Retromer-
Komplexes in Säugetieren, als Interaktionspartner von MuRF3 identifiziert. SNX5, das eine 
wichtige Rolle in subzellulären Transport-Signalwegen spielt, interagiert über seine BAR-
Domäne mit MuRF3. Außerdem wurde gezeigt, dass SNX5 und MuRF3 co-lokalisieren und 
mit vesikulären Strukturen des subzellulären Transport-Signalweges assoziieren. Des 
Weiteren wurde SNX5 als Substrat von MuRF2 identifiziert. MuRF2 bindet und ubiquitiniert 
SNX5 in vivo und vermittelt damit dessen Abbau über das UPS. Interessanterweise 
stabilisierte MuRF3 SNX5 und inhibierte dessen MuRF2-vermittelten Abbau. 
Die Rolle von MuRF2 und MuRF3 bei der Stabilisierung von Mikrotubuli wurde bisher nur in 
Bezug auf Muskeldifferenzierung und Kontraktion beschrieben. In dieser Studie konnten sie 
zum ersten Mal mit einem in subzellulärem Transport aktiven Protein in Verbindung gebracht 
werden, das direkt mit Mikrotubuli assoziiert und funktionell von einem stabilen Mikrotubuli-
Netzwerk abhängig ist. Dies legt eine mögliche regulatorische Rolle von MuRF2 und MuRF3 
in Mikrotubuli-abhängigen subzellulären Transportwegen nahe. 
 
Schlagwörter: MuRF, UPS, SNX5, Mikrotubuli 





1.1. The skeletal muscle 
The skeletal muscle is the largest body compartment and the most abundant tissue in adult 
vertebrates, comprising 40-50% of total body mass. Its main function is maintaining the 
integrity of the skeleton and generating force for motion. In addition, skeletal muscle is the 
primary target of glucose uptake and by undergoing size - remodeling, it represents the 
determining factor of endurance, physical strength and performance (Fanzani A. et al., 2012). 
Furthermore, skeletal muscle is the largest protein reservoir of the body. Through protein 
degradation, skeletal muscle serves as a source of amino acids which can be used for energy 
production by various organs including the heart, liver and brain. This is essential not only in 
extreme situations like stress, inflammation and fasting, but also during longer catabolic 
periods, such as in cancer, sepsis, burn injury, heart failure and AIDS (Karagounis L.G. and 
Hawley J.A., 2010, Bonaldo P. and Sandri M., 2013).  
1.1.1. Structure and composition 
Muscle cells, or myocytes, are formed through the fusion of developmental myoblasts 
(embryonic progenitor cells) in a process known as myogenesis. These long cylindrical cells, 
also called myofibers, contain multiple nuclei, mitochondria and sarcomeres, and are the 
contractile units of the skeletal muscle (Fig. 1).  Muscle fibers are each surrounded by a thin 
layer of connective tissue called the endomysium, and 20-80 of them are bundled together in a 
parallel arrangement to form the muscle fascicle. Muscle fascicles are each encapsulated by 
the perimysium, and a large number of them are enveloped by a thick collagenous external 
layer extending from the tendons, called the epimysium, to form a single skeletal muscle (Fig. 
1; Boron W.F. and Boulpaep E.L., 2009, Korthuis R.J., 2011).  

















Figure 1: The anatomy and composition of the striated skeletal muscle. Muscle cells or fibers are enveloped 
by a thin collagenous layer, the endomysium. A bundle of parallelly arranged myofibers form the muscle 
fascicle, which is surrounded by the perimysium. A large number of muscle fascicles, encapsulated by a thick 
collagenous layer extending from the tendon called epimysium, form the skeletal muscle. Skeletal muscles are 
supplied by a large number of blood vessels and nerves. By courtesy of Encyclopaedia Britannica, Inc., 
copyright 2015; used with permission.  
 
Different muscle fibers are classified not only by their histology, but also by the rapidity of 
their contraction, the ability to resist fatigue and the expression of specific myosin heavy 
chain (MHC) isoforms. The rate of contraction in the different muscle fiber types is related to 
the ATPase activity of the specific MHC isoform expressed in this particular muscle fiber 
type (Korthuis R.J., 2011). Type I fibers are slow-twitch red myofibers, which are thinner and 
contain a dense capillary network and a large amount of the oxygen-binding protein 
myoglobin. They are resistant to fatigue, contain high amounts of mitochondria and oxidative 
enzymes and low glycogen levels and glycolytic enzyme activity, thus relying on oxidative 
metabolism for energy production. Type II fibers are fast-twitch myofibers, which are sub-
classified into red type IIa and white type IIb fibers. Type IIa myofibers are fatigue-resistant, 
contain myoglobin, high amounts of mitochondria and rely on oxidative metabolism. Type IIa 
muscle fibers are also glycogen-abundant. Type IIb myofibers contain less mitochondria, 
oxidative enzymes and myoglobin and therefore rely on the energy stored in glycogen and 
phosphocreatine. They are less resistant to fatigue (Armstrong R.B., 1996; Boron W.F. and 




Boulpaep E.L., 2009). In humans three muscle fiber types were classified as I, IIa and IIx 
(Gundersen K., 2010; Schiaffino S. and Reggiani C., 2011). Fiber type IIx was previously 
known as IIb, and was shown to express a MHC gene homologous to the IIx gene of a fourth 
isoform discovered in rodents (Schiaffino S. and Reggiani C., 1996; Ennion S. et al., 1995; 
Smerdu V. et al., 1994). Fascicles are composed of two or more fiber types, but usually one of 
these fiber types predominates in the different muscle types (Korthuis R.J., 2011). 
The plasma membrane of the muscle cell is known as sarcolemma. It surrounds the myofibrils 
and generates specialized invaginations, called T-tubules, which penetrate into the muscle 
interior. T-tubules communicate with the calcium reservoir, stored in the sarcoplasmic 
reticulum. Calcium is released from the sarcoplasmic reticulum upon nerve stimulation to 
initiate muscle contraction. In addition to the T-tubules, there are further specialized regions 
of the sarcolemma, such as the neuromuscular junctions (NMJs), where motor neurons 
contact the muscle, the digit-like projections that form myotendinous junctions (MTJs), which 
are major force transmission sites, and sites of myoblast fusion during myogenesis and muscle 
repair (Clark K.A. et al., 2002; Sanes J.R. et al., 1999; Burden S.J. et al., 2002). An intact 
membrane trafficking system to and from these unique membrane regions of the muscle cell 
is essential for maintaining muscle structure and function, as well as muscle myogenesis and 
regeneration (Towler M.C. et al., 2004 a). 
1.1.2. Skeletal muscle physiology - the sarcomere 
The sarcomere is the smallest functional contractile unit of the muscle fiber (McComas A.J. et 
al., 1996). It comprises of the myofibrillar proteins myosin (the thick filament), actin and its 
associated proteins (the thin filament). The interaction between myosin and actin allows the 
muscle to contract (Plowman S.A. et al., 1997). Myosin is a very large protein which is 
composed of six polypeptides: two heavy chains and four light chains, of which two are 
regulatory and two are alkali. One regulatory and one alkali light chain are associated with 
one of the heavy chains. The head region of the MHC is not only the domain which interacts 
with actin allowing the muscle to contract, but it also contains an adenosine triphosphate 
(ATP) binding site and functions as an ATPase for hydrolyzing ATP into adenosine 
diphosphate (ADP) and inorganic phosphate (PI), providing the necessary energy for muscle 
contraction (Plowman S.A. et al., 1997). The thin filament consists of actin and two 
regulatory proteins, troponin and tropomyosin (McComas A.J. et al., 1996).  
 




Muscle contraction occurs when the muscle fiber receives a stimulus in the form of an action 
potential, which leads to the release of calcium from the sarcoplasmic reticulum. Calcium 
then binds to troponin, a small globular protein with three subunits (TnT, TnI, TnC), which as 
a result undergoes a conformational change and pulls tropomyosin from its blocking position 
on the actin filament, exposing the myosin binding sites and allowing myosin heads to interact 
with actin. Myosin pulls the thin filament along the thick filament, which leads to the 
shortening of the sarcomere and contraction of the muscle. In the presence of Ca2+ and ATP, 
the myosin heads will attach to the actin molecules, pull the actin, release, and reattach. This 
process is known as cross-bridge cycling (Plowman S.A. et al., 1997; Scott W. et al., 2001).  
A third filament system in the sarcomere is composed of one single molecule, titin, the largest 
vertebrate protein identified to date (Maruyama K. et al., 1977; Wang K. et al., 1979). While 
actin-containing thin filaments are anchored in the so-called Z-lines and extend toward the 
middle of the sarcomere where they interact with myosin to drive contraction, the large titin 
filaments span half sarcomeres, with their N-termini overlapping the Z-lines and C-termini 
overlapping the M-lines, thus forming a continuous filament system between adjacent 
myofibrils. Based on its assembly and structure, titin is proposed to function as a template for 
myofibrillogenesis (Obermann W.M. et al., 1997; Gregorio C. et al., 1998, 2005; Mues A. et 
al., 1998).           
1.2. Skeletal muscle atrophy  
The skeletal muscle makes up a very large proportion of the total body mass, and in particular 
total body protein. Under normal physiological conditions, the protein homeostasis of the 
muscle fiber is guaranteed by a well coordinated balance between protein degradation and 
protein synthesis, which in turn has a significant effect on the general protein homeostasis of 
the body (Schiaffino S. et al., 2013). Skeletal muscle atrophy takes place when this 
homeostasis is disrupted and protein degradation exceeds protein synthesis, leading to a 
decrease in muscle mass. Muscle atrophy can be physiological (i.e. as a consequence of 
aging) or pathological. Age-related muscle atrophy, or sarcopenia, is defined as the presence 
of both low muscle mass and low muscle function (Cruz-Jentoft A.J. et al., 2010), which 
leads to decrease in the individual’s mobility and life quality. Other triggers of muscle atrophy 
are malnutrition, severe burns, as well as muscle disuse (i.e. long periods of immobilization or 
bed rest, denervation, or spaceflight; Thomas, D. R., 2007).  




Moreover, muscle atrophy represents the severe clinical syndrome known as cachexia, which 
accompanies many chronic illnesses such as chronic heart failure (CHF), chronic obstructive 
pulmonary disease (COPD), chronic kidney disease (CKD), cancer, AIDS, sepsis, immune 
disorders, myopathies and dystrophies (Thomas, D. R., 2007). Cachexia is defined as weight 
loss greater than 5% or weight loss greater than 2% and a body mass index (BMI) lower than 
20 (Fearon K. et al., 2011). This complex metabolic syndrome is characterized by excessive 
loss of muscle mass and body fat, weakness and increase in morbidity and mortality (Bonaldo 
P. and Sandri M., 2013). 
Regardless of the triggering factor, the main characteristics of muscle atrophy are a decrease 
in protein content, a reduction of the cross-sectional area of myofibers, decreased muscle 
strength and fatigue resistance (Vandervoort A.A., 2002). The clinical consequence of muscle 
atrophy, whether caused by physiological or pathological conditions, is similar, namely a 
severe deterioration of life-quality and the inability to manage daily activities (Fanzani A. et 
al., 2012). 
The different types of conditions inducing muscle atrophy are an indication for different types 
of molecular triggers and signaling pathways for muscle atrophy. Indeed, many different 
catabolic factors, such as cytokines (e.g. tumor necrosis factor (TNF)-α, interleukin-1, 
interleukin-6), the transforming growth factor (TGF)-family (e.g. TGF-β, myostatin, activin), 
glucocorticoids, angiotensin II, low insulin-like growth factor (IGF)-1, but also stress stimuli 
and DNA damage, activate different signaling pathways, which in turn activate proteolytic 
pathways leading to muscle atrophy. The two major protein degradation pathways in 
eukaryotic cells are the ubiquitin-proteasome system (UPS) and the autophagy lysosome 
pathway. Under physiological conditions the UPS is responsible for the degradation of short-
lived proteins, and the autophagy lysosome pathway regulates the levels of long-lived proteins 
and cell-organelles. Both pathways have been shown to crosstalk and play important roles in 
muscle atrophy (Jagoe R.T. et al., 2002; Glass D.J. et al., 2005; Jackman R.W. and Kandarian 
S.C., 2004; Fanzani A. et al., 2012).   
1.3. Ubiquitin proteasome system   
The UPS is responsible for the highly specific recognition and degradation of a large number 
of target proteins, which in turn control and regulate numerous cellular processes such as cell 
cycle, transcription and protein quality control (i.e. the degradation of misfolded or damaged 
proteins). The UPS comprises about 1000 components and is subjected to stringent regulation 




at different steps of the cascade. Aberrations in its function can lead to different diseases such 
as myopathies (i.e. limb girdl muscular dystrophy, protein aggregate myopathy, hypertrophic 
cardiomyopathy; Mathews K.D. and Moore S.A., 2003; Predmore J.M., 2010), cancer, 
inflammatory and neurodegenerative disorders (Hershko A. and Ciechanover A, 1998; 
Weissman A.M., 2011). 
Ubiquitin is a heat-stable, abundant and highly conserved 8-kDa polypeptide, which is 
ubiquitously expressed in eukaryotic cells. It is effective only by covalent attachment to other 
proteins in the ATP-dependent process of ubiquitination, which results in mono- or 
polyubiquitinated proteins (Ciechanover A. et al., 1980 a; Ciechanover A. et al., 1980 b). 
Within the polyubiquitin chain, the single molecules are connected through isopeptide bonds, 
formed between the C-terminal glycine 76 of one molecule and a lysine residue of the other 
ubiquitin molecule. Ubiquitin exhibits seven lysine residues (Lys 6, 11, 27, 29, 33, 48 and 
63), but Gly76-Lys48 linked ubiquitin chains are the predominant recognition signal for 
subsequent proteasomal degradation (Glickman M. H. and Ciechanover A., 2002; Wilkinson 
K. D., 2000). 
The addition of polyubiquitin (at least four molecules) to a substrate protein as a recognition 
signal for subsequent degradation at the proteasome is a reversible and regulated multistep 
reaction, which requires three distinct enzymatic components; an E1 ubiquitin-activating 
enzyme, an E2 ubiquitin-conjugating enzyme and an E3 ubiquitin-ligating enzyme (Hershko 
A. et al., 1983; Hershko A. and Ciechanover A., 1998; Weissman A.M., 2001). In mammals, 
two E1-, approximately 40 E2- and several hundred E3-enzymes are known (Pickart C.M., 
2001; Weissman A.M., 2011). Substrate specificity of the UPS is mediated by the E3 
ubiquitin ligase. There are two major groups of E3 ubiquitin ligases which differ in their 
mechanism of action; the homologous to E6 associated protein C- terminus (HECT) domain 
E3 ligases, and the RING (Really Interesting New Gene) finger domain E3 ligases. The latter 
can function as a single enzyme or a multi-subunit protein complex. Single-subunit E3 
enzymes mediate ubiquitination using the RING domain for E2 enzyme binding and a 
different domain to bind the substrate. Multi-subunit RING E3 ligases, such as the SCF (Skp-
Cullin-F-box) complex, contain a cullin protein family member as scaffold, RING finger 
protein as E3 ligase and additional proteins as adaptors for substrate recognition and E2-
enzyme binding (Kandarian S.C. and Stevenson E.J., 2002; Pickart C.M., 2004; Ciechanover 
A. and Iwai K., 2004; Deshaies R.J. and Joazeiro C.A., 2009). 




The ubiquitin-proteasome cascade starts with the ATP-dependent activation of ubiquitin by 
the E1-enzyme, which uses ATP to form a high energy labile E1-thiol ester intermediate. The 
activated ubiquitin is then transferred to the E2-enzyme to generate a similar thiol ester 
intermediate. The activated ubiquitin can then either be transferred directly from E2 to an 
internal lysine residue of a substrate protein, which is already bound to a RING finger domain 
containing - E3- ligase, or it can be transferred from the E2 to a HECT domain - containing 
E3 ligase to form a third labile thiol ester intermediate. It is then transferred to the substrate 
protein, where a stable isopeptide bond between the activated ubiquitin and an internal lysine 
residue in the substrate is formed. Ubiquitin-conjugated substrates bind to the proteasome 
either directly or through shuttling proteins, where they are degraded to short peptides by the 
26S proteasome. The ubiquitin chain is then disassembled by deubiquitinating enzymes 
(DUBs), which can also function as antagonists for E3s (Fig. 2; Hershko A. et al., 1983; 
Glickman M.H. and Ciechanover A., 2002; Pickart C.M., 2000; Weissman A.M. et al., 2011). 
            
Figure 2: Schematic illustration of the ubiquitin-proteasome system. (a) Ubiquitin-activating enzyme (E1) 
activates ubiquitin (Ub) in an ATP-dependent step, forming a high-energy, labile E1-thiol ester intermediate. (b) 




A similar thiol ester intermediate is formed when the activated ubiquitin is transferred to an ubiquitin-
conjugating enzyme (E2). (c) Activated ubiquitin can then be transferred to a HECT domain-containing 
ubiquitin-protein ligase (E3) to form a third labile thiol ester intermediate. Ubiquitin is then transferred to the 
substrate (S), where a stable isopeptide bond is formed. A polyubiquitin chain is generated when additional 
ubiquitin moieties are added. (d) Alternatively, activated ubiquitin can be transferred directly from E2 to the Lys 
residue of a substrate that is already bound to a RING finger domain-containing ubiquitin ligase. (e) Ubiquitin-
conjugated substrates bind directly or through shuttling proteins to the 26S proteasome, where they are degraded 
to short peptides. (f) Polyubiquitin chains are mostly disassembled by de-ubiquitinating enzymes (DUBs). 
Adapted by permission from Macmillan Publishers Ltd: Nature reviews molecular cell biology, Weissman A.M. 
et al., copyright 2011 http://www.nature.com/nrm/index.html  
Protein degradation in the UPS is mediated by the 26S proteasome, a large protein complex 
composed of two sub-complexes: the catalytic active 20S core particle (CP) and the 19S 
regulatory particle (RP). The CP consists of four stacked heptameric rings, outer α- and inner 
β- rings, giving it a barrel-shaped structure. Three of the β- subunits display proteolytic 
activity. The RP consists of two sub-complexes, called lid and base, with the base sub-
complex associating with the outer α- rings of the CP. The RP is the subunit responsible for 
substrate recognition, recruitment, de-ubiquitination and translocation into the CP, where it is 
subsequently degraded (Finley D., 2009; Schmidt M. and Finley D., 2013; Weissman A.M. et 
al., 2011). 
1.4. Muscle specific ubiquitin E3 ligases  
Muscle-specific RING-finger (MuRF) proteins were identified by Spencer et al. (Spencer J.A. 
et al., 2000) while searching for interaction partners of the serum response factor (SRF). 
MuRF-proteins are expressed specifically in cardiac and skeletal muscle and possess ubiquitin 
ligase activity (Spencer J.A. et al., 2000). They belong to the RING-B-box-coiled-coil 
(RBCC) subclass of RING-finger proteins, which are characterized by an NH2-terminal 
RING-finger followed by a zinc-finger domain (B-box), two leucine-rich coiled-coil domains 
and a C-terminal acidic region (Spencer J.A. et al., 2000;  Centner T. et al., 2001; Dai K.S. 
and Liew C.C., 2001). The tripartite organization of the RBCC domains is highly conserved, 
which explains the important functional role of this protein structure. The RING-finger 
domain is a zinc-binding cysteine-histidine protein motif found in numerous proteins involved 
in signal transduction, gene transcription, differentiation, morphogenesis and ubiquitination of 
target proteins as ubiquitin E3 ligases (Borden K.L., 1998; Centner T. et al., 2001).  
1.4.1. Muscle specific RING finger protein 1 (MuRF1) 
MuRF1, which is encoded by the gene Trim63 (tripartite motif containing 63), was 
characterized as a muscle specific ubiquitin E3 ligase in 2001 by Bodine et al., together with 




the muscle specific F-box protein Atrogin 1/MAFbx (muscle atrophy F-box), as both proteins 
were shown to be upregulated during skeletal muscle atrophy caused by denervation, 
hindlimb suspension and immobilization in rats (Bodine S.C. et al., 2001; Gomes M.D. et al., 
2001). Both were later shown to be also upregulated in multiple animal models of muscle 
atrophy, such as sepsis- and starvation-induced atrophy (Wray C.J. et al., 2003; Kee A.J. et 
al., 2003). Interestingly, knockout mice for either Trim63 or Fbxo32 are phenotypically 
normal. However, these mice are resistant to muscle atrophy induced by denervation (Bodine 
S.C. et al., 2001). Trim63 knockout mice are also resistant to dexamethasone-induced muscle 
atrophy (Baehr L.M. et al., 2011). Therefore, MuRF1 and MAFbx are used as early markers 
for skeletal muscle atrophy, aiding in the diagnosis of muscle disease (Bodine S.C. et al., 
2001).  
MuRF1 interacts with and controls the half-life of several important muscle structural 
proteins, including troponin I (Kedar V. et al., 2004), myosin heavy chains (Clarke B.A. et 
al., 2007; Fielitz J. et al., 2007b), actin (Polge C. et al., 2011), myosin binding protein C and 
myosin light chains (Cohen S. et al., 2009). Furthermore, MuRF1 binds to titin at the M-band 
of the sarcomere, which has been shown to maintain the stability of the sarcomeric M-line 
region (Centner T. et al., 2001; McElhinny A.S. et al., 2002; Gotthardt M. et al., 2003). 
MuRF1 has been implicated in cardiac hypertrophy (Willis M.S. et al., 2007).  
1.4.2. Muscle specific RING finger protein 2 (MuRF2) 
MuRF2 is encoded by the gene Trim55 (tripartite motif containing 55). MuRF2 is expressed 
in at least four isoforms generated by two distinct differential splicing mechanisms. Three 
splice variants share the common N-terminal RING-finger and B-box domains and end in a 
common C-terminal sequence. They encode peptides of 27, 50 and 60 kDa, and are also 
referred to as MuRF2A. The smallest MuRF2 isoform, MuRF2A p27, is cardiac specific. The 
forth isoform, MuRF2B p60, has an alternative C-terminus, which is generated by alternative 
reading frame use due to a frameshift of the last coding exon, a novelty in muscle proteins 
(Pizon V. et al., 2002; McElhinny A.S. et al., 2004). 
A recent study by Pizon et al. (Pizon V. et al., 2013) showed that the expression ratio between 
MuRF2A and MuRF2B isoforms changes during differentiation of skeletal muscle cells, and 
that this shift in isoform expression follows the sequential activation of the autophagic or the 
proteasomal degradation pathway. Furthermore, MuRF2B interacts with microtubule-
associated protein 1A/1B light chain 3A (LC3), a protein needed for autophagic vesicles 




formation (Pizon V. et al., 2013), whereas MuRF2A isoforms can form complexes with the 
autophagic proteins p62 and neighbor of BRCA1 gene 1 (NBR1) in myogenic cells. These 
two proteins act as cargo receptors for the degradation of ubiquitinated substrates by 
autophagy (Musa H. et al., 2006; Lange S. et al., 2005).  
MuRF2 expression analysis during mouse embryonic cardiac and skeletal muscle 
development shows that expression of MuRF2A p50 and p60 isoforms is developmentally 
regulated, with the expression shifting from the embryonic predominant p50 isoform to the 
p60 isoform, which dominates postnatally. Furthermore, MuRF2A expression during 
embryonic development parallels that of the autophagic proteins LC3, p62 and NBR1 (Perera 
S. et al., 2011; Perera S. et al., 2012). MuRF2B isoform was also shown to be 
developmentally controlled (Pizon V. et al., 2013). 
During atrophic stress, MuRF2 is briefly translocated to the nucleus and nuclear lamina in 
cardiomyocytes (Lange S. et al., 2005; Pizon V. et al., 2002), and in skeletal muscle in vivo 
(Lange S. et al., 2005; Ochala J. et al., 2011), suggesting a role in the transcription program 
during myocyte differentiation. 
In mature cardiac myocytes, endogenous MuRF2 associates with the M-band of the sarcomere 
(Pizon V. et al., 2002). Apart from titin and myosin, it has been shown to interact with 
nebulin, troponin I and T, myotilin and T-cap in yeast two-hybrid assays (Witt S.H. et al., 
2005). To date, very little is known about the E3 ligase function of MuRF2, and no MuRF2 
substrate proteins have been identified thus far. 
1.4.3. Muscle specific RING finger protein 3 (MuRF3)  
MuRF3 is encoded by the gene Trim54 (tripartite motif containing 54). It was the first MuRF-
protein to be identified and characterized. Two human and one mouse isoforms for MuRF3 
have been identified. It associates with and stabilizes microtubules, and is required for skeletal 
myocyte differentiation and development and formation of cellular microtubular networks 
(Spencer J.A. et al., 2000; Centner T. et al., 2001). MuRF3 is upregulated only postnatally 
(Perera S., et al., 2011). 
MuRF3, like MuRF1 and 2, localizes to the M-line and Z-disc of the sarcomere, forms 
homodimers and heterodimers with the other two MuRF-proteins (Centner T. et al., 2001; 
McElhinny A.S. et al., 2004; Gregorio C., 2005), and exhibits an E3 ligase activity (Kedar V. 
et al., 2004). It has been shown to play an important role in maintaining cardiac integrity and 




function after acute myocardial infarction, by regulating the turnover of its target proteins 
four-and-a-half LIM domain (FHL2) and γ-filamin. FHL2 and γ-filamin are sarcomere 
associated proteins, FHL2 interacts with the M-band portion of titin and γ-filamin localizes to 
the Z-discs and functions as actin-cross-linking protein. Mice lacking Trim54 showed 
diminished cardiac function and susceptibility to ventricular rupture after acute myocardial 
infarction (Fielitz J. et al., 2007 a).   
MuRF3 and MuRF1 are the two key E3 ubiquitin ligases for the UPS-dependent turnover of 
contractile sarcomeric proteins. They mediate the ubiquitination and degradation of MHCIIa 
and β/slow MHC, with UbcH5a, -b or -c functioning as E2 ubiquitin-conjugating enzymes. 
Combined deficiency in both Trim63 and Trim54 in double knockout mice results in a protein 
aggregate myopathy, characterized by subsarcolemmal MHC accumulation in skeletal and 
cardiac myocytes, accompanied by skeletal muscle myopathy, reduced maximal force 
development, hypertrophic cardiomyopathy and decreased cardiac function, indicating their 
importance in the maintenance of skeletal and cardiac muscle structure and function (Fielitz J. 
et al., 2007 b).   
1.4.4. Association of MuRF2 and MuRF3 with microtubules  
MuRF2 plays an important role in the earliest steps of heart and skeletal muscle 
differentiation. During myogenic differentiation, glutamylated microtubules are transiently 
formed, while the dynamic pool of tyrosinated tubulin is simultaneously reduced (Gundersen 
G. et al., 1989). These glutamylated microtubules seem to be involved in the active transport 
of sarcomeric proteins to the sites of myofibrillogenesis (Pizon V. et al., 2002). Through its 
transient association with stable glutamylated microtubules, MHC and titin during early 
myofibrillogenesis MuRF2 acts as an adaptor between the sarcomeric proteins and the 
microtubule network. During this complex, dynamic and extremely precise process, MuRF2 
first binds microtubules at the exclusion of tyrosinated tubulin. Through transient association 
with sarcomeric myosin and A-band titin, these MuRF2-associated microtubules are 
suggested to play a regulatory role in the subsequent incorporation of myosin into nascent 
sarcomeres and the elongation of titin when non-striated myofibrils differentiate into mature 
sarcomeres (Pizon V. et al., 2002). However, MuRF2 is excluded from the mature skeletal 
sarcomeres, which is in agreement with the very weak expression in adult cardiac and skeletal 
tissues, and its down-regulation during myocyte differentiation (Centner T. et al., 2001; Pizon 
V. et al., 2002). 




MuRF3 also associates with microtubules, thus regulating their dynamics. Like MuRF2, it 
associates with the stable glutamylated microtubules during myofibrillar assembly (Pizon V. 
et al. 2002; Spencer J.A. et al., 2000). The leucine-rich coiled coil domain of MuRF3 is 
necessary and sufficient for this interaction. However, amino acids 168-211 are required for 
optimal association, and the RING-finger domain is required for continuous binding along 
and stabilization of microtubules in vivo (Spencer J.A. et al., 2000). Therefore, MuRF3 plays 
a role in establishing and maintaining a stable microtubule array which is required for muscle 
differentiation (Gundersen G. et al., 1989; McElhinny A.S. et al., 2004).  
1.5. Membrane trafficking pathways in skeletal muscle 
Skeletal muscle cells exhibit the usual housekeeping membrane trafficking pathways for the 
sorting of newly synthesized proteins, internalizing cell surface receptors for hormones and 
nutrients and mediating membrane repair. However, due to the unique muscle-specific 
membrane structures, the special metabolic requirements, and the high demand for membrane 
repair in a tissue which is constantly under mechanical stress, these trafficking pathways are 
further specialized (Towler M.C. et al., 2004 a). One example is the muscle-specific 
regulation of glucose transporter type 4 (GLUT4) trafficking, which is critical for glucose 
metabolism in this energy-demanding tissue (Rudich A. et al., 2003). Another example is the 
identification of increasing numbers of muscle-specific isoforms of proteins (e.g. muscle-
specific clathrin heavy chain 22) known to play a role in trafficking pathways, as well as 
novel muscle-specific proteins, which seem to be involved in tissue-specific aspects of muscle 
membrane trafficking (Liu S.H. et al., 2001). Although membrane repair occurs in all 
eukaryotic cells, it appears to be more complex in muscle, where mechanical stress 
continuously challenges membrane integrity. Thus, specialized proteins such as dysferlin are 
required for maintaining mechanical integrity of the muscle. Dysferlin is associated with the 
sarcolemma and plays a role in muscle membrane traffic. Mutations in human dysferlin are 
linked to slow progressive forms of muscular dystrophy and dysferlin-null mice have a defect 
in muscle membrane repair pathways (Bansal D. et al., 2003).  
In the last two decades, great progress has been made in skeletal muscle research which 
focused mainly on structural and cytoskeletal proteins. However, it has become obvious that 
these alone cannot coordinate a functional unit, and that the orchestration of the multi-
functional events in skeletal muscle requires additional signaling and membrane trafficking 
proteins. Moreover, a large number of hereditary myopathies are caused by mutations in 
genes encoding for proteins involved in the organization of muscle membrane and the 




coordination of interactions between internal muscle structures, muscle membrane and the 
extracellular matrix (ECM; reviewed in Towler M.C. et al., 2004 a). Therefore, a better 
understanding of specialized muscle membrane trafficking pathways is important for gaining 
insights into muscle disease and processes critical for muscle development and repair. 
1.5.1. Endosomal trafficking pathway 
The endosomal network comprises a series of interconnected tubulovesicular membranous 
compartments that begins at the plasma membrane with the internalization of cargo through 
endocytosis, where it enters the early endosome (EE; Mayor S. and Pagano R.E., 2007). The 
EE is a dynamic compartment with a high homotypic fusion capacity, high contents of 
phosphatidylinositol 3-monophosphate (PtdIns(3)P), and a characteristic morphology of 
vacuolar and tubular subdomains (Cullen P.J., 2008). It displays a complex and pleiomorphic 
structure which consists of a central cisternal region (referred to as cis region which receives 
incoming vesicles from the plasma membrane and the trans-Golgi network) from which 
tubular and vesicular elements emanate (the trans region of the organelle; Fig. 3; Gruenberg J. 
and Howell K.E., 1989; Mukherjee S. and Maxfield F.R., 2000).  
 
Figure 3: The endosomal trafficking pathway. Endosomal cargo export pathways originate from multiple, 
functionally distinct gateways along the entire endosome maturation pathway. Endocytic vesicles deliver their 
contents and membranes to early endosomes (EEs) in the peripheral cytoplasm. During endosome maturation, 
endosomes move towards the perinuclear space along microtubules (MT), leading to the formation of late 




endosomes (LEs), which inherit the vacuolar domains of the EE network with endocytosed cargo combined with 
newly synthesized lysosomal hydrolases and membrane components from the secretory pathway. During 
maturation, endosomes undergo homotypic fusion, grow in size and acquire more intraluminal vesicles (ILVs), 
before they finally fuse with a lysosome, generating a transient hybrid organelle, the endolysosome, which is 
subsequently converted to the classical dense lysosome. Adapted by permission from John Wiley & Sons Inc.: 
The EMBO Journal, Huotari J. and Helenius A., copyright 2011 http://emboj.embopress.org/  
EEs represent the first and main cargo sorting station in the pathway, primarily into two 
distinct pathways, which are very well separated, both topologically and functionally: the 
endosomal-lysosomal degradative pathway, one major function of which is the down-
regulation of signaling receptors, and several distinct retrieval and recycling pathways, such 
as recycling toward the plasma membrane or retrograde transport toward the trans-Golgi 
network (TGN; Cullen P.J. and Korswagen H.C., 2013). Although the different compartments 
of these pathways can be easily identified due to their characteristic organization and 
topology, the boundaries between two distinguishable compartments in the same pathway are 
blurred at the molecular level. This is partially because key proteins which regulate membrane 
transport are often found in more than one compartment (Fig. 3; Gruenberg J., 2001). 
In higher eukaryotic cells, endocytosis of proteins and lipids is mainly mediated by clathrin-
coated vesicles. The common clathrin is a large protein which comprises three heavy and 
three light chains and polymerizes into a triskelion. Clathrin-triskelions assemble into 
polyhedral lattices to form clathrin coats (Mayor S. and Pagano R.E., 2007). After cargo is 
endocytosed into the mildly acidic lumen (pH ≈ 6.2) of EEs, its efficient sorting occurs. 
Recycling receptors are rapidly segregated away from their ligands and transported in 
recycling endosomes (REs) to the plasma membrane, whereas ligands, together with down-
regulated receptors, follow the endosomal-lysosomal degradation pathway (Gruenberg J., 
2001; Maxfield F.R. and McGraw T.E., 2004). Quantitatively, endocytosis and recycling back 
cargo to the plasma membrane represent the major membrane trafficking pathways of 
mammalian cells. Therefore, membrane lipids and proteins must be recycled in an efficient 
and accurate manner (Howes M.T. et al., 2010). REs differ from EEs in their acidification 
properties and the selective subset of proteins and lipids they contain, including the Rab 
GTPases (Scott C.C. and Gruenberg J., 2011; Hsu V.W, and Prekeris R., 2010). Small 
GTPases of the Rab family are selectively associated with each compartment, and provide the 
most important identity markers and master regulators in the cytotic pathway. While Rab5 
and its effectors determine the functions of EEs, such as membrane fusion, recycling of 
receptor molecules to the plasma membrane occurs either directly and rapidly in a Rab4-
controlled pathway, or indirectly via REs in a Rab11-dependent manner (Chavrier P. et al., 




1990; Ullrich O. et al., 1994; Galvez T. et al., 2012). Another recycling pathway is the 
retrograde transport pathway of cargo from EEs to the TGN. Retrograde sorting to the TGN is 
mediated by the retromer complex (Seaman M.N., 2012; Burd C. and Cullen P.J., 2014), 
which will be discussed later in detail.  
1.5.2. Endosome maturation 
The transport from early to late endosomes (LEs), a pathway also known as endosome 
maturation, is also accompanied by major protein and lipid remodeling and changes in the 
endosomal luminal milieu. The limiting membrane of LEs contains lysosomal membrane 
proteins such as lysosomal-associated membrane protein 1 (LAMP1) and the lumen contains 
a complement of acid hydrolases causing a decrease in luminal pH values from ≈ 6.2 in EE to 
≈ 5.5/5.0 in LEs (Scott C.C. and Gruenberg J., 2011). In addition, endosome maturation 
involves a conversion from Rab5 (in EEs) to Rab7 (in LEs), a so-called Rab switch, which 
also appears to control recruitment of the retromer to endosomal membranes (Rojas R. et al., 
2008; Seaman M.N., 2012). Rab7 and its effectors regulate the functions of LEs and 
lysosomes (Rink J. et al., 2005; Jovic M. et al., 2010). Endosome maturation begins with the 
sorting of proteins that need to be degraded, such as activated signaling receptors, into 
luminal invaginations of the EE membrane, which branch off as free cargo-containing 
intraluminal vesicles (ILVs), a step which controls signaling. These ILVs then detach from 
EEs and become free multivesicular bodies (MVBs), or endosomal carrier vesicles (ECVs). 
Once formed, MVB/ECVs rapidly acidify and mediate microtubule-dependent transport 
toward LEs, with which they eventually fuse, delivering their protein and lipid cargo. Just like 
EEs, LEs show high homotypic fusion activity, and contain multivesicular regions and highly 
dynamic tubulo-cisternal elements. They serve as a second trafficking hub and sorting station 
in the endocytic pathway. ILVs and their cargo can either be packaged into lysosomes for 
degradation, or sorted toward other destinations, e.g. they can be released extracellularly as 
exosomes upon endosome fusion with the plasma membrane (Fig. 3; Bissig C. and Gruenberg 
J., 2013; Huotari J. and Helenius A., 2011; Raposo G. and Stoorvogel W., 2013). LEs also 
function at a crossroad with the autophagy pathway, which provides an additional entry route 
into the endocytic pathway for the degradation of cytosolic components and organelles at the 
lysosome (Sandri M., 2011; Lamb C.A. et al., 2013). LEs and lysosomes undergo rapid fusion 
events of their membranes (kiss and run fusion), forming a transient hybrid organelle, the 
endolysosome, and allowing interchange of cargo and enzymes. Endolysosomes are then 




converted into the classical lysosomes (Fig. 3; Luzio J.P. et al., 2007; Huotari J. and Helenius 
A., 2011; Scott C.C. et al., 2014).  
1.5.3. Retrograde and recycling pathways and the Retromer - complex 
In the past years, a lot has been reported about the signals and mechanisms of cargo sorting 
into the endo-lysosomal degradative pathway. Nevertheless, understanding recycling 
pathways, and how cargo is retrieved from lysosomal degradation, is still limited. While the 
main cargoes of retrograde pathways are sorting receptors and molecules whose functions 
depend on continual retrieval from the endosomal system back to the biosynthetic pathway, 
plasma membrane recycling cargoes include nutrient transporters, signaling and cell adhesion 
receptors, and are therefore more diverse in structure. Retrieval of cargoes is mediated by the 
assembly of coat complexes, which recognize specific cargoes, drive membrane remodeling 
and elicit scission to form cargo-enriched carriers which bud from the endosomes into the 
cytoplasm (Bonifacino J.S. and Rojas R., 2006; Johannes L. and Popoff V., 2008; Grant B.D. 
and Donaldson J.G., 2009; Maxfield F.R. and McGraw T.E., 2004). In recent years, the 
protein family of sorting nexins (SNX) has been shown to play very important roles as coat 
complexes in multiple endosomal recycling pathways, prominently as subunits of the 
retromer-complex (Fig. 4; Cullen P.J., 2008; Cullen P.J. and Korswagen H.C., 2013; Burd C. 
and Cullen P.J., 2014). 





Figure 4: Domain architecture of the mammalian sorting nexins. A depiction of the 33 mammalian sorting 
nexins known to date, which are classified into 3 subfamilies: those which only an isolated SNX-PX domain 
(middle); those which contain a C-terminal BAR domain in addition to the SNX-PX domain (SNX-BAR, left); 
and those which contain other recognized domainsin addition to the SNX-PX domain (right). FERM= 
protein4.1, ezrin, radixin, moesin; PDZ= postsynaptic density protein-95, Discs-large, Zona-occludens-1; 
RhoGap= Rho GTPase-activating protein; SH3= Src- homology-3. Adapted by permission from Macmillan 
Publishers Ltd: Nature reviews molecular cell biology, Cullen P.J., copyright 2008 
http://www.nature.com/nrm/index.html  
SNXs are an evolutionarily conserved family of proteins classified by the presence of a 
unique type of a PtdIns(3)P-binding phox-homology (PX) domain, the SNX-PX domain. 
SNXs are associated with PtdIns(3)P-enriched elements of the endosomal pathway, and play 
roles in diverse processes such as endocytosis, endosomal sorting and signaling. Based on the 
presence of a C-terminal Bin/Amphiphysin/Rvs (BAR) domain, several SNXs have been 
classified as the SNX-BAR subfamily (Fig. 4; Teasdale R.D. et al., 2001; Carlton J.G. et al., 
2004; Cullen P.J., 2008).  
The retromer is an endosomal coat multi-protein complex which was first identified in yeast, 
where it mediates the retrieval of a TGN sorting receptor (Vps10) from the endosome to the 
TGN. It is formed through the association of two sub-complexes: the first is a highly 
conserved and stable heterotrimeric complex of the subunits Vps26, Vps29 and Vps35, which 
recognizes cargo proteins and is therefore called the cargo selective complex (CSC). The CSC 
does not have an intrinsic membrane binding activity and relies on the association with the 




second sub-complex for endosome recruitment (Seaman M.N. et al., 1997; 1998). The second 
sub-complex contains a heterodimer of the SNX-BAR-proteins Vps5 and Vps17, which 
induce and/or stabilize the formation of membrane tubules (van Weering J.R. et al., 2012 a; 
2012 b; Burd C. and Cullen P.J., 2014). In mammals, Vps5 has two orthologs, SNX1 and 
SNX2, whereas Vps17 has the orthologs SNX5, SNX6 and possibly SNX32. 
Heterodimerization occurs when one Vps5 ortholog dimerizes with one Vps17 ortholog 
(Wassmer T. et al., 2007; van Weering J.R. et al., 2010; Koumandou V.L. et al., 2011). In 
addition to these two sub-complexes, the retromer recruits additional proteins that mediate 
further cargo capture and packaging, such as SNX3 and SNX27 (Strochlic T.I. et al., 2007; 
Temkin P. et al., 2011), as well as accessory proteins like EHD1 which regulates maturation 
and scission of the retromer tubules (Gokool S. et al., 2007; Gomez T.S. and Billadeau D.D., 
2009; Harbour M.E. et al., 2010; Seaman M.N. et al., 2009; Wassmer T. et al., 2009). 
 Cargo selection sub-complex 
The core component of the CSC is Vps35, which forms a horseshoe-shaped α-helix onto 
which Vps26 and Vps29 independently bind at either distal end (Norwood S.J. et al., 2011; 
Hierro A. et al., 2007). Most retromer cargoes possess at least one hydrophobic motif, F/W-L-
M/V, which is required for retromer-dependent sorting, and their interaction with the CSC is 
of low affinity (Seaman M.N., 2007). Although little is known about the manner by which the 
CSC recognizes cargo, it is assumed that multiple direct and indirect cargo-recognition 
mechanisms exist (Cullen P.J. and Korswagen H.C., 2013). 
 SNX-BAR-sub-complex and membrane remodeling 
The PX domain of SNX1 and SNX2 has been shown to associate with endosomal PtdIns (3)P 
and phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2) (Cozier G.E. et al., 2002). Upon 
dimerization with SNX5 and SNX6 through their BAR-domains, a positively charged 
crescent-shaped surface is formed, which has the ability to sense, and through electrostatic 
interactions, bind membrane curvature (Peter B.J. et al., 2004; Carlton J. et al., 2004; 2005). 
In addition, SNX1 and SNX2 are capable of inducing membrane remodeling which leads to 
membrane tubulation. Both of them contain amphipathic helixes in their N-BAR domains that 
form in the cytosol-lipid interface causing surface tension between the leaflets of the bilayer, 
which the membrane accommodates by generating positive curvature (i.e. bends into the 
cytosol). This membrane curvature is stabilized by the curvature-sensing properties of the 
BAR-domains (Frost A. et al., 2009; Bhatia V.K. et al., 2009). Recently, it has been 




suggested that the retromer SNX-BARs switch between curvature-sensing and curvature-
inducing modes, thus driving the formation of endosomal tubules (van Weering J.R. et al., 
2010). 
Retromer-mediated sorting is initiated when the CSC concentrates cargo into the SNX-BAR 
defined membrane tubule prior to a fission event that generates the endosome-to-TGN 
carriers. This is followed by multiple fission and fusion events, which progressively enrich 
retromer-labeled endosomes with specific cargo as they migrate from the cell periphery 
towards the TGN in the perinuclear region (Wassmer T. et al., 2009). 
1.5.4. Endosome motility along microtubules 
Endosome maturation is a dynamic process, in which endosome movement and location in the 
cytoplasm are tightly linked to their stage of maturation, size, cargo contents and function. 
During the formation of EEs in the cell periphery, they are subjected to slow short-range back 
and forth movements along microtubules, but as they mature, they undergo long-range 
saltatory oscillations with a net movement towards the perinuclear region, where the majority 
of lysosomes are localized (Nielsen E. et al. 1999; Bananis E. et al., 2000; 2004; Driskell O.J. 
et al., 2007; Loubery S. et al., 2008). The centripetal movement along microtubules that 
radiate out from the microtubule organizing center (MTOC) is mediated by kinesin and 
dynein motor proteins, which provide opposing forces that move endosomes in opposite 
directions (Murray J.W. et al., 2000; Soppina V. et al., 2009). Kinesins constitute a large 
family of mainly plus-end-directed motor proteins, some of which, like KIF16B and KIF3A, 
have been implicated in EE and LE motility. KIF16B is a kinesin-3 motor protein and a 
member of the SNX family. It is also known as SNX23 (Fig. 4). It attaches to EEs through its 
PtdIns(3)P binding PX domain when Rab5 is activated, and seems to alter the balance 
between degradation and recycling of cargo; its depletion leads to a block of cargo recycling 
and an increase in cargo degradation whereas its overexpression has the opposite effect 
(Hirokawa N. et al., 2009; Hoepfner S. et al., 2005; Brown C.L. et al., 2005). On the other 
hand, dynein-dependent, minus-end-directed endosome motility brings cargo to the proximity 
of lysosomes in the perinuclear area (Bananis E. et al., 2004). Organelles bind to dynein 
motors either directly or indirectly through adaptor protein complexes, such as the dynactin 
multiprotein complex (Huotari J. and Helenius A., 2011). This motor activity is required for 
fission of EEs, sorting of cargo into recycling and degradative compartments and fusion of 
endosomes during endosome maturation (Bananis E. et al., 2000; Driskell O.J. et al., 2007).  




Recent studies have shown that SNX5 and SNX6 are functionally and mechanistically 
associated with the microtubule cytoskeleton through their interaction with the dynactin 
component p150glued (also known as dynactin subunit 1, DCTN1), an activator of the minus-
end-directed microtubule motor dynein. By recruiting the dynein/dynactin motor complex, the 
SNX-BAR retromer subcomplex coordinates cargo sorting and tubular-based carrier 
formation at the donor endosomal membrane with long-range minus-end-directed 
microtubule-based transport and carrier recognition at the recipient TGN membrane. This 
association regulates the dynamic spatial organization of the endosomal network, which is 
required for efficient retromer-mediated endosomal protein sorting along the microtubules 
towards the MTOC where the TGN is localized (Cullen P.J., 2008; Wassmer T. et al., 2009; 
Hong Z. et al., 2009).  
1.6. Sorting nexin 5 (SNX5) 
SNX5 was identified as a new member of the SNX-BAR subfamily by Otsuki et al. when it 
was reported to bind the Fanconi anemia complementation group A protein (FANCA; Otsuki 
T. et al., 1999). As a product of the sorting nexin 5 gene, SNX5 is 46.8 kDa and consists of 
one phosphoinositide-binding PX-domain and one BAR-domain, which contains three coiled 
coil domains (Fig. 4; Worby C.A. and Dixon J.E., 2002; Hara S. et al., 2008). SNX5 interacts 
with SNX1 and SNX2 and shares 66% amino-acid identity with SNX6, suggesting they might 
share cellular functions (Worby C.A. and Dixon J.E., 2002; Wassmer T. et al., 2007; 
Bonifacino J.S. and Hurley J.H., 2008). 
SNX5 plays a role in the retrograde transport of the cation-independent mannose 6-phosphate 
receptor (CI-MPR)/ insulin-like growth factor II receptor (IGF2R; Seaman M.N., 2005; Hara 
S. et al., 2008; Wassmer T. et al, 2007), the endosomal trafficking of epidermal growth factor 
receptor (EGFR), and E-Cadherin (Liu H. et al., 2006; Merino-Trigo A. et al., 2004; Sun Y. et 
al., 2013; Schill N.J. et al., 2014). SNX5 binds to type I gamma phosphatidylinositol 
phosphate 5-kinase i5 (PIPKIγi5), an enzyme which synthesizes PtdIns4,5P2, and they both 
prevent the ubiquitination of the Hrs protein which facilitates its association with EGFR, thus 
leading to EGFR sorting into ILVs and its degradation (Sun Y. et al., 2013).  However, SNX5 
can also act antagonistically to PIPKIγi5, preventing the lysosomal degradation of E-Cadherin 
(Schill N.J. et al., 2014).    
                                                                                                                                                                  
In addition, SNX5 functions as modulator of macropinocytosis by playing an essential role in 
macropinosome biogenesis. Macropinocytosis mediates the endocytosis of solute molecules, 




nutrients and antigens, and is therefore important in functions associated with immune 
responses (Kerr M.C. et al., 2006; Lim J.P. et al., 2008; Wang J.T. et al., 2010; Lim J.P. et 
al., 2012). Furthermore, SNX5 interacts with Mind bomb-1 (Mib1), an E3 ubiquitin ligase 
which is a key regulator of ligands of the Notch signaling pathway, and is suggested to 
regulate the functions of Mib1 and therefore plays an essential role in cell fate determination 
in mammalian early development (Yoo K.W. et al., 2006; Weinmaster G. and Fischer J.A., 
2011). A recent in vivo study of SNX5 showed that mice lacking the Snx5 gene exhibited 
partial perinatal mortality, with approximately 40% of the animals dying within a day of birth. 
Neonatal mice lacking the Snx5 gene showed significant breathing defects associated with 
cyanosis and reduced pulmonary air space at birth, and histological analysis revealed they had 
reduced alveolar epithelial type I cells, indicating that Snx5 is necessary for the differentiation 
of these cells during perinatal murine lung development (Im S.K. et al., 2013). 
1.7. SNX5 and the GLUT4 trafficking pathway 
In a study by Towler et al. in 2004, SNX5 was identified as an interaction partner of the 
muscle specific isoform of clathrin heavy chain, CHC22 (Towler M.C. et al., 2004 b). CHC22 
was discovered during the human genome project analysis of chromosome 22 (Kedra D. et 
al., 1996; Long K.R. et al., 1996; Sirotkin H. et al., 1996). It is expressed at high levels in 
skeletal muscle, somewhat lower levels in cardiac muscle and testes, and only at low levels in 
other tissues. Although the sequences of CHC22 and the ubiquitously expressed CHC17, 
which forms the clathrin coated vesicles, are 85% identical, initial studies showed that the two 
CHCs have different intracellular distributions, some distinct biochemical properties and are 
apparently regulated differently (Liu S.H. et al., 2001; Towler M.C. et al., 2004 b). While 
each CHC17 subunit in the clathrin triskelion is bound by a regulatory light chain (LC), 
CHC22 trimerizes but does not bind clathrin LCs. Instead, SNX5 binds to the region in 
CHC22 where the light chain would normally bind to CHC17 for negative regulation of 
clathrin assembly (Brodsky M. et al., 2001). SNX5 does not bind CHC17 indicating a muscle 
tissue-specificity for the function of both CHC22 and SNX5. In addition, CHC17 and CHC22 
bind different subsets of adaptor proteins (Towler M.C. et al., 2004 a). In mature muscle 
CHC22 is preferentially concentrated at neuromuscular and myotendinous junctions, 
suggesting a role at sarcolemmal contacts with extracellular matrix. CHC22 expression is 
increased during myoblast differentiation and also in regenerating muscle fibers, indicating a 
role in muscle repair (Towler M.C. et al., 2004 b). 




In a recent study, CHC22, which exists in mice only as a pseudogene, exhibiting species-
specificity (Wakeham D.E. et al., 2005), has been shown to play an important role in human 
glucose metabolism (Vassilopoulus S. et al., 2009). In muscle and fat tissues, the intracellular 
trafficking of glucose transporter GLUT4, the major GLUT isoform responsible for glucose 
translocation in mammalian skeletal muscle, is triggered during the body’s response to insulin 
and exercise. GLUT4 is then exported from the intracellular GLUT4 storage compartments 
(GSCs) to the plasma membrane to clear glucose from the bloodstream (Bryant N.J. et al., 
2002; Hou J.C. et al., 2007; Huang S. et al., 2007). GLUT4 membrane trafficking is disrupted 
in some forms of human type 2 diabetes leading to expanded and defective GSCs and 
increased intracellular sequestration (Garvey W.T. et al., 1998; Maianu L. et al., 2001). 
CHC22 was shown to be involved in the biogenesis of insulin-responsive GSCs in human 
muscle and adipocytes, independent from CHC17, and it exhibits high levels in the expanded 
GSCs in muscle from type 2 diabetic patients (Vassilopoulus S. et al., 2009). CHC22 
mediates an intermediate stage of retrograde endosomal sorting of GLUT4 to the perinuclear 
TGN, which occurs after the CHC17-dependent step required for retrograde cargo exit from 
EEs, and is essential for its subsequent transport to GSCs. This CHC22-mediated sorting of 
GLUT4 requires the recruitment of retromer through binding to SNX5 and does not overlap 
with CHC17 function (Esk C. et al., 2010). It has also been shown to require dynein/dynactin 
motor activity on microtubules and an intact microtubule-network (Guilherme A. et al., 2000; 
Shigematsu S. et al., 2002; Ishiki M. and Klip A., 2005). 
The expression of both CHC22 and GLUT4 is elevated in regenerating rat muscle, as well as 
regenerating skeletal muscle fibers from patients with inflammatory and other myopathies, 
implicating a role of the GLUT4 transport pathway in muscle regeneration (Towler M.C. et 











1.8.   Aim of the study 
The aim of this study was using quantitative mass spectrometric analyses for the identification 
and characterization of novel interaction partners and target proteins of MuRF1, MuRF2 and 
MuRF3. This experimental approach allowed the investigation of different cellular conditions 
and the changes in MuRF protein-interactions which occur during a specific cellular process 
such as myocyte differentiation or atrophy of myotubes. Furthermore, it enabled the 
comparison between the interactomes of the different MuRF-proteins. By identifying and 
characterization of MuRF-interaction partners and target proteins, this technique was expected 
to offer a better understanding of the functions of MuRF proteins as ubiquitin E3 ligases, and 
the role they play in protein homeostasis, stabilizing of microtubules and myocyte 
differentiation.  




2 Materials and Methods 
2.1. Materials and instruments 
2.1.1. Equipment and instruments 
Table 1: Equipment and instruments used in this study 
Instrument                Company  
-80°C refrigerator ultra low                                       
6 well plates                                                               
Agarose gel chamber BlueMarine™ 200                  
 
Bacteria hood 
                                                             
Balance  
Cell culture hood FAZ3  
                                            
Cell culture flasks    
Cell scrapers   
 




Ceramic spheres   
 
CT15RE Centrifuge 
Development machine Curix 60     
Dissecting instruments   
 
DNA/RNA UV-Cleaner UVT-S-AR  
 
Electrophoresis Power Supply EPS 301    
FastPrep®-24 Instrument    
Fluo Star optima     
Fluorescence microscope    
 
Gene pulser cuvettes 0.1 cm   
 
High performance chemiluminescence 
films             
Incubator   
Invers microscope     
 
 Sanyo, München, Germany 
              BD Biosciences, Heidelberg, Germany 
              SERVA Electrophoresis GmbH, Heidelberg,  
              Germany               
              BDK Luft- und Reinraumtechnik GmbH, 
              Sonnenbühl-Genkingen, Germany 
              FAUST GmbH, Meckenheim, Germany 
              Waldner Electronics GmbH & Co., Gräfelfing, 
              Germany      
              BD Biosciences, Heidelberg, Germany 
              TPP Techno Plastic Products AG,   
              Trasadingen, Switzerland  
              SIGMA Laborzentrifugen GmbH, Osterode 
              am Harz, Germany  
              Laborzentrifugen GmbH, Osterode 
              am Harz, Germany           
              PEQLAB Biotechnology GmbH, Erlangen, 
              Germany 
              VWR, Darmstadt, Germany 
              Agfa-Gevaert N.V., Mortsel, Belgium 
              Fine Science Tools GmbH, Heidelberg, 
              Germany 
              Biolabo Scientific Instruments, châtel-St-Denis, 
              Switzerland 
              GE Healthcare GmbH, Solingen, Germany 
              MP Biomedicals GmbH, Eschwege, Germany 
              BMG Labtech GmbH, Ortenberg, Germany 
 Leica Microsystems GmbH, Wetzlar, 
              Germany 
              Bio-Rad Laboratories GmbH, München, 
              Germany 
              GE Healthcare GmbH, Solingen, Germany 
              
              Thermo Fischer Scientific inc., Waltham,   USA 
              Nikon GmbH, Düsseldorf, Germany 
 




Instrument                   Company  
KS 4000i Control Incubator Shaker     
 
MicroAmp® Fast Optical 96-Well Reaction 
Plate      
Micro wave 
 
MicroPulser Electroporator  
 
Mini Centrifuge 
Mini Trans-Blot Cell     
 




peqSTAR 96 Universal Gradient PCR 
machine  
Photometer Gene quant 
Pipets 




Roll mixer RM5  
Safety hood 
 
Sanyo CO2 incubator 
Software LAS 
 
Software LAS AF 
 
SPE Confocal Microscope 
 








                 IKA®-Werke GmbH & Co. KG, Staufen, 
                 Germany 
                 Life Technologies Corporation, Carlsbad, 
                 California, USA 
                 SEVERIN Elektrogeräte GmbH, Sundern, 
                 Germany 
                 Bio-Rad Laboratories GmbH, München, 
                 Germany 
                 ROTH, Karlsruhe, Germany 
                 Bio-Rad Laboratories GmbH, München, 
                 Germany 
                 Bio-Rad Laboratories GmbH, München, 
                 Germany 
                 Thermo Fischer Scientific inc., Waltham, 
                 USA   
                 PEQLAB Biotechnology GmbH, Erlangen, 
                 Germany 
                 GE Healthcare GmbH, Solingen, Germany 
                 Eppendorf AG, Hamburg, Germany 
                 Bio-Rad Laboratories GmbH, München, 
                 Germany 
                 Liebherr-International Deutschland GmbH, 
                 Biberach an der Riss, Germany 
                 NeoLab, Heidelberg, Germany 
                 Köttermann GmbH & Co KG, 
                 Uetze/Hänigsen, Germany 
                 Cotech Vertriebs GmbH, Berlin, Germany 
                 Leica Microsystems GmbH, Wetzlar, 
                 Germany 
                 Leica Microsystems GmbH, Wetzlar, 
                 Germany 
                 Leica Microsystems GmbH, Wetzlar, 
                 Germany 
                 Life Technologies Corporation, Carlsbad, 
                 California, USA 
                 Eppendorf AG, Hamburg, Germany 
                 Phase, Lübeck, Germany 
                 Biosciences GmbH, Fernwald, 
                 Gemany 
                 ROTH, Karlsruhe, Germany 
                 GFL Gesellschaft für Labortechnik mbH, 
                 Burgwedel, Germany 
 
 




2.1.2. Reagents and chemicals 
Table 2: Reagents and chemicals used in this study 
Reagent                                   Company  
1 kb DNA marker 




Acrylamide 30 % 
Advantage® HD Polymerase 
Agarose 
Albumin Fraction V (Bovine Serum 
Albumin) 





Anti FLAG M2 Affinity Gel 
 










cOmplete, EDTA-free Protease 
Inhibitor Cocktail Tablets 
Cycloheximide 
 
dFBS (dialyzed FBS)      
 





DMEM, low glucose (1 g/l), 
with L glutamine 
                                 ROTH, Karlsruhe, Germany 
                                 ROTH, Karlsruhe, Germany 
                                 ROTH, Karlsruhe, Germany 
                                 ROTH, Karlsruhe, Germany 
                                 ROTH, Karlsruhe, Germany 
                                 Merck KGaA, Darmstadt, Germany 
                                 Clontech, Mountain View, USA 
                                 ROTH, Karlsruhe, Germany 
                                 ROTH, Karlsruhe, Germany 
                                 
                                 ROTH, Karlsruhe, Germany 
                                 Sigma-Aldrich Chemie GmbH, München, 
                                 Germany 
                                 New England Biolabs GmbH,  
                                 Frankfurt/Main, Germany 
                                 Sigma-Aldrich Chemie GmbH, München, 
                                 Germany 
                                 Thermo Fischer Scientific inc., Waltham,    
                                 USA      
                                 Sigma-Aldrich Chemie GmbH, München, 
                                 Germany 
                                 Qiagen, Hilden, Germany 
                                 Qiagen, Hilden, Germany 
                                 Qiagen, Hilden, Germany 
                                 Sigma-Aldrich Chemie GmbH, München, 
                                 Germany 
                                 ROTH, Karlsruhe, Germany 
                                 Roche Deutschland Holding GmbH,      
                                 Grenzach-Wyhlen, Germany  
                                 Sigma-Aldrich Chemie GmbH, München, 
                                 Germany 
                                 Sigma-Aldrich Chemie GmbH, München, 
                                 Germany 
                                 Agfa-Gevaert N.V., Mortsel, Belgium 
                                 Sigma-Aldrich Chemie GmbH, München, 
                                 Germany 
                                 Sigma-Aldrich Chemie GmbH, München, 
                                 Germany 
                                 PAA Laboratories GmbH, Pasching, Austria 
 
                                                            




Reagent                                        Company  
DMEM, high glucose (4.5 g/l), 









Ethanol 99 % 
Ethidium bromide 1 % 
Fetal bovine serum (FBS) 
Fixer solution G354 
Fugene6 Transfection Reagent 
 





Hybond ECL Nitrocellulose 
Membrane 






L-glutamine 200 mM  
LiChrosolv Water for  
Chromatography 








Magnesium chloride (MgCl2) 
Magnesium sulphate (MgSO4) 
 
                                      PAA Laboratories GmbH, Pasching, Austria 
 
                                      PEQLAB Biotechnology GmbH, Erlangen, 
                                      Germany 
                                      Sigma-Aldrich Chemie GmbH, München, 
                                      Germany 
                                      PAA Laboratories GmbH, Pasching, Austria 
 
                                      Sigma-Aldrich Chemie GmbH, München, 
                                      Germany 
                                      ROTH, Karlsruhe, Germany 
                                      ROTH, Karlsruhe, Germany 
                                      PAA Laboratories GmbH, Pasching, Austria 
                                      Agfa-Gevaert N.V., Mortsel, Belgium  
                                      Roche Deutschland Holding GmbH,   
                                      Grenzach-Wyhlen, Germany                       
                                      PAA Laboratories GmbH, Pasching, Austria 
                                      R & D Systems 
                                      R & D Systems 
                                      Merck KGaA, Darmstadt, Germany 
                                      ROTH, Karlsruhe, Germany 
                                      GE Healthcare GmbH, Solingen, Germany 
 
                                      Sigma-Aldrich Chemie GmbH, München, 
                                      Germany 
                                      Sigma-Aldrich Chemie GmbH, München, 
                                      Germany 
                                      ROTH, Karlsruhe, Germany 
                                      ROTH, Karlsruhe, Germany 
                                      PAA Laboratories GmbH, Pasching, Austria 
                                      Merck KGaA, Darmstadt, Germany 
 
                                      Life Technologies Corporation, Carlsbad, 
                                      California, USA 
                                      Linde AG, Pullach, Germany 
                                      Waco, Osaka, Japan 
                                      Sigma-Aldrich Chemie GmbH, München, 
                                      Germany 
                                      Cambridge Isotope Laboratories, Inc. 
                                      Cambridge Isotope Laboratories, Inc. 
                                      ROTH, Karlsruhe, Germany 
                                      ROTH, Karlsruhe, Germany 
                                       
 








MG132 protease inhibitor 
Milk powder  
N-Ethylmaleimide (NEM)    
 
Ni-Sepharose-6 Fast Flow 
Nonidet P-40 
 
Nuclease free water 
NucleoBond® Xtra Maxi 
 
NucleoSpin® Gel and PCR  
Clean-up 




Phenylmethanesulfonyl fluoride  
(PMSF) 




Power SYBR Green Master Mix 
 





RNaseOUT Recombinant  
Ribonuclease Inhibitor 
SILAC DMEM 
SNX5 recombinant protein   
Sodium chloride (NaCl) 
Sodium deoxycholate 
 
Sodium dodecylsulphate  
(SDS) Pellets 
 
                                      Sigma-Aldrich Chemie GmbH, München, 
                                      Germany 
                                      ROTH, Karlsruhe, Germany 
                                      Merck KGaA, Darmstadt, Germany 
                                      ROTH, Karlsruhe, Germany 
                                      Thermo Fischer Scientific inc., Waltham,   
                                      USA 
                                      GE-Healthcare GmbH, Solingen, Germany 
                                      Sigma-Aldrich Chemie GmbH, München, 
                                      Germany 
                                      Qiagen, Hilden, Germany 
                                      MACHEREY-NAGEL GmbH & Co. KG, Düren, 
                                      Germany 
                                      MACHEREY-NAGEL GmbH & Co. KG, Düren, 
                                      Germany 
                                      Thermo Fischer Scientific inc., Waltham, 
                                      USA 
                                      Merck KGaA, Darmstadt, Germany 
                                      PAA Laboratories GmbH, Pasching, Austria 
                                      Sigma-Aldrich Chemie GmbH, München, 
                                      Germany 
                                      New England Biolabs GmbH,     
                                      Frankfurt/Main, Germany 
                                      Life Technologies Corporation, Carlsbad, 
                                      California, USA 
                                      Life Technologies Corporation, Carlsbad, 
                                      California, USA 
                                      Life Technologies Corporation, Carlsbad, 
                                      California, USA 
                                      Life Technologies Corporation, Carlsbad, 
                                      California, USA 
                                      Qiagen, Hilden, Germany 
                                      Life Technologies Corporation, Carlsbad, 
                                      California, USA 
                                      PAA Laboratories GmbH, Pasching, Austria 
                                      Enzo Life Sciences 
                                      ROTH, Karlsruhe, Germany 
                                      Sigma-Aldrich Chemie GmbH, München, 
                                      Germany 
                                      ROTH, Karlsruhe, Germany 
 
                                       
 
 




Reagent                                   Company  
Sodium ethylendiamine                   
Tetraacetate (Na2-EDTA) 
Sodium orthovanadate (Na3VO4) 
 
Superscript II Reverse Transcriptase 
 















WEST-ZOL plus Western Blot 
Detection 
Whatman filter paper 
Yeast extract 
 
                                 ROTH, Karlsruhe, Germany 
 
                                 Sigma-Aldrich Chemie GmbH, München, 
                                 Germany 
                                 Life Technologies Corporation, Carlsbad, 
                                 California, USA 
                                 New England Biolabs GmbH,  
                                 Frankfurt/Main, Germany 
                                 ROTH, Karlsruhe, Germany  
                                 ROTH, Karlsruhe, Germany 
                                 Sigma-Aldrich Chemie GmbH, München, 
                                 Germany 
                                 Sigma-Aldrich Chemie GmbH, München, 
                                 Germany 
                                 ROTH, Karlsruhe, Germany 
                                 Life Technologies Corporation, Carlsbad, 
                                 California, USA 
                                 PAA Laboratories GmbH, Pasching, Austria 
                                 ROTH, Karlsruhe, Germany 
                                 Sigma-Aldrich Chemie GmbH, München, 
                                 Germany 
                                 HiSS Diagnostics GmbH, Freiburg, Germany 
 
                                 VWR, Darmstadt, Germany 





Table 3: Primary antibodies used for western blot (WB) and immunocytochemistry (ICC) 













              Mouse  
 
              Rabbit  
 
              Rabbit 
              Mouse 
             
              Mouse  
 
              Rabbit  
              Mouse 
 
               
       1:30,000/ - 
 
       1:1000/ 1:250  
 
       1:1000/1:250       
       1:1000/1:250  
       
       1:1000/ 1:250    
 
       1:1000/1:250  
       1:1000/ -      
 
  
 Millipore GmbH 
   




















Anti LAMP1  
Anti MuRF2 
Anti MuRF3 
              Mouse 
 
              Rabbit 
              Mouse  
              Mouse 
              Rabbit 
              Rabbit 
 
       1:1000/ -       
 
       1:1000/ -      
       - / 1:250                     
       - / 1:250  
       1:300/ 1:50 
       1:300/ 1:50                                                                                          
Sigma-Aldrich Chemie GmbH 
Santa Cruz Biotechnology 
BD Biosciences 
BD Biosciences 
Generated at AG Fielitz lab 
Generated at AG Fielitz lab 
 
Table 4: Secondary antibodies used for western blot (WB) and immunocytochemistry (ICC) 
Antibody             Species      Dilution (WB/ICC) Company  
Anti-mouse IgG HRP linked 
Anti-rabbit IgG HRP linked 
Anti-mouse Alexa Fluor®488 
Anti-rabbit Alexa Fluor®488 
Anti-mouse Alexa Fluor®555 
Anti-rabbit Alexa Fluor®555 
Anti-mouse Alexa Fluor®647 
           Horse  
           Goat  
           Goat 
           Goat  
           Goat 
           Goat 
           Goat 
    1:2000/ - 
    1:2000/ - 
    - / 1:500 
    - / 1:500 
    - / 1:500 
    - / 1:500 
    - / 1:500   
Cell Signaling Technology 
Cell Signaling Technology 
Life Technologies Corp. 
Life Technologies Corp. 
Life Technologies Corp. 
Life Technologies Corp. 




Table 5: Primers used for cloning-, mutagenesis- and RT- PCR-reactions. Restriction enzymes used for 
cloning are included in the name of the primer (i.e. EcoRI, XbaI, KpnI, HindIII etc.). 
Primer                            Sequence (5’-3’) 
Mm MuRF1 His/Myc EcoRI for 
Mm MuRF1 His/Myc KpnI rev 
Mm MuRF2 His/Myc XhoI for 
Mm MuRF2 His/Myc KpnI rev 
Mm MuRF3 His/Myc XbaI for 
Mm MuRF3 His/Myc KpnI rev 
Mm MuRF1 pMal EcoRI for 
Mm MuRF1 pMal XbaI rev 
Mm MuRF2 pMal salI for 
Mm MuRF2 pMal HindIII rev 
Mm MuRF3 pMal EcoRI for 
Mm MuRF3 pMal XbaI rev 
                          CAGAATTCATGGATTATAAATCTAGCCTG 
                          CTTGGTACCTTGGTGTTCTTCTTTACCCTC 
                          GACTCGAGATGAGCACTTCTCTGAATTAC 
                          CTTGGTACCTTCATTTAGGGAATTCAACCAG 
                          TCTAGACTATGAACTTCACGGTGGGTTTCAA 
                          GGTACCGTGCAGGCCTGAGCCTTCTGGCAC 
                          CCGGAATTCGATTATAAATCTGGCCTGATTC 
                          GCTCTAGATCATTGGTGTTCTTCTTTAC 
                          GCGTCGACAGCACTTCTCTGAATTACAAG 
                          CGAAGCTTTTATTCATTTAGGGAATTCAAC 
                          CCGGAATTCAACTTCACGGTGGGTTTCAAG 
                          GCTCTAGATCAGTGCAGGCCTGAGCCTTC  








Primer                 Sequence (5’-3’) 
Mm MuRF1 Flag EcoRI for 
Mm MuRF1 Flag ApaI rev 
Mm MuRF2 Flag ClaI for 
Mm MuRF2 Flag ApaI rev 
Mm MuRF3 Flag EcoRI for 
Mm MuRF3 Flag ApaI rev 
Mm MuRF2 C42S His/Myc for 
Mm MuRF2 C42S His/Myc rev 
Mm MuRF2 C50S His/Myc for 
Mm MuRF2 C50S His/Myc rev 
Mm Snx5 His/Myc BamHI for 
Mm Snx5 His/Myc KpnI rev 
Mm Snx5 Flag ClaI for 
Mm Snx5 Flag XbaI rev 
Mm Snx5 BAR Flag ClaI for 
Mm Snx5 PX Flag XbaI rev 
Mm Snx5 BAR∆Helix1 for 
Mm Snx5 BAR∆Helix1 rev 
Mm Snx5 BAR∆Helix2 for 
Mm Snx5 BAR∆Helix2 rev 
Mm Snx5 BAR∆Helix3 for 
Mm Snx5 BAR∆Helix3 rev  
Mm Snx5 Sybr for 
Mm Snx5 Sybr rev 
 
               GCGAATTCGATTATAAATCTAGCCTGA 
               GCGGGCCCTCATTGGTGTTCTTCTTT 
               GCATCGATAGCACTTCTCTGAATTACAAGTCTT 
               GCGGGCCCTTATTCATTTAGGGAATT 
               GCGAATTCAACTTCACGGTGGGTTTCAA 
               GCGGGCCCTCAGTGCAGGCCTGAGCCTTC 
               GCCTGTGGTCATTCTCCCTAGCCAGCACAA 
               TTCGTGAACATCTCTAGGCAGATGGGACAG 
               GCACAACCTGTGCAGGAAAAGTGCCAGTGACATC 
               TGGCAAGGGAGAATGACCACAGGCTTCGTGAACA 
               CGGGATCCATGGCCGCGGTTCCCGAGTT  
               GGGGTACCGTTGTTCTTGAATAAGTCGATGCAGCTC 
               CCATCGATGCCGCGGTTCCCGA   
               GCTCTAGATCAGTTGTTCTTGAATAAGTCGATGC 
               CCATCGATCAGGATCTAAGTGTTAGACG 
               GCTCTAGAATCATATTCCAAGAAAACATGAAA 
               GAAGAACCCACAGTCATCAAAAAGT                  
               CACCTCCTTAACTCCAGAAAAAAGG 
               AAGGCCCGGTTAAAAAGCAAAGATGTCAAG 
               GACTGTGGGTTCTTCCAAGGCCAGG 
               ATCGACTTATTCAAGAACAACTGA 
               CTGATGAGTCTCTGCCAACT 
               GTTCCCGAGTTGCTGGAG 
               GCGATGGGTCAACATTCAG 
 
2.1.5. Expression plasmids  
Table 6: Expression plasmids used in this study 
Vector      Selection marker      Company   
pcDNA3.1 (+) FLAG 
pcDNA3.1 (-)A- Myc(His)6 
pMAL-c4E 
pmCherry-N1 
           
 
   Ampicillin     
   Ampicillin 
   Ampicillin 
   Kanamycin/Neomycin 
     Life Technologies Corporation 
     Life Technologies Corporation 
     New England Biolabs 
     Clontech 
  
 
2.2.  Molecular biological methods 
2.2.1.  Polymerase chain reaction (PCR)  
Amplification of DNA was performed using a PCR reaction according to the program in table 
8. For amplification from cDNA, 20-30 ng of DNA template were used, whereas 5-10 ng of 
plasmid DNA were sufficient. For DNA analysis, the advantage® High Fidelity (HD) 




polymerase was used with its corresponding PCR buffer supplied by the manufacturer (Table 
7).  
 
Table 7: Components of a PCR reaction 
Components                 Volume for one reaction [µl] 
DNA template 
5x adv. HD Buffer 
5µM forward primer 
5µM reverse primer 
dNTPs (10 mM) 
Adv. HD-polymerase 
H2O 
                                 X  
                                10 
                                 4 
                                 4 
                                 1 
                                 0.5 
                                 ad 50 µl 
 
PCR was carried out in a PCR- thermocycler. The Standard PCR reaction program (Table 8) 
was adjusted according to the quantity and quality of template DNA, the length and G/C 
content of the primers and the length of the amplified sequences. A list of PCR primers used 
in this study can be found in table 5. PCR products were purified by using the NucleoSpin® 
Gel and PCR Clean-up Kit according to manufacturer’s protocol and as described in 2.2.9. 
Table 8: Standard program of a PCR reaction 
PCR reaction step Temperature [°C]    Time [min]      Cycles  




5 Terminal elongation 
          95 
          95 
       50-70 
          72 
          72 
         5 
      0.5-1 
         1 
        1-3 
        10 
      1 
 
      35 x steps 2-4 
 
      1 
 
2.2.2.  Site - directed mutagenesis PCR 
With the Phusion™ Site-Directed Mutagenesis Kit, point mutations and deletions were 
introduced in plasmid DNA by using the highly processive Phusion™ Hot Start High-Fidelity 
DNA polymerase. PCR amplification of target plasmid was performed with two 
phosphorylated primers, which were designed so that they would anneal back to back to the 
plasmid. For point mutations, they were created by designing one or two base-mismatches in 
the forward primer, whereas deletions were created by designing primers that border the 
deleted area on both sides while being perfectly matched on their entire length. A list of 
primers can be found in table 5. Primers were phosphorylated at the 5’ end to eliminate the 
need for a separate phosphorylation step before direct ligation. Phosphorylation was carried 
out using T4 Polynucleotide Kinase and its 10xT4 Polynucleotide Kinase Buffer and by 




adding ATP to the reaction according to manufacturer’s protocol. The reaction was carried 
out for 30 min at 37°C. Mutagenesis PCR was performed using 20-30 ng of template plasmid 
DNA. Components of the reaction are listed in table 9. 
Table 9: Components of a site-directed mutagenesis PCR reaction 
Components                 Volume for one reaction [µl] 
DNA template 
5xPhusion ™HF Buffer 
5µM phosphor. forward primer 
5µM phosphor. reverse primer 
dNTPs (10 mM) 
Hot-Start DNA-polymerase 
H2O 
                                 X  
                                10 
                                 4 
                                 4 
                                 1 
                                 0.5 
                                 ad 50 µl 
 
PCR was carried out in a PCR- thermocycler according to the PCR reaction program shown in 
table 10. Annealing temperature was adjusted according to the length and G/C content of the 
primers and elongation time according to the length of the linearized plasmid DNA to be 
mutated (point mutations), or the linearized plasmid DNA without the deleted segment (in the 
case of deletion mutations). 
Table 10: Program of a site-directed mutagenesis PCR reaction 
PCR reaction step Temperature [°C]       Time      Cycles  




5 Terminal elongation 
          98 
          98 
       50-70 
          72 
          72 
      30 sec 
      10 sec 
   10-30 sec 
     3-4 min 
     10 min 
      1 
 
      25 x steps 2-4 
 
      1 
 
Following the reaction, PCR product was digested with the restriction enzyme DpnI. This 
digest is crucial because DpnI only cleaves at methylated sites, so it digests the template 
plasmid but not the PCR product. Since the transformation efficiency of the template plasmid 
is much better than the circularized PCR product, without the DpnI digest a large number of 
colonies would be the parental DNA. DpnI restriction digestion was carried out by adding 1µl 
(20 U) of DpnI enzyme to the PCR product and incubating it at 37°C for 1 h. PCR products 
were purified by using the NucleoSpin® Gel and PCR Clean-up Kit according to 
manufacturer’s protocol and as described in 2.2.9. Mutated PCR products were circularized 
by using T4 DNA ligase as described in 2.2.6.  




2.2.3. Transformation of competent bacteria with DNA  
• SOC medium: 2% (w/v) bacto tryptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 
mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose  
 
 Transformation of chemically competent bacteria 
 
For transformation of E.coli with plasmid DNA 100 μl of chemically competent bacteria were 
taken out of the -80°C freezer and thawed carefully on ice. Bacteria were mixed with 10μl of 
ligation reaction or 50ng of plasmid DNA preparation and incubated for 30 minutes on ice. A 
brief heat shock (42°C, 45 sec) was followed by incubation on ice for 10 min. 500 μl of SOC 
medium were added and after incubation for 1h at 37°C and 250rpm, cell suspension was 
streaked on LB agar plates, containing the suitable antibiotic (100 μg/ml ampicillin or 50 
μg/ml kanamycin). Plates were incubated at 37°C overnight. The bacteria strain E.coli XL1-
Blue was used for all cloning experiments and DNA preparation, and E.coli BL21 was used 
for expression of recombinant proteins. 
 
 Electrotransformation of E.coli XL1-Blue 
 
Electrotransformation of bacteria with DNA was alternatively carried out by mixing 2.0-4.0 
μl of the ligation reaction with 50 μl of electrocompetent E. coli XL1-Blue and pipetting the 
cells into a 0.1 cm gene pulser cuvette. Electrotransformation was performed with the Ec1 
program with 1.8 kV in the MicroPulser Electroporator. Immediately afterwards, transformed 
bacteria were mixed with 500 μl of SOC medium and incubated for 1 h at 37°C and 250 rpm. 
Cell suspension was streaked on LB agar plates, containing either 100 μg/ml ampicillin or 50 
μg/ml kanamycin. Plates were incubated at 37°C overnight. 
 
2.2.4. Preparation of plasmid DNA by alkaline lysis with SDS 
Minipreparation 
• P1 buffer: 50 mM Tris-HCl, 1 mM EDTA, 10 μg/ml RNaseA, pH8.0 
• P2 buffer: 200 mM NaOH, 1% (w/v) SDS 
• P3 buffer: 3 M potassium acetate, pH5.5 
 
For the preparation of plasmid DNA, 3 ml of LB medium containing 100 μg/ml ampicillin or 
50 μg/ml kanamycin were inoculated with transformed bacteria colonies from LB plates (see 
2.2.3.) and incubated overnight at 37 °C and 250 rpm. 2 ml of the overnight culture were spun 




down for 10 min at 13,000 g and 4 °C for sedimentation of the cells. Bacteria pellets were 
resuspended in 200 μl of buffer P1, supplemented with 100μg/ml RNaseA. For alkaline lysis 
of bacteria, 200 μl of buffer P2 were added and the reaction tube was inverted several times. 
The solution was neutralized by adding 200 μl of buffer P3, vigorous mixing and incubation 
for 5 min at RT. Centrifugation at 13,000 g and 4°C for 10 min was performed, and 500 μl of 
the supernatant were transferred into a new reaction tube. DNA was precipitated by adding 
350 μl of 2-Propanol and centrifugation for 20 min at 13,000 g and 4°C. DNA pellets were 
washed with 1 ml of ice-cold 70% (v/v) ethanol and centrifuged for 10 min at 13,000 g and 
4°C, then dried at RT, dissolved in 30 μl of nuclease- free water and stored at -20 °C. 
 
Maxipreparation  
To yield a high content of DNA, maxi preparations were performed. The maxi preparation of 
plasmid DNA from a 200 ml bacteria culture was carried out using the Nucleobond Xtra Maxi 
kit according to the manufacturer’s protocol. 
2.2.5. Cleavage of DNA using restriction endonucleases 
Both analytical and preparative restriction digestions were carried out using suitable 
restriction endonucleases and recommended buffers according to manufacturer’s instructions 
(New England Biolabs Inc., table 5). For analytical digestions 0.5-1.0μg DNA, 10% 
10xbuffer, and 0.5 U of restriction enzyme were mixed and adjusted to a final volume of 20μl 
with water before incubation at 37°C for 1 h. Preparative digestions were carried out in a total 
volume of 50μl, containing 2μg DNA, 10% 10xbuffer, and 1.0-2.0 U of restriction enzyme. 
Final volume was also adjusted to 50μl with water, and samples were incubated at 37°C for 2-
3 h. In both digestions 10% 10xBSA were added when needed, according to the 
manufacturer’s protocol. The cleaved DNA was analyzed by agarose gel electrophoresis.  
2.2.6. Ligation of DNA fragments 
Ligation was carried out by mixing linearized insert DNA and the vector in a ratio of 3:1, 
respectively. Ligation buffer (1 μl) and 1 U T4-DNA-ligase (1 μl) were added, and after 
adjusting the final volume to 10μl with water, the ligation reaction was incubated at 14°C 
overnight. 
 




2.2.7. DNA sequence analysis 
Sequencing of plasmids was performed by the company Eurofins MWG Operon in Ebersberg, 
Germany, according to the Sanger sequencing method.  
2.2.8. DNA gel electrophoresis  
• TAE buffer: 40 mM Tris-HCl, 1 mM EDTA, pH8.4 
• DNA loading buffer: 40% (w/v) sucrose, 0.5% (w/v) SDS and 0.25% (w/v) 
bromophenol blue 
 
For the analysis of PCR products and DNA fragments resulting from restriction by 
endonucleases, DNA fragments were separated electrophoretically according to their size in 
horizontal agarose gels. Depending on the size of the DNA fragment of interest, the 
appropriate amount of agarose was dissolved in TAE buffer by heating at a concentration of 
1.0-2.0% (w/v). For visualization of bands on the gel, ethidium bromide was added at a final 
concentration of 0.5μg/ml after cooling. Bromophenol blue was used as loading buffer and 
TAE buffer was used as running buffer. DNA fragments were visualized via the intercalated 
ethidium bromide using a UV transluminator. The size of the fragments was estimated by 
standard size markers such as the 100bp or 1KB DNA ladders, run on the same gel. 
2.2.9. Extraction of DNA fragments from agarose-gels   
DNA extraction was carried out using NucleoSpin® Gel and PCR Clean-up Kit and following 
manufacturer’s instructions. DNA bands were visualized using a UV transilluminator and 
desired bands isolated by excising the respective piece of agarose. Gel slices were transferred 
into 2ml tubes and their weight was determined before NT buffer was added in a 
200μl/100mg ratio (for PCR products 200 μl NT buffer/100 μl PCR-product). Gel fragments 
were incubated at 50°C and 1200rpm in a thermo-mixer, until they melted completely. 
Samples were loaded onto NucleoSpin Extract columns, which were placed into 1.5 ml 
collection tubes, and centrifuged at 11,000 g for 1 min. The flow-through was discarded and 
columns were placed back into the collecting tubes. For washing the silica membranes 700μl 
NT3 washing buffer were added, followed by 1 min centrifugation at 11,000 g. For drying the 
silica membranes, columns were centrifuged at 11,000 g for additional 2 min. Columns were 
placed into new 1.5 ml reaction tubes, and DNA was eluted with 20 µl pre-heated water, 
which were pipetted in the middle of the silica membrane. After incubation for 1 min at RT, 
columns were centrifuged for 1 min at 11,000 g. Eluted DNA occurred in the flow-through. 




2.2.10. RNA isolation from cells and tissues 
For the analysis of mRNA expression, total RNA was isolated from cells or tissues using 
TRIzol® Reagent. Cells in 6 well plates were lysed by adding 1 ml of TRIzol® Reagent per 
well. Lysed cells were transferred to 1.5 ml tubes. In the case of tissue samples, a small piece 
of tissue was homogenized in 1 ml TRIzol® Reagent in the FastPrep®-24 Instrument in 3 
cycles for 20 sec and 4 m/s each and using lysis matrix tubes with a matrix of six 2.8 mm 
ceramic spheres. After centrifugation at 12,000 g for 10 min at 4 °C, homogenized cells were 
transferred to new 1.5 ml tubes. For phase separation, homogenized samples were incubated 
for 5 min at RT, and 200 μl of chloroform was added. Tubes were shaken vigorously by hand 
for 15 sec and incubated for 3 min at RT. After centrifugation at 12,000 g and 4°C for 15 min, 
the RNA containing aqueous phase was transferred to a new tube and 500 μl of 100% 2-
Propanol were added, mixed and incubated on ice for 10 min for RNA precipitation. Samples 
were centrifuged at 12,000 g and 4°C for 10 min. The supernatant was removed and RNA 
pellet was washed with 1 ml of 75 % (v/v) ethanol. Samples were vortexed briefly then 
centrifuged at 7,500 g and 4°C for 5 min. Ethanol was discarded and RNA pellets were air-
dried for 10-15 min then dissolved in 30-50 μl of RNase-free water. Before measuring the 
concentration, RNA samples were incubated in a heat block at 55°C for 10 min. RNA 
concentration was determined using the NanoDrop1000. RNA samples were stored at -80 °C.  
2.2.11. cDNA synthesis 
The enzyme Superscript II Reverse Transcriptase was used for the reverse transcription of 
RNA to cDNA. Transcription was started by mixing 1 µl of 50-250 ng random primers and 1 
μl of dNTP Mix (10 mM each) with 1 µg of total RNA and adding RNase-free water to a final 
volume of 12 µl. Solution was incubated at 65°C for 5 min, then placed on ice. 4 µl of 5xFirst 
Strand buffer, 2 µl of 0.1 M DTT, 1 µl of RNaseOUT (40 units/μl) and 1 µl of SuperScriptII 
(200U) were added and mixed. Solution was incubated at 25°C for 10 min, then at 42°C for 
50 min and finally at 70°C for 15 min for deactivation of  the SuperScriptII enzyme. The 
reaction was performed in the peqSTAR 96 Universal Gradient PCR machine. The cDNA 
was stored at 4°C for short term or at -20°C for long term storage.  
2.2.12. Quantitative real - time polymerase chain reaction (qRT-PCR) 
For the analysis of gene expression by quantitative real-time polymerase chain reaction (qRT-
PCR), the SYBR Green-based approach was used in a StepOnePlus™ Real-Time PCR 




System and by using MicroAmp® Fast Optical 96-well reaction plates. In a qRT-PCR 
reaction, 10 ng of cDNA were combined with the components shown in table 11.  
 
Table 11: Components for one quantitative RT-PCR reaction 
Components                 Volume for one reaction [µl] 
5µM forward primer 
5µM reverse primer 
Power SYBR Green Master Mix 
5ng/ µl cDNA in nuclease-free H2O 
Nuclease-free H2O 
                                 1 
                                 1 
                                10 
                                 2 
                                 6 
 
The PCR program used for qRT-PCR is shown in table 12. To ensure specificity of the PCR 
reaction, a melting curve was generated after each run. DNA amount was calculated by a 
cDNA dilution curve (“standard curve”). To generate a standard curve, 5 μl of each cDNA 
sample were collected and pooled, and a serial 1:2 dilution of the cDNA-pool was carried out. 
This standard curve was used as a reference for every reaction performed. The expression of 
the specific mRNAs was normalized to the expression level of Gapdh. 
Table 12: Program used for quantitative RT-PCR reaction 
PCR reaction step Temperature [°C] Time [min] 
1 Initial Denaturation 
2 Denaturation 
3 Annealing, elongation 
4 Cycling 




41x step 2 and 3 





2.3. Protein biochemical methods 
2.3.1. Immunocytochemistry (ICC) of mammalian cells 
Cells were seeded on glass coverslips in 6 well plates. 24 h after transfection, cells were 
washed twice with 1xPBS and fixed using 4% Paraformaldehyde in PBS (pH 7.0) for 20 min 
at 4°C. Permeabilization of cells was carried out by using 0.2% Triton-x-100 in 1xPBS for 30 
min at RT. Cells were then incubated in blocking solution containing 5% FBS in 1xPBS for 1 
h at RT. Subsequently, cells were incubated with a specific primary antibody, which was 
diluted in PBS/5% FBS (blocking solution) in a humid environment for 1-2 h at RT. 
Alternatively, this step was carried out overnight at 4°C. After washing the cells 3 times with 
1xPBS, they were incubated with the corresponding secondary antibody, which was diluted in 




1xPBS, in a dark and humid environment for 1 h at RT. Cells were briefly washed with 
1xPBS and coverslips were mounted cell-side down on glass microscope slides using DAPI- 
containing ProLong® Gold Antifade mounting solution. Slides were stored at 4°C in a dark 
environment. 
To determine co-localization of proteins, double- and triple-immunofluorescence staining 
experiments were performed, whereas two or three specific primary antibodies and their 
corresponding secondary antibodies (with different fluorescence labels) were used and 
incubated as described in the single staining procedure. 
2.3.2. Isolation of proteins from cells and tissues 
Protein sample preparation for western blot analyses 
• RIPA-buffer: 50 mM Tris-HCl, 150 mM NaCl, 0.5% (w/v) Sodium-deoxycholate, 
1% (v/v) Nonidet P-40, 1 mM Na2EDTA, 0.2% (w/v) SDS, 1x cOmplete EDTA-free 
Protease Inhibitors, 1 mM Na3VO4, 1 mM PMSF 
 
Cells grown in a 6-well plate were washed once with 1xPBS and lysed with 200 μl of RIPA 
buffer containing protease inhibitors for 20-30 min at 4°C. The lysed cells were harvested 
with a cell scraper, transferred into a pre-cooled 1.5 ml reaction tube and the cell lysate was 
centrifuged at 15,000 rpm for 15 min. The supernatant was collected, transferred to a new 1.5 
ml tube and either subjected to SDS-PAGE and western blot or stored at -80 °C for later use. 
 
For the isolation of proteins from tissue samples, a FastPrep®-24 Instrument was used for 
tissue homogenization. A small piece of tissue was transferred into a 2 ml lysis matrix tube 
with a matrix of six 2.8 mm ceramic spheres and 500-1000 μl (depending on the size and 
origin of the tissue) of RIPA buffer containing protease inhibitors were added. Tissue samples 
were lysed in three homogenization rounds of 20 s and 4 m/s each. The lysis tubes were 
centrifuged at 15,000 rpm and the clear supernatant was collected and transferred into a new 
1.5 ml tube. Samples were stored at -80°C. 
 
Protein sample preparation for MS analysis of SILAC labeling efficiency 
For preparing the samples for the labeling efficiency test, cells were seeded in a 6 well plate 
and incubated at 37°C and 5% CO2 for 24 h. The next day cells were washed with 1xPBS, 
harvested with a cell scraper and collected using 8M Urea/ 2M Thiourea in 10 mM HEPES 
buffer (pH 8.0). Cell lysates were frozen at -80°C for at least an hour then thawed on ice. Cell 
membranes were destroyed using a syringe (needle size Ø 0.40 x 20 mm), and cell lysates 




were centrifuged for 10 minutes at 15000 rpm. The supernatant was collected in a separate 
tube and analyzed by mass spectrometry (MS) for labeling efficiency. 
 
Protein sample preparation for Nickel-NTA and MS analysis 
Cells were lysed with a cell scraper from 6 well plates or T75 cell culture flasks using TRIS 
(10 mM)/ NaCl (150 mM) - buffer with protease inhibitors. Cell lysates were frozen at -80°C 
for at least an hour then thawed on ice (in case of myotubes, several freeze-thaw cycles were 
carried out). Cell membranes were destroyed using a syringe with needle size Ø 0.40 x 20 
mm. cell lysates were sedimented with low speed centrifuge at 300 g for 10 min. Supernatants 
were collected and centrifuged again in an ultracentrifuge at 50000 rpm for 15-20 min. The 
clear middle phase was collected for Nickel-pull-down assays and subsequent MS analysis. 
2.3.3. Affinity purification- and co-immunoprecipitation-assays 
Nickel-Pull down assays   
Affinity purification of His-tagged proteins for subsequent MS-analysis was carried out in 
Nickel-pull down assays using Ni-Sepharose-6 Fast Flow. Proteins were isolated from T75 
cell culture flasks or 6 well-plates of transiently- or stably- transfected cells (see 2.3.2. and 
2.4.5.). Ni-Sepharose (50 µl) was washed 3 times with cold 1xPBS and centrifuged after each 
washing step for 1 min at 15000 rpm and 4°C. After the third washing step, PBS was removed 
entirely and cell lysates were added to the beads in a 2 ml tube. Cold 1xPBS was added to a 
total volume of 1.5 ml. Reaction tubes were rotated in an overhead shaker for 2-3 h at 4°C and 
15 rpm.  Alternatively, this step was carried out overnight at 4°C. Cell lysates and slurry were 
transferred to 1.5 ml tubes, and beads were washed 3 times with cold 1xPBS. After each 
washing step samples were centrifuged for 1 min at 15000 rpm and 4°C. After the third 
washing step, PBS was removed entirely by using a syringe (needle size Ø 0.40 x 20 mm). 
Affinity purified proteins were eluted by careful resuspension with 100 µl of 120 mM EDTA 
(pH 7.4) at RT, followed by a short centrifugation step and collecting the supernatants 
(eluates). Elution was repeated 4 times. Samples were combined, mixed and stored at -80°C 
or analyzed by MS.  
Co-immunoprecipitation assays 
• Potassium-phosphate-buffer (pH 7.4): 50mM [KH2PO4 (pH 4.0)/K2HPO4 (pH 9.3)], 
150 mM NaCl  
• Lysis-buffer: Potassium-phosphate-buffer (pH 7.4), 0.2% Triton-x-100, 1x cOmplete 
EDTA-free Protease Inhibitors  




HEK293 cells were seeded in 6 well plates and transfected using PEI-reagent as described 
below (2.4.4.). Cells were lysed using pre-cooled lysis buffer (200 µl/ well) and a cell scraper, 
and cell lysates were transferred into 2 ml tubes and frozen at -80°C for at least 30 min. Cell 
lysates were thawed on ice and rotated in an overhead shaker for 30 min at 4°C, then 
centrifuged at 10,000 g and 4°C. Supernatant was transferred into a new pre-cooled 2 ml tube, 
and 10% of the lysate were used as input control. FLAG-M2-Agarose (30 µl) was washed 
twice using pre-cooled potassium-phosphate-buffer and centrifuged after each washing step at 
800 g and 4°C. Agarose was brought to a final volume of 100 µl slurry using lysis buffer and 
cell lysates were added. Pre-cooled potassium-phosphate-buffer was added to a total volume 
of 1.5 ml and reaction tubes were rotated in an overhead shaker for 3 h at 4°C and 15 rpm. 
Cell lysates and slurry were transferred to 1.5 ml tubes, and beads were washed with 
potassium-phosphate-buffer 3 times, each followed by a 3 min centrifugation at 800 g and 
4°C. After the third washing step, washing buffer was removed entirely by using a syringe 
with needle size of Ø 0.40 x 20 mm. Elution was carried out with 30 µl 2xLaemmli-buffer 
without β-mercaptoethanol, which were added to and carefully mixed with the beads. Samples 
were heated for 3 min at 95°C and 500 rpm. After a short centrifugation the supernatant was 
transferred into a new tube, 3 µl of 100% β-mercaptoethanol were added and the precipitates 
were heated for additional 7 min at 95°C and 500 rpm. Input- and eluate-samples were 
subjected to SDS-PAGE and western blot analyses. 
2.3.4. Sodium Dodecyle Sulfate Polyacrylamide Gel Electrophoresis     
(SDS-PAGE)   
• Electrophoresis running buffer: 25 mM Tris, 200 mM glycine, 0.1% (w/v) SDS 
• Resolving gel 10%: 4 ml H2O, 3.3 ml 30 % acrylamide, 2.5 ml 1.5 M Tris (pH8.8), 
100 μl 10 % (w/v) SDS, 100 μl 10 % (w/v) APS, 4 μl TEMED  
• Stacking gel 5%: 2.75 ml H2O, 0.65 ml 30 % acrylamide, 0.5 ml 1 M Tris (pH6.8), 
40 μl 10 % (w/v) SDS, 40 μl 10 % (w/v) APS, 4 μl TEMED  
• 6x Laemmli buffer: 300 mM Tris-HCl pH6.8, 12 % (w/v) SDS, 0.1 % (w/v), 
bromophenol blue, 50 % (v/v) glycerol 
 
For the separation of proteins under denaturing conditions and according to their molecular 
weight, sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed using a discontinuous gel buffer system (Laemmli U.K., 1970). Protein samples 
were mixed at a ratio of 6:1 (v/v) with 6x Laemmli-buffer containing 15% (v/v) β-
mercaptoethanol and heated at 95 °C for 5 min. Samples were shortly centrifuged and loaded 
into the pockets of a 10 % (v/v) acrylamide gel. Separation of proteins was performed in the 




Mini-PROTEAN® Tetra Electrophoresis System at 100-200 V for 1-2 h and by using 
Electrophoresis running buffer. The molecular weight of the separated proteins was estimated 
by comparison with a pre-stained standard size marker (protein ladder), which was separated 
on the same gel.      
2.3.5. Western blot analysis 
• Transfer buffer: 25 mM Tris, 192 mM glycine, 10 % (v/v) methanol  
• TBS-T: 20 mM Tris, 150 mM NaCl (pH 7.6), 0.1 % (v/v) Tween20 
• Blocking buffer: TBS-T, 5 % (w/v) milk powder 
• Stripping buffer: 50 mM Tris (pH6.8), 2% (w/v) SDS, 100 mM β-mercaptoethanol 
 
Transfer of proteins from an SDS gel onto a nitrocellulose membrane was performed by the 
tank blot procedure (Towbin, H. et al. 1979), in which the equilibrated Hybond ECL 
Nitrocellulose membrane was placed on the gel with layers of wet Whatman filter paper and 
sponges on both sides. This so-called “sandwich” was set into the Mini-PROTEAN Tetra 
Electrophoresis System and the transfer was performed in transfer buffer for 1-1.5 h at 100 V. 
Subsequently, the nitrocellulose membrane was incubated in blocking buffer for 1 h, followed 
by incubation with the primary antibody, which was diluted in blocking buffer, over night at 4 
°C. The next day, the membrane was washed for 10 min with TBS-T. This washing step was 
repeated two more times before the membrane was incubated with a suitable horseradish 
peroxidase-labeled secondary antibody in blocking buffer for 1 h at RT. Another three 
washing steps in TBS-T were performed for 10 min each. For detection of protein bands, the 
membrane was incubated with WEST-ZOL plus Western Blot Detection Reagent according to 
manufacturer’s instructions for 5 min. The chemiluminescent signal was detected on a high 
performance chemiluminescence film which was developed in a Curix-60 developing 
machine. To reuse the nitrocellulose membrane, antibodies and remaining WEST-ZOL plus 
Western Blot Detection Reagent were removed by incubating the membrane for 10 min at 55 
°C in stripping buffer. After three washing steps in TBS-T, the membrane was blocked again 
and the detection reaction was performed as described before.  
2.3.6. Ubiquitination assays 
 In vitro ubiquitination assays 
In a cell-free system, the ubiquitination of a substrate protein and auto-ubiquitination of 
ubiquitin E3 ligase proteins was initiated under optimal conditions. The following 
components were mixed together on ice: 50 mM Tris-HCl, 5 mM MgCl2, 8mM ATP (pH 




7.4), 0.5 mM DTT, 20 µg Ubiquitin, 1xcOmplete EDTA-free Protease Inhibitors. 
Recombinant ubiquitin-activating enzyme GST-E1, ubiquitin-conjugating enzyme GST-
UbcH5a (E2) and the recombinant ubiquitin E3 ligases MBP-MuRF1, MBP-MuRF2, MBP-
MuRF3, as well as the putative substrate SNX5 recombinant protein, were added to the 
reaction accordingly. For negative controls the different components were respectively left 
out of the reaction. Reaction tubes were incubated at 30°C and 350 rpm for 1.5 h. Samples 
were mixed at a ratio of 6:1 (v/v) with 6x Laemmli-buffer containing 15% (v/v) β-
mercaptoethanol and heated at 95 °C for 5 min and subsequently subjected to SDS-PAGE and 
western blot analysis. 
 In vivo ubiquitination assays  
In vivo ubiquitination assays were carried out like the previously described FLAG-co-
immunoprecipitation assays (2.3.3.) while additionally applying the proteasome inhibitor 
MG132 and the de-ubiquitinase inhibitor N-Ethylmaleimide (NEM). 24 h after transient 
transfection, cells were incubated in 10 µl MG132 for 6 h before cell lysis, whereas NEM (20 
mM) was added to lysis buffer. Further steps were performed as described before (2.3.3.). 
2.3.7. Establishing MBP-MuRF recombinant proteins  
 Expression of proteins in E. coli 
• Column buffer: 20 mM Tris-HCl (pH 7.4), 200 mM NaCl 
 
Maltose binding protein (MBP) - tagged recombinant fusion proteins were expressed in the 
BL-21 chemically competent E.coli strain. Therefore the bacteria were transformed with the 
pMAL-MuRF expression plasmids and streaked on LB-amp agar plates, which were 
incubated overnight at 37°C. A single colony was picked and seeded in 10 ml liquid LB-amp 
medium and shaken over night at 37°C. The next day, 250 ml LB medium with 10mM 
glucose and ampicillin were inoculated with the 10 ml overnight-culture and grown at 37°C 
until an OD600 of 0.5 was reached. Then 0.3 mM Isopropyl β-D-1-Thiogalactopyranoside 
(IPTG) were added to the culture to induce protein expression. Incubation was continued at 
32°C for 2-4 h followed by cell sedimentation for 20 min at 4000 g and 4°C. Aliquots were 
taken before and after IPTG induction to analyze the protein expression via SDS-PAGE and 








 Purification of recombinant proteins 
• Elution buffer: Column buffer and 10 mM Maltose 
 
Cells were thawed and frozen at -80°C in three freeze/thaw cycles before being sonicated 8 
times in short pulses of 15 seconds, and sedimented at 9000 g and 4°C for 20 min. 
Supernatant was transferred to a new pre-cooled tube. Amylose resin (4 ml slurry) was 
prepared for the binding of expressed proteins by washing with column buffer and a short 
centrifugation at 4°C. Supernatant was added to the amylose resin and tubes were incubated 
in an overhead shaker overnight at 4°C. Beads were washed 3 times with 10 ml column 
buffer, and after the third time a syringe with needle size Ø 0.40 x 20 mm was used to remove 
the rest of the buffer entirely. Elution was carried out by adding 2 ml Elution buffer to the 
beads and allowing the mixture to shake gently for 15 min at RT. After a short centrifugation, 
the supernatant with the precipitated recombinant protein was collected and stored at -80°C. 
2.3.8. Mass spectrometric analysis  
Mass spectrometric analyses and processing of data were carried out by Dr. Rick Scavetta 
(AG-Gunnar Dittmar) at the mass spectrometry core facility of Max-Delbrück-Center in 
Berlin, Buch. 
 Preparation of samples  
Samples were resuspended in 100 µl of denaturation buffer [6M urea, 2M thiourea, 10mM 
HEPES (pH=8)]. They were reduced by incubating with 2µl of 10mM tris(2-carboxyethyl) 
phosphine (TCEP) for 45 min at RT, followed by an alkylation step using 2 µl of 55mM 
chloroacetamide for 60 min at RT. The samples were first digested using 0.25 mg/ml 
endopeptidase LysC for 3 hours. The samples were diluted by adding 100 µl of 50mM 
ammonium bicarbonate (pH=8.5). The digestion was stopped by acidifying each sample to 
pH<2.5 by adding 10% trifluoroacetic acid solution. The peptide extracts were purified and 
stored on stage tips according to Rappsilber J.et al. (2003).  
High through-put LC-MS/MS analysis   
After Stage-Tip extraction, the eluted peptides were lyophilized and resuspended in 3% 
trifluoro- acetic acid/5% acetonitrile buffer. Peptides were separated on a Proxeon nLC-II 
system (Thermo Scientific), resolved with a reversed-phase column (15 cm in length, 75 mm 
ID [inner diameter of the fused silica capillary tubing used to make the column], 3 mm Dr. 
Maisch GmbH C18) by a gradient from 4 to 42% B in 240 min. MS and MS/MS spectra were 
analyzed coupled to a QExactive mass spectrometer (Thermo Scientific). The mass 




spectrometer was operated in a data-dependent acquisition mode with dynamic exclusion 
enabled (30 s). Survey scans (mass range 300-1700 Th) were acquired at a resolution of 
70,000 with the twenty most abundant multiply charged (z ≥ 2) ions selected with a 3-Th 
isolation window for HCD fragmentation. MS/MS scans were acquired at a resolution of 
35000 and injection time of 120 ms. 
Processing of mass spectrometry data 
Protein and peptide quantitation information were extracted from MaxQuant 1.2.2.5 (Cox J. et 
al, 2008). Results were filtered to 1% false discovery rate at peptide level by MaxQuant. 
2.4. Cell culture methods 
2.4.1. Cell lines and culturing of cells 
• High-glucose growth medium: DMEM high glucose (4.5 g/l), 10 % (v/v) FBS, 2mM    
L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin. 
• Low-glucose growth medium: DMEM low glucose (1 g/l), 10 % (v/v) FBS, 2mM    
L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin. 
 
C2C12, COS7 and HEK293 cells were grown in sterile T75 cell culture flasks, C2C12 and 
COS7 cells in low glucose, and HEK293 cells in high glucose growth medium. After reaching 
an approx. 80% (C2C12) or 90-100% (COS-7 and HEK293) confluence, cells were 
subcultured by removing the growth medium, briefly washing the cells with 1xPBS and 
incubating the cells in 2.5 ml 1x trypsin/EDTA solution for 2-4 min at 37°C and 5% CO2. 
After detachment from the flask surface, cells were collected using serum containing growth 
medium for inactivation of trypsin. Cell suspension was then transferred into a sterile 15 ml 
tube, and cells were sedimented by centrifugation at 1000 g for 4 min. Cell pellet was 
resuspended in fresh medium and 10-20% of cells were plated into a new T75 flask. All cells 
were incubated at 37°C and 5% CO2 in a sterile and humid atmosphere.  
2.4.2.  Differentiation and atrophy of mouse skeletal muscle cells 
• Differentiation medium: DMEM low glucose (1 g/l), 2 % FBS, 100 U/ml penicillin, 
100 µg/ml streptomycin.  
 
Mouse skeletal muscle C2C12 myoblasts were differentiated into myotubes by using low 
glucose growth medium supplemented with 2% FBS. Cells were plated in 6 well plates 
(approx. 150,000 cells per well) and grown in growth medium and for 24 h before briefly 
washing the cells with 1xPBS and replacing the medium with differentiation medium. Cells 




were differentiated for 5-8 days and differentiation medium was exchanged daily. Skeletal 
muscle atrophy was induced by 10µM Dexamethasone in differentiation medium for 24 h or 
48 h.  
2.4.3. Cryoconservation and thawing of cells  
• Freezing medium: 20% FBS, 10% (v/v) sterile Di-Methyl-Sulfoxide (DMSO) in 
DMEM low glucose (1 g/l) or DMEM high glucose (4.5 g/l) 
 
In order to freeze cells they were trypsinized and harvested from the cell culture flask surface 
(large flask, 75 cm2 surface) as described above. After cells were sedimented the cell pellet 
was resuspended in 4 ml freezing medium. Cell suspension was then quickly aliquoted into 4 
cryoconservation tubes (1 ml each). Tubes were placed immediately in a cryoconservation 
box, which was filled with pre-cooled 2-Propanol. The box was frozen at -80°C for a few 
days, before the cell-containing vials were transferred into liquid nitrogen container for long 
term storage at approx. -196°C.  
 
Thawing of cells was done quickly in a 37°C water bath immediately after taking the vials out 
of the nitrogen tank. Vial content was transferred into a 15 ml tube containing 10 ml of pre-
warmed complete medium. Cell suspension was sedimented at 1000 g for 5 min. The 
supernatant was removed and the cell pellet was resuspended in 10ml complete growth 
medium. Cell suspension was transferred into a sterile T75 cell culture flask, which was 
incubated at 37°C and 5% CO2. 
2.4.4. Transfection of mammalian cells  
• Serum-free medium: DMEM high glucose (4.5 g/l) or DMEM low glucose (1 g/l) 
 
C2C12 cells  
 
Transfection of C2C12 cells was performed using Lipofectamine transfection reagent and 
PLUS reagent according to the manufacturer’s protocol. C2C12 cells were seeded in 6-well 
plates (5x104-105 cells per well) and incubated at 37°C and 5% CO2 for 24 h before 
transfection. Transfection was prepared in two separate vials. In the first vial, 12 μl of PLUS 
reagent were diluted in 100 μl of low glucose serum free medium (SFM) and 2 μg of plasmid 
DNA were added. Contents were mixed and incubated for 15 min at RT. In the second vial, 8 
μl of Lipofectamine transfection reagent were diluted in 800 μl of serum free medium. The 
contents of the two vials were then combined, mixed and incubated for 15 min at RT. Cells 
were washed with 1xPBS and the transfection mix was pipetted dropwise onto the cells. Cells 




were incubated for 3.5 h at 37°C and 5% CO2 before the transfection reaction was stopped by 
adding 2 ml of complete growth medium per well. Cells were incubated for 24 h at 37 °C and 
5% CO2.  
 
 COS7 and HEK293 cells  
 
COS7 and HEK293 cells were transfected using either Fugene6® or Polyethylenimine (PEI)-
transfection reagent according to the manufacturer’s protocol. Cells were seeded in 6-well 
plates (5x104 COS7 cells/well or 3x105 HEK293 cells/well) and incubated at 37°C and 5% 
CO2 for 24 h before transfection. For a transfection using Fugene6®, 6 μl of Fugene6® 
reagent were diluted in 100 μl of SFM and 2 μg of plasmid DNA were added. The 
transfection mix was incubated for 20-30 min at RT. For transfection using PEI-reagent, 
transfection was prepared in two separate vials. In the first vial, 6 μl of PEI-reagent (1 μg/ μl) 
were diluted in 100 μl of SFM, and in the second vial 2 μg of plasmid DNA were also diluted 
in 100 μl of SFM. Both vials were incubated for 5 min at RT, then contents were mixed and 
the transfection mix was incubated for 20-30 min at RT. In both methods, cells were washed 
briefly with 1xPBS and culture growth medium was exchanged before the transfection mix 
was pipetted dropwise onto the cells. Cells were incubated for 24 h at 37 °C and 5% CO2. 
2.4.5. Establishing stably transfected cell lines 
• Selection growth medium: DMEM low glucose (1 g/l), 10 % (v/v) FBS, 2mM L-
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mg/ml Neomycin 
 
C2C12 cells were plated in 6 well plates at a concentration of 5x104 cells per well and 
incubated in growth medium for 24 h at 37°C and 5% CO2. Cells were then transfected with 
one of pcDNA3.1(-)A-MuRF-Myc(His)6 constructs as discussed above (2.4.4.). 24 h after 
transfection growth medium was exchanged with selection medium containing the antibiotic 
neomycin. Because the transfected DNA plasmid contains an aminoglycoside 
phosphotransferase gene (neo gene) as a selectable marker, which confers a neomycin 
resistance, cells expressing the MuRF-protein would exhibit neomycin resistance and 
therefore were expected to survive, whereas those which were not transfected with the neo 
carrying DNA plasmid were expected to die off when the culture was treated with neomycin. 
Selection was maintained for 4-10 days and cells which survived were trypsinized, harvested, 
counted and seeded in 96 well plates in selection medium and at an average of 2-3 cells per 
well. Plates were screened for single cell colonies and those wells were marked. When cells 
reached an 80% confluence, they were harvested and transferred to 24 well plates, then to 6 




well plates and subsequently to cell culture flasks while maintaining selection the whole time. 
To test the stable transfection, DNA and proteins were isolated from the cells and subjected to 
PCR- and western blot analyses, respectively.  
2.4.6. Stable Isotope Labeling by Amino acids in Cell culture (SILAC) 
• SILAC growth medium: SILAC DMEM high glucose (w/o glutamine, lysine and 
arginine), 10% (v/v) dialyzed FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 
2mM L-glutamine, 20 µg/ml arginine, 40 µg/ml normal lysine (lysine0) or 50 µg/ml 
non-radioactive lysine4- or lysine8- isotope. 
At a concentration of 5x104 cells per well, C2C12 cells were plated in 6 well plates in 
complete growth medium for 24 h. Growth medium was then exchanged with SILAC growth 
medium, supplemented with a non-radioactive isotopically labeled form of lysine, lysine4 
(Lys4) or lysine8 (Lys8). Cells were passaged in a 1:4 ratio once every two days as described 
above. In every cell passage, cell pellets were washed and resuspended twice with 1xPBS, 
before they were collected with fresh SILAC medium. After five rounds of cell passaging, the 
incorporation efficiency of lysine4 and lysine8 was tested in MS-analysis as described above. 
After reaching a labeling efficiency of approx. 100%, cells were transferred into sterile T75 
cell culture flasks and grown in SILAC growth medium at 37°C and 5% CO2. 
2.4.7. Cycloheximide chase assays 
For analysis of protein stability, C2C12 cells expressing the respective protein were seeded in 
6 well plates and incubated at 37°C for 24 h. Cells were then incubated in complete  medium 
with cycloheximide (dissolved in DMSO) at a final concentration of 100 µg/ml for 0, 1, 2, 4, 
and 6 hours. Cells were harvested at the different time points of cycloheximide-treatment. 
Proteins were isolated and subjected to SDS PAGE and western blot analysis. 
2.5. Animal experiments 
The following experiments were performed by colleagues at the lab of AG-Fielitz who kindly 
provided RNA and protein samples for respective RT-PCR and western blot analyses shown 
in this study. All animals were kept and treated according to the German animal protection 
law. 




2.5.1. Denervation-induced skeletal muscle atrophy 
Skeletal muscle atrophy was induced by ligation and dissection of the left sciatic nerve of 
adult male C57BL/6N mice at 12 weeks of age, resulting in the disuse of the lower hindlimb 
muscles.  The muscle tissue of the contra-lateral leg and muscle tissue from unaffected mice 
were used as controls. 6 operated mice and 6 sham mice were sacrificed after 7, 14 and 21 
days of denervation. Skeletal muscles M. gastrocnemius/plantaris (GP), M. tibialis anterior 
(TA), M. Extensor digitorum longus (EDL), and M. soleus (Sol) were obtained. Body weight 
and the weight of skeletal muscles were determined. Tibia length was measured and used as a 
reference. A loss of skeletal muscle weights and an up-regulated gene expression of the 
atrophy-related genes Trim63 and Fbxo32 in GP and TA muscles were determined, 
confirming muscular atrophy. RNA and protein samples isolated from GP muscles of 
denervated and sham mice were used in this study.  
2.5.2. Starvation-induced skeletal muscle atrophy 
Male C57BL/6N mice at the age of 6-8 weeks were food deprived for 24 h and 48 h but given 
free access to drinking water. For each time period 6 food deprived mice were sacrificed. 
Male littermate control mice were treated accordingly except that they were not exposed to 
starvation, and they were sacrificed after 0 h, 24 h and 48 h. Skeletal muscles (GP, TA, EDL, 
and Sol), left and right atria, left and right ventricles, and the interventricular septum were 
obtained. Body weight and the weight of skeletal muscles were determined. Tibia length was 
measured and used as a reference. A loss of skeletal muscle weights and an up-regulated gene 
expression of the atrophy-related genes Trim63 and Fbxo32 in GP and TA were determined, 
confirming muscular atrophy. RNA and protein samples isolated from GP muscles of food-
deprived and control mice were used in this study. 
2.6. Fluorescence and confocal microscopy 
Fluorescence microscopy was performed with Leica CTR 6500HS fluorescence microscope, 
using a black-white camera. Confocal microscopy was performed at a Leica SPE confocal 
microscope. Fluorescence and confocal images were analyzed with Leica software LASAF 
2.3.5 build 5379 Version 2010.  





3.1. Detection of novel interaction partners for MuRF1, 2 and 3 using 
SILAC-AP-MS  
3.1.1. Cloning and over-expression of MuRF1, MuRF2, and MuRF3 and 
SILAC labeling of cells 
The coding sequences of MuRF1, 2, and 3 - proteins were amplified from mouse muscle 
cDNA using polymerase chain reactions (PCRs) and cloned into the expression plasmid 
pcDNA3.1(-)A-Myc(His)6, which carries sequences encoding C-terminal hexahistidine- and 
Myc-tags resulting in MuRF1-Myc(His)6, MuRF2-Myc(His)6, and MuRF3-Myc(His)6 cDNA 
expression plasmids. To test the expression of these cDNA expression plasmids, COS7 cells 
were transfected with either one of these constructs, proteins were isolated from cell-lysates 
and a western blot analysis was carried out. Lysates from cells transfected with pcDNA3.1(-) 
A-Myc(His)6 were used as control. Specific antibodies against the His- and Myc-tag were 
used for detection of the fusion proteins (Fig. 5). MuRF1 and MuRF3 were both detected at 
43kDa, whereas full length MuRF2 was detected at 80kDa. While the band size of MuRF1 
and MuRF3 corresponded with the predicted size of the proteins, the detected band of MuRF2 
was larger than the predicted size of the protein which is 60kDa. This could be due to 
posttranslational modifications or the relative charge of the protein. Furthermore, another 
smaller yet to be described MuRF2 isoform was also discovered and was detected at 60kDa in 
western blot analyses. The sequence of this MuRF2-isoform showed that it lacked exon 9, 
compared with the sequence encoding the full length MuRF2-protein. It was therefore called 
MuRF2∆ex9 (Fig. 5).  
 
Figure 5: Testing the expression of MuRF-myc(His)6 in COS7 cells. COS7 cells were transfected with 
MuRF1-Myc(His)6, MuRF2-Myc(His)6, MuRF2∆ex9-Myc(His)6 or MuRF3-Myc(His)6. Western blot analysis 
was carried out to detect the overexpressed proteins. Anti-His- (left) or anti-myc- antibodies (right) were used for 
detection. MuRF1 and MuRF3 were detected as predicted at 43kDa. Full length MuRF2 was detected at 80kDa 
and MuRF2∆ex9, a novel MuRF2 isoform, was detected at 60kDa.  




3.1.2. SILAC- labeling of mouse skeletal muscle cells  
This study was carried out in two screens to identify novel interaction partners of MuRF1, 
MuRF2 and MuRF3. These experiments were based on the method of stable isotope labeling 
of amino acids in cell culture (SILAC), coupled with affinity purification assays and mass 
spectrometric analyses (SILAC-AP-MS). Cells used for these assays were mouse skeletal 
muscle cells (C2C12). These cells were used for establishing cell lines stably expressing 
MuRF2-Myc(His)6 as well as the transient transfection of MuRF1-Myc(His)6, MuRF2-
Myc(His)6, and MuRF3-Myc(His)6. 
For SILAC labeling, three different C2C12 cell lines, carrying different isotope-labeling, were 
established. While Lysine0-cells carried the normal (so-called light, Lys0) lysine, two other 
cell lines were grown in media lacking this standard essential amino acid but supplemented 
with a non-radioactive, isotopically labeled form of lysine, in this case the medium Lysine4 
(Lys4) or the heavy Lysine8 (Lys8), respectively. To ensure sufficient isotope labeling, 
C2C12 cells were cultivated in isotope-containing medium for at least 5 passages before their 
labeling efficiency was tested in mass spectrometric analysis. All labeling tests showed at 
least 97% labeling efficiency, which means that at least 97% of lysines in these cells have 
been replaced by either Lysine4 or Lysine8 (Fig. 6). 
                        
Figure 6: Labeling-efficiency test of Lys4- and Lys8- cell lines. In mass spectrometric analysis the 
incorporation rate of Lysine4 and lysine8 in C2C12 cells was tested. In both cell lines at least 97% of normal 
lysines were replaced by the medium or heavy isotopes. 




To test the stability of overexpressed MuRF-proteins in C2C12 cells, their expression was 
detected in western blot analysis 24 h, 48 h and 72 h after transfection. All MuRF-proteins 
were detectable after 24 h and 48 h but not 72 h after transfection. MuRF2 was also not 
detectable in stably transfected C2C12 cells, although it could be shown in PCR- and RT-
PCR-analyses that MuRF2-DNA was integrated in the cell genome. It was therefore assumed, 
that MuRF1, MuRF2 and MuRF3 get degraded if they are continuously and/or increasingly 
overexpressed. Therefore, the proteasome inhibitor MG132 was used to prevent degradation 
of MuRF-proteins. When C2C12 cells stably expressing MuRF2-Myc(His)6 were treated with 
10µM MG132 for different time points, MuRF2 was detectable after 6 h of treatment (Fig. 7).  
         
                
Figure 7: Stabilizing MuRF2-expression using the proteasome inhibitor MG132. MuRF2-stably transfected 
C2C12 cell line was treated with the proteasome inhibitor MG132 (10µM) for different time points as indicated. 
Cell lysates were subjected to western blot analysis using anti-Myc antibody for the detection of MuRF2. 
Expression of MuRF2 was recovered after at least 6 hours of MG132 incubation.  
 
3.1.3. Detection of MuRF1, 2, or 3- interaction partners in C2C12 myoblasts 
For identification of MuRF interaction partners in C2C12 myoblasts, the first screen was 
performed, in which up- or down-regulation of proteins in relation to MuRF-protein 
overexpression was investigated (Fig. 8). In this assay Lys0-C2C12 cells were transiently 
transfected with MuRF1-Myc(His)6, MuRF2-Myc(His)6, or MuRF3-Myc(His)6, whereas 
Lys4-C2C12 cells were mock-transfected with control pcDNA3.1(-)A-Myc(His)6. A Lys4- 
labeled stable cell line containing pcDNA3.1(-)A-Myc(His)6 served as a control for the Lys0-
labeled MuRF2-Myc(His)6 stable cell line. Transiently transfected cells were lysed 24 h after 
transfection and cell lysates were subjected to protein affinity purification (Nickel pull down 
assays). Stably transfected cells were treated with 10µM MG132 for 8 h before cell lysis. 
Nickel sepharose was used for purification of His-tagged proteins. Elution was performed 
with EDTA and eluates of Lys0 and Lys4 labeled cells were mixed and analyzed by MS. The 
abundance ratio of the same protein in Lys0 and Lys4 (Lys0/Lys4) labeled cells for an 
overexpressed MuRF-protein led to the identification of putative interaction partners of this 
MuRF-protein. Presumably, a protein which was enriched in Lys0-MuRF-overexpressing 




cells compared to Lys4-mock-transfected cells was considered a putative interaction partner 
of this particular MuRF-protein (Fig. 8). 
            
Figure 8: Scheme of experiment for identifying MuRF- interaction partners in C2C12 myoblasts. C2C12 
myoblasts were SILAC-labeled, using the isotopes Lys0 (light) or Lys4 (medium). Lys4 myoblasts were stably 
or transiently mock-transfected with an empty expression plasmid and served as control, whereas Lys0 
myoblasts were stably or transiently transfected with one of the MuRF-Myc(His)6 - constructs. 24 hours after 
transfection, cells were either lysed (transient transfection), or incubated for 8 hours in MG132 before lysis 
(stable transfection). Cell lysates were subjected to affinity purification assays using His-Sepharose (Nickel pull 
downs). Eluates were analyzed in mass spectrometric analyses. 
 
Analysis of mass spectrometric data revealed over 6% of proteins which were significantly 
either up- or down-regulated in myoblasts overexpressing a MuRF-protein in comparison with 
the control. Several of these proteins detected in myoblasts overexpressing MuRF1, MuRF2 
or MuRF3 are shown in tables 13, 14 and 15, respectively. One of the interesting proteins 
detected was the mammalian retromer component sorting nexin 5 (SNX5). SNX5 exhibited a 
1.9 fold up-regulation in MuRF3-overexpressing myoblasts, and was particularly interesting 
because of the diversity of its roles in different cellular processes and pathways.   




Table 13: Mass spectrometric data of proteins with a significant abundance difference in myoblasts 
overexpressing MuRF1 compared with the control. A total of 1865 proteins were detected in this screen, of 
which 123 were proteins whose abundance has significantly changed as a result of MuRF1-overexpression, 
which make approx. 6.6%. 70 proteins were significantly up-regulated and 53 proteins were significantly down-
regulated. Significance was set to p-value < 0.05 (according to Benjamini-Hochberg False Discovery Rate). 
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Table 14: Mass spectrometric data of proteins with a significant abundance difference in myoblasts 
overexpressing MuRF2 compared with the control. A total of 2030 proteins were detected in this screen, of 
which 124 were proteins whose abundance has significantly changed as a result of MuRF2-overexpression, 
which make approx. 6.1%. 65 proteins were significantly up-regulated and 59 proteins were significantly down-
regulated. Significance was set to p-value < 0.05 (according to Benjamini-Hochberg False Discovery Rate). 












    




















Sorting nexin 8 1.9 0,00721413 
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Table 15: Mass spectrometric data of proteins with a significant abundance difference in myoblasts 
overexpressing MuRF3 compared with the control. A total of 2177 proteins were detected in this screen, of 
which 135 were proteins whose abundance has significantly changed as a result of MuRF3-overexpression, 
which make 6.2%. 85 proteins were significantly up-regulated and 50 proteins were significantly down-
regulated. Significance was set to p-value < 0.05 (according to Benjamini-Hochberg False Discovery Rate). 












    
























































































































    






















































Ubiquitin E3 ligase RNF25 
 
 































      
 
3.1.4. Detection of MuRF1, 2, or 3- interaction partners during skeletal 
muscle differentiation and atrophy 
To identify putative interaction partners and targets for MuRF1, MuRF2 or MuRF3 during 
myocyte differentiation or atrophy of myotubes, an assay specifically addressing these 
processes was performed. Figure 9 shows a schematic illustration and timeline of this 
experiment. Three C2C12 cell lines with different isotope labeling were used.  Lys0-cells 
were left as myoblasts (MBs). Lys4-labeled cells were differentiated for 5 days (MTs), and 
Lys8-labeled cells were differentiated and subjected to atrophy for 24 h using dexamethasone. 
All three differently labeled cell lines were transfected with MuRF1-Myc(His)6, MuRF2-
Myc(His)6, and MuRF3-Myc(His)6, respectively, at the blast stage. Lys0-cells were lysed 24 h 
after transfection. Lys4-labeled cells were treated with MG132 for 8 h after differentiation 
and then lysed. Lys8-labeled cells were treated with MG132 for 8 h after they were 
differentiated and subjected to atrophy and afterwards lysed. After treatment with MG132 and 
cell lysis, overexpressed MuRF-proteins were affinity purified in Nickel-pull down assays. 
Elution was carried out several times using EDTA and eluates were analyzed by western blot 
to identify the precipitated MuRF-protein (Fig. 10). Same procedure was carried out with 
labeled MuRF2-stably transfected cell lines (Fig. 11). Elution-samples from cell lines with 
three different labels (MBs, MTs and MTAs), but overexpressing the same MuRF-protein, 
were then collected, mixed and analyzed by MS (Fig. 9). Three biological replicates of each 
of these assays were carried out and separately analyzed. In a mass spectrometric analysis, the 
abundance difference of the same protein in the different cell populations (with different 
isotope labeling) was measured, which provided important information about the probable 
enrichment or down-regulation of this protein in two different cell conditions, in this case 
during myocyte differentiation (Lys4/Lys0) or atrophy of myotubes (Lys8/Lys4).  





Figure 9: Scheme of the experiment for the detection of MuRF- interaction partners during skeletal 
muscle - differentiation and - atrophy. C2C12 cells were SILAC-labeled using the isotopes Lys0 (light), Lys4 
(medium) or Lys8 (heavy). Cells were either stably or transiently transfected with one of the MuRF-Myc(His)6 -
constructs. Lys0 cells were lysed 24 hours after transfection as myoblasts and served as a control and starting 
condition for differentiation and/or atrophy. Lys4 cells were differentiated for 5 days using DMEM containing 
2% dFBS. Cells were then incubated in MG132 (10µM) for 8 hours before they were lysed. Lys8 cells were also 
differentiated for 5 days and atrophied for 24 hours using 10 µM Dexamethasone before lysis. All cell lysates 
were subjected to affinity purification assays using Ni-Sepharose (Nickel pull downs). Eluates were analyzed in 
mass spectrometric analyses. 





Figure 10: Western blot analysis of MuRF-protein affinity purification assays. MuRF1-Myc(His)6, MuRF2-
Myc(His)6 or MuRF3-Myc(His)6 were transiently expressed in C2C12 cells. Cell lysates were subjected to Ni - 
Sepharose in affinity purification assays and the bound proteins were eluted in three elution steps using EDTA. 
Purified, overexpressed MuRF1 (A), MuRF2 (B), and MuRF3 (C) were detected in western blot analyses using 
anti-His antibody. MB= myoblasts, MT= myotubes, MTA= atrophied myotubes, S= supernatant, E1, E2, E3= 
Elution steps 1, 2 and 3, respectively. B= beads.                                 
                              
Figure 11: Western blot analysis of protein affinity purification assays for stably expressed MuRF2. 
MuRF2-Myc(His)6 was stably expressed in C2C12 cells. Cell lysates were subjected to Ni - Sepharose in an 
affinity purification assay and the bound proteins were eluted in four elution steps using EDTA. Purified, 
overexpressed MuRF2 was detected in western blot analysis using anti His antibody. MB= myoblasts, MT= 
myotubes, MTA= atrophied myotubes, S= supernatant, E1, E2, E3, E4= Elution steps 1, 2, 3 and 4, respectively. 
B= beads. 
A summary of most interesting proteins showing a significant abundance change in cells 
overexpressing MuRF1, MuRF2 or MuRF3 during differentiation and atrophy can be found in 
Tables 1-6 (Appendix). The distribution of these proteins was schematically illustrated in 
figures 1-3 (Appendix). 




3.2. Endogenous expression of SNX5  
3.2.1. Endogenous expression of SNX5 in mouse tissues 
SNX5 expression in skeletal and heart muscle tissues was investigated in qRT-PCRs and 
western blot analyses. For this purpose, RNA and proteins were isolated from four different 
mouse skeletal muscle tissues; M. gastrocnemius plantaris (GP), M. tibialis anterior (TA), M. 
extensor digitorum longus (EDL) and M. soleus (Sol), as well as the left and right atrium and 
left and right ventricle. Results of qRT-PCR showed Snx5 mRNA expression in all four 
skeletal muscles and both atria and ventricles of the heart. Snx5 expression was much higher 
in the heart compared to skeletal muscle tissues (Fig. 12, A). Western blot analyses using 
specific antibodies against MuRF2, MuRF3 and SNX5 were carried out. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used as loading control. SNX5 was expressed in all 
four skeletal muscles, and the left and right ventricles. No significant difference in Snx5 
mRNA expression or SNX5 protein content among the different skeletal muscle types was 
observed (Fig. 12, A).    
                                                                            
 
Figure 12: SNX5 endogenous expression pattern in mouse tissues. Western blot analyses were carried out 
using protein samples isolated from different skeletal- and heart- muscle tissues (A, left), and from different 
mouse organs (B, left). SNX5 was detected using a specific anti SNX5 antibody. GAPDH was used as loading 
control. Quantitative real-time-PCR-analyses of Snx5 expression in skeletal- and heart- muscle tissues (A, right), 




and in different mouse organs (B, right), were also carried out. Data are presented as mean ± SEM. 
GP=Gastrocnemius-plantaris, TA=Tibialis-anterior, EDL=Extensor digitorum longus, Sol=Soleus, RA=right 
atrium, LA=left atrium, RV=right ventricle, LV=left ventricle. 
RNA and proteins were also isolated from different mouse organs. Snx5 mRNA expression 
and protein content were detected in qRT-PCR and western blot analysis, respectively. 
Interestingly, qRT-PCR data showed an especially high expression in the pancreas, lung and 
spleen, while western blot results showed a ubiquitous SNX5 protein expression (Fig. 12, B).      
3.2.2. SNX5 expression during myocyte differentiation and atrophy of 
myotubes 
SNX5 expression during C2C12 myocyte differentiation and atrophy of myotubes was 
examined. C2C12 cells were differentiated for 1 to 8 days (Fig. 13, A and B). Myotubes were 
subjected to atrophy for 1 or 2 days by using dexamethasone (Fig. 13, A and C). Western blot 
analysis using specific antibodies against SNX5, myogenin (differentiation marker) and 
MHC-slow was performed, and showed that neither differentiation nor atrophy of C2C12 
cells had an effect on SNX5 expression (Fig. 13, A). 
                    
    
Figure 13: Differentiation and atrophy of skeletal muscle cells does not affect the endogenous expression 
of SNX5. C2C12 cells were differentiated with DMEM-medium containing 2%FBS. Atrophy was induced using 
10µM Dexamethasone for 24 or 48 hours. Cell samples were collected every day and analyzed in western blot. 




Specific antibodies against SNX5, slow-twitch MHC (NOQ7) and myogenin were used for detection. GAPDH 
was used as loading control (A). Light microscopy images show differentiated C2C12 cells (7 days) (B) and 
atrophied C2C12 myotubes (48 h) (C). Scale bar, 50µm.  
3.2.3. Subcellular localization of SNX5 in myoblasts 
Immunocytochemistry was used to examine the subcellular expression of endogenous SNX5 
in C2C12 myocytes. Cells were fixed and stained with a specific anti-SNX5 antibody. A 
perinuclear and cytosolic staining pattern was observed for SNX5, which has not been 
described in muscle cells, thus far (Fig. 14). 
 
Figure 14: SNX5 endogenous expression pattern in C2C12 myoblasts. C2C12 cells were plated onto glass 
coverslips for 24 hours, then fixed and stained with a specific anti-SNX5 antibody, and an Alexa555 coupled 
secondary antibody. Nuclei were stained with DAPI. Scale bar, 25 µm.  
 
Immunofluorescence staining was performed to investigate the subcellular localization of 
SNX5 to early and late endosomes and lysosomes. Early endosome antigen 1 marker (EEA1) 
was used for EE staining, and lysosomal-asssociated membrane protein 1 marker (LAMP1) 
was used for the staining of LEs and lysosomes. COS7 cells were fixed and stained with anti-
SNX5 and EEA1 marker (Fig. 15, A), or anti-SNX5 and LAMP1 marker (Fig. 15, B). SNX5 
co-localized with EEA1 but not LAMP1, indicative to its localization to EEs and not to LEs 
and lysosomes (Fig. 15). 





Figure 15: SNX5 localizes to early endosomes and does not localize to late endosomes and lysosomes. 
COS7 cells were plated onto glass coverslips for 24 h before they were fixed and stained using specific 
antibodies against SNX5 and EEA1 (A) or SNX5 and LAMP1 (B), and fluorophore – conjugated secondary 
antibodies Alexa488 (green) and Alexa555 (red). Nuclei were stained with DAPI. Scale bar, 25 µm. 
 
3.3. Identification of SNX5 as a MuRF3 interaction partner 
3.3.1. SNX5 interacts physically with MuRF3  
To investigate a possible physical interaction between SNX5 and MuRF-proteins, co-
immunoprecipitation assays were carried out after co-expressing SNX5-FLAG with one of the 
three MuRF-Myc(His)6 in HEK293 cells. Anti-FLAG-coupled agarose was used for 
immunoprecipitation of SNX5, and anti-Myc antibody was used for detection of MuRF-
Myc(His)6 proteins in the precipitates (Fig. 16). As positive controls for the co-
immunoprecipitation, the known interactions between MuRF2-Myc(His)6 and MuRF1-FLAG 
and between Histone Deacetylase 5 (HDAC5-Myc) and protein kinase D2 (PKD2-FLAG) 
were used. MuRF3 co-immunoprecipitated with SNX5 verifying their physical interaction. 
Because MuRF1 was also detected in the SNX5-precipitate, it might also interact with SNX5. 
An interaction between SNX5 and MuRF2 was not detectable (Fig. 16). 




             
Figure 16: SNX5 physically interacts with MuRF3 in Co-Immunoprecipitation-assays. HEK293 cells were 
co-transfected with expression plasmids encoding either one of the MuRF-Myc(His)6 - proteins and SNX5-
FLAG or empty FLAG-vector. As positive control HEK293 cells were co-transfected with MuRF1-FLAG and 
MuRF2-Myc(His)6, or HDAC5-Myc and PKD2-FLAG. Inputs (make up 5% of total cell lysates) were analyzed 
by Immunoblotting (IB), using anti-Myc and anti-FLAG antibodies, and are shown in the upper and middle 
panels, respectively. Immunoprecipitates (IP) were analyzed using anti-Myc antibody and are shown in the lower 
panel.  
3.3.2. SNX5 co-localizes with MuRF3 in myocytes 
To provide further evidence for the interaction between SNX5 and MuRF3, 
immunofluorescence staining was performed to show possible co-localization. MuRF3-
Myc(His)6 and SNX5-FLAG were overexpressed in C2C12 cells. Cells were fixed and stained 
with either anti-Myc antibody or anti-FLAG antibody. SNX5 showed a perinuclear and 
cytosolic staining, whereas MuRF3 showed its typical microtubule-like staining pattern, 




where fine threads or filament-like structures radiate from the perinuclear region into the 
cytoplasm (Fig. 17; Spencer J.A. et al., 2000). 
 
Figure 17: Immunostaining of overexpressed MuRF3 and SNX5 in C2C12 myoblasts. C2C12 cells were 
plated onto glass coverslips for 24 h before they were transfected either with SNX5-FLAG (right image) or 
MuRF3-Myc(His)6 (left image). Cells were fixed and stained using specific primary antibodies (anti-FLAG and 
anti-Myc), and fluorophore - conjugated secondary antibodies (Alexa555, red and Alexa488, green). Nuclei were 
stained with DAPI. Scale bar, 25 µm. 
 
MuRF3-Myc(His)6 and SNX5-FLAG were co-expressed in C2C12 cells for 24 h and stained 
using anti-Myc and anti-FLAG antibodies. Images showed a co-localization of MuRF3 and 
SNX5 (Fig. 18). While MuRF3 showed its typical microtubule-like staining pattern, SNX5 
changed its subcellular localization and was co-localized with MuRF3, and therefore 












Figure 18: SNX5 co-localizes with MuRF3 in C2C12 myoblasts. C2C12 cells were plated onto glass 
coverslips for 24 h before they were co-transfected with SNX5-FLAG and MuRF3-Myc(His)6. Cells were fixed 
and stained using specific primary antibodies (anti-FLAG and anti-Myc), and fluorophore - conjugated 
secondary antibodies (Alexa555, red and Alexa488, green). Nuclei were stained with DAPI. 
Immunofluorescence microscopy was performed using 63X objective on a Leica SPE confocal microscope. 
 
Immunofluorescence staining was also performed to investigate the effect of MuRF3-
overexpression on the subcellular localization of endogenous SNX5. MuRF3-Myc(His)6 was 
overexpressed in C2C12 cells which were stained with anti-Myc and anti-SNX5 antibody. 
Endogenous SNX5 co-localized with MuRF3 (Fig. 19). 
  





Figure 19: MuRF3 co-localizes with endogenous SNX5. C2C12 cells were transfected with MuRF3-
Myc(His)6. Cells were fixed and stained using specific primary antibodies (anti-SNX5 and anti-Myc), and 
fluorophore - conjugated secondary antibodies (Alexa555, red and Alexa488, green). Nuclei were stained with 
DAPI. Scale bar, 25 µm. 
 
3.3.3. MuRF3 and SNX5 co-localize and associate with early endosomes 
SNX5 predominantly localizes to the membrane of early endosomes (Teasdale R.D. et al., 
2001; Merino-Trigo A. et al., 2004; Sun Y. et al., 2013). This could also be shown in this 
study for endogenous SNX5 (Fig. 15). To show if this was also the case for overexpressed 
SNX5, SNX5-FLAG was overexpressed in COS7 cells, which were stained with anti-FLAG 
and anti-EEA1 or with anti-FLAG and anti-LAMP1. Overexpressed SNX5 co-localized with 
EEA1 (Fig. 20 A, upper panel) but not with LAMP1 (Fig. 20 A, lower panel), indicative to its 
localization to early endosomes and not to late endosomes or lysosomes. 
To investigate the association of MuRF3 with early and late endosomes and lysosomes, 
MuRF3-cherry (MuRF3 was expressed in pmCherry-N1 expression plasmid, also expressing 
a red fluorescence protein) was overexpressed in COS7 cells. Cells were stained with either 
anti-EEA1 or anti-LAMP1. MuRF3 showed its typical microtubule-like structure, where 
microtubules radiate out of a perinuclear region, the microtubule organizing center (MTOC), 
where LAMP1, thus most late endosomes and lysosomes are located (Fig. 20 B, lower panel). 
EEA1 co-localized partially with MuRF3, indicating that early endosomes, which are 
predominantly located in the cell periphery, are localized to microtubules and thus to MuRF3 
(Fig. 20 B, upper panel). 




Having shown that SNX5 and MuRF3 co-localize, the logical next step was to analyze their 
association with early endosomes in a triple immunostaining experiment of MuRF3, SNX5 
and EEA1. SNX5-FLAG and MuRF3-cherry were co-expressed in COS7 cells, which were 
stained with anti-FLAG and anti-EEA1. While MuRF3-cherry carried the red-colored 
fluorescence marker, a green and a blue fluorophore conjugated secondary antibodies were 
used for the detection of SNX5 and EEA1, respectively (Fig. 20, C). MuRF3 and SNX5 co-
localized and showed the microtubule-like staining pattern. EEA1 staining showed cytosolic, 
mostly peripheral distribution, partially along the microtubule-like structures, indicative of a 
partial localization of early endosomes to MuRF3 and SNX5 (Fig. 20, C). 
 






Figure 20: MuRF3 and SNX5 interaction and association with early endosomes. (A) SNX5-FLAG was 
overexpressed in COS7 for 24 h before they were fixed and stained with anti-FLAG and anti-EEA1 or anti-
FLAG and anti-LAMP1. Fluorophore conjugated secondary antibodies Alexa488 (green) and Alexa555 (red) 
were used. Nuclei were stained with DAPI. (B) MuRF3cherry was overexpressed in COS7 cells for 24 h before 
they were fixed and stained with anti-EEA1 or anti-LAMP1. Fluorophore conjugated secondary antibody 
Alexa488 (green) was used. Nuclei were stained with DAPI. (C) Triple staining of COS7 cells, in which SNX5-
FLAG and MuRF3cherry were co-expressed for 24 h before they were fixed and stained with anti-FLAG and 
anti-EEA1. Fluorophore conjugated secondary antibodies Alexa488 (green) and Alexa647 (blue) were used. 
Nuclei were stained with DAPI (grey). Images were obtained at a Leica SPE confocal microscope. Scale bar, 25 
µm. 
 




3.3.4. Mapping the interaction domains of SNX5 and MuRF3  
For the characterization of the interaction between MuRF3 and SNX5, mapping analyses of 
the interaction domains of both proteins were carried out. In order to determine the interaction 
domain of MuRF3, its cDNA was cloned into pcDNA3.1(+)-FLAG expression plasmid and 
deletion mutants, which spanned the full length of MuRF3, were generated. In these deletion 
mutants the different functionally important domains of MuRF3 were partially or completely 
deleted (Fig. 21 A). While the deletion mutant MuRF3aa1-81 included only the RING-finger 
domain and part of the MuRF-family conserved domain, MuRF3aa1-277 deletion mutant 
lacked the C-terminal acidic rich region and MuRF3aa203-277 only contained the second 
coiled coil domain (Fig. 21 A). Co-immunoprecipitation assays were carried out after 
overexpressing wild type SNX5 with either wild type MuRF3 or one of the MuRF3 deletion 
mutants in HEK293 cells. The expression of the deletion mutants lacking MuRF3 C-terminus 
was not detectable in western blot. The expression of MuRF3aa1-81, MuRF3aa82-117, 
MuRF3aa118-159, MuRF3aa160-202, MuRF3aa203-277, as well as MuRF3aa278-267 could 
not be detected due to their small size (Fig. 21, B). Deletion mutants including either one of 
the two MuRF3 coiled coil domains; MuRF3aa1-202, MuRF3aa1-277, MuRF3aa118-367, 
MuRF3aa160-367, MuRF3aa203-367, as well as MuRF3aa160-202, which only included the 
first coiled coil domain and none of the other domains, were all found to interact with SNX5, 
indicating that MuRF3-coiled coil domains mediated the interaction. In addition, deletion 
mutant MuRF3aa1-159 interacted with SNX5 as well although it only contained an 18 aa 
residue of the first coiled coil domain in addition to the RING-finger domain, the MuRF-
family conserved (MFC)-domain and the B-Box. Deletion mutant MuRF3aa82-367 which 
contained both coiled coil domains did not interact with SNX5 (Fig. 21 B).  






Figure 21: Mapping the interaction between MuRF3-deletion mutants and wild type SNX5. (A) A 
schematic diagram of MuRF3-domain organization and the different deletion mutants used in co-
immunoprecipitation assays for determining the MuRF3-interaction domain. (B) HEK293 cells were co-
transfected with expression plasmids encoding wild type SNX5-Myc(His)6 and either one of the MuRF3-FLAG 
deletion mutants or empty FLAG-vector. Wild type MuRF3 was used as positive control. Inputs (make up 5% of 
total cell lysates) were analyzed by Immunoblotting (IB), using anti-Myc and anti-FLAG antibodies, and are 
shown in the upper and middle panels, respectively. Immunoprecipitates (IP) were analyzed using anti-Myc 
antibody and are shown in the lower panel. Red asterisks show the precipitates in which SNX5 was co-
immunoprecipitated with the MuRF3-deletion mutant. MFC=MuRF-family conserved domain, CC1=coiled coil 
domain 1, CC2=coiled coil domain 2, ARR=acidic rich region. 




For a more accurate characterization of the MuRF3-interaction domain, three additional 
deletion mutants of MuRF3 were generated in which either the first (MuRF3∆aa141-186), the 
second (MuRF3∆aa227-262), or both coiled coil domains (MuRF3∆aa141-262), were deleted. 
A schematic diagram of these deletion mutants is shown in Fig. 22 A. Co-
immunoprecipitation assays were carried out to examine the interaction of these deletion 
mutants with wild type SNX5. Results showed a very weak interaction compared to the 
interaction between SNX5 and wild type MuRF3, confirming that the MuRF3 coiled coil 
domains are responsible for the interaction (Fig. 22, B).     
  
                        
Figure 22: Mapping of the interaction between MuRF3-coiled-coil domain-deletion mutants and wild type 
SNX5. (A) A schematic diagram of MuRF3 coiled coil-domain deletion mutants. (B) HEK293 cells were co-
transfected with expression plasmids encoding wild type SNX5-Myc(His)6 and one of the three MuRF3-FLAG 
coiled coil domain deletion mutants or empty Flag-vector. Wild type MuRF3 was used as positive control. Inputs 
(make up 5% of total cell lysates) were analyzed by Immunoblotting (IB), using anti-Myc and anti-FLAG 




antibodies, and are shown in the upper and middle panels, respectively. Immunoprecipitates (IP) were analyzed 
using anti-Myc antibody and are shown in the lower panel. SNX5 was co-immunoprecipitated with all three 
MuRF3-deletion mutants. MFC=MuRF-family conserved domain, CC1=coiled coil domain 1, CC2=coiled coil 
domain 2, ARR=acidic rich region.  
 
To determine which domain of SNX5 is responsible for its interaction with MuRF3, five 
different deletion mutants were generated (Fig. 23, A). SNX5-PX deletion mutant lacked the 
BAR domain, SNX5-BAR lacked the Phox domain and SNX5∆aa206-256, SNX5∆aa262-327 
and SNX5∆aa344-397 had deletions in the first, second or third coiled coil domain (CCD) of 
the BAR-domain, respectively (Fig. 23, A). SNX5-FLAG deletion mutants were 
overexpressed with wild type MuRF3-Myc(His)6 in HEK293 cells and co-
immunoprecipitation assays were carried out. Results showed that the BAR domain of SNX5 
mediated its interaction with MuRF3. Also, deleting one of the three CCDs composing the 
BAR domain did not affect the interaction, although the first and the third CCDs might be 
more essential for the interaction, since it was weaker when either one was deleted. SNX5-
Phox-domain did not mediate MuRF3- interaction (Fig. 23, B).  
 
                     
           




                         
Figure 23: Mapping of the interaction between SNX5-deletion mutants and wild type MuRF3. (A) 
Schematic diagram of five SNX5 deletion mutants which were generated to determine the accurate interaction 
domain of SNX5. (B) Co-immunoprecipitation assays were performed after co-transfection of HEK293 with 
expression plasmids encoding wild type MuRF3-Myc(His)6 and either one of the five SNX5-FLAG deletion 
mutants or the empty Flag-vector. Wild type SNX5 was used as positive control. Inputs (make up 5% of total 
cell lysates) were analyzed by Immunoblotting (IB), using anti-Myc and anti-FLAG antibodies, and are shown in 
the upper and middle panels, respectively. Immunoprecipitates (IP) were analyzed using anti-Myc antibody and 
are shown in the lower panel. MuRF3 was only co-immunoprecipitated with SNX5-BAR domain, or SNX5-
BAR domain lacking one of its CCDs, but not with SNX5-PX-domain. SNX5-PX=SNX5-Phox homology 
domain. CCD=coiled coil domain. 
 
These results were confirmed in immunofluorescence assays. Wild type MuRF3-Myc(His)6 
and either wild type SNX5-FLAG or one of its deletion mutants were co-expressed in C2C12 
cells, which were stained with anti-Myc and anti-FLAG. SNX5-BAR domain co-localized 
with MuRF3, whereas no co-localization was observed between SNX5-PX and MuRF3 (Fig. 
24). The BAR-domain deletion mutants, with each lacking one of the three CCDs, also co-
localized with MuRF3, confirming results of co-immunoprecipitation assays (Fig. 25). 
 







Figure 24: MuRF3 co-localized with SNX5-BAR-domain and not SNX5-PX-domain. C2C12 cells were 
plated onto glass coverslips for 24 h before they were co-transfected with either SNX5-BAR-FLAG or SNX5-
PX-FLAG (red) and MuRF3-Myc(His)6 (green). Cells were fixed and stained using specific primary antibodies 
(anti-FLAG and anti-Myc), and fluorophore - conjugated secondary antibodies (Alexa555, red and Alexa488, 
green). Nuclei were stained with DAPI. Immunofluorescence microscopy was performed using 63X objective on 















Figure 25: MuRF3 co-localized with all three SNX5-BAR-domain deletion mutants. C2C12 cells were co-
transfected with either one of the three SNX5-BAR-FLAG deletion mutants (red), each lacking one of the three 
CCDs of the BAR domain, and MuRF3-Myc(His)6 (green). Cells were fixed and stained using specific primary 
antibodies (anti-FLAG and anti-Myc), and fluorophore - conjugated secondary antibodies (Alexa555, red and 
Alexa488, green). Nuclei were stained with DAPI. Immunofluorescence microscopy was performed using 63X 
objective on a Leica SPE confocal microscope. 




3.4. SNX5 is a target protein of MuRF2 
3.4.1. MuRF2-overexpression causes SNX5 depletion in C2C12 cells  
Once co-expressed with MuRF2, SNX5 expression decreased. This observation was made 
repeatedly in several expression tests, leading to the assumption that SNX5 was a putative 
MuRF2 substrate. To further investigate this, expression assays were carried out, in which 
C2C12 cells were co-transfected with increasing amounts of MuRF2-Myc(His)6 or MuRF3-
Myc(His)6 and a constant amount of SNX5-FLAG. Western blot analysis, using anti-Myc and 
anti-FLAG antibodies showed a decrease in SNX5 expression the more MuRF2-Myc(His)6 
was expressed. On the other hand, increasing amounts of MuRF3 had no effect on SNX5 (Fig. 
26, A). Because the RING finger domain of MuRF-proteins mediates their E3 ligase activity 
(Lorick K.L. et al., 1999; Joazeiro C.A. and Weissman A.M., 2000; Spencer J.A. et al., 2000), 
two of the four functionally essential cysteine residues in the MuRF2 RING-finger domain 
(cysteines 42 and 50) were mutated to serine residues through site directed mutagenesis, 
generating the E3 ligase deficient MuRF2-[(C42S; C50S)]. In another expression assay, 
increasing amounts of MuRF2-[(C42S; C50S)]-Myc(His)6 and a constant amount of SNX5-
FLAG were co-transfected in C2C12 cells. Western blot analysis, using anti-Myc and anti-
FLAG antibodies showed that increasing expression of E3 ligase deficient MuRF2 did not 
affect SNX5 expression, indicating that SNX5 was subjected to MuRF2-mediated degradation 
(Fig. 26, B).  
                  




                         
Figure 26: SNX5 is a target of MuRF2 and not MuRF3. (A) C2C12 cells were co-transfected with increasing 
amounts of MuRF2-Myc(His)6 or MuRF3-Myc(His)6 and a constant amount of SNX5-FLAG. Cells were lysed 
24 h later and overexpressed proteins were analyzed in a western blot using anti-Myc and anti-FLAG antibodies 
for detection. (B) The same analysis was carried out with the E3 ligase deficient MuRF2-[(C42S; C50S)]-
Myc(His)6, in which two functionally essential cysteine residues (42 and 50) of its RING finger domain were 
mutated to serines, thus inactivating its E3 ligase function. In this case, as in the case of overexpressing MuRF3, 
no decrease in SNX5 was observed.  
 
For further investigation of SNX5 degradation by MuRF2, Cycloheximide (CHX) chase 
experiments were performed. First, SNX5-FLAG, MuRF2-Myc(His)6 and MuRF3- 
Myc(His)6 were overexpressed separately in C2C12 cells for 24 h. Cells were then treated 
with CHX for different time points. Western blot analysis showed that overexpressed SNX5 
had a half-life of 2 hours. MuRF2 was stable even after 6 hours of CHX treatment, and 
MuRF3 was stable after 4 hours but showed a decrease in protein content after 6 hours of 
CHX treatment (Fig. 27, A). SNX5 and MuRF2 were also co-expressed in C2C12 cells for 24 
hours, which were then treated with CHX. Western blot results showed that even without 
CHX treatment (time point 0 h), a decrease in SNX5 expression was observed when co-
expressed with MuRF2. In comparison with CHX-chase of SNX5 alone, an enhanced SNX5 
degradation was observed when co-expressed with MuRF2, indicating that MuRF2 increases 
the degradation of SNX5 (Fig. 27, B). The densitometrical analysis of SNX5 expression 
showed 0% remaining SNX5 after 6 hours of CHX treatment when co-expressed with MuRF2 
compared with over 10% remaining SNX5 when expressed alone (Fig. 27, D). The same 
experimental approach was used to investigate the effect of MuRF3 on SNX5. Interestingly, 
MuRF3 not only did not increase SNX5 degradation, but it rather stabilized SNX5 protein 
content throughout the course of the experiment, with over 30% of SNX5 remaining after 6 
hours of CHX treatment, when it was co-expressed with MuRF3  (Fig. 27, C and D).  





Figure 27: MuRF2 enhanced SNX5 degradation in Cycloheximide chase experiments. (A) SNX5-FLAG, 
MuRF2-Myc(His)6 and MuRF3-Myc(His)6 were overexpressed separately for 24 h in C2C12 cells which were 
then treated with Cycloheximide for 0, 1, 2, 4, or 6 h. Anti-Myc and anti-FLAG antibodies were used for 
detection of protein expression. (B) SNX5-FLAG was co-expressed with MuRF2-Myc(His)6 or with MuRF3-
Myc(His)6 (C) in C2C12 cells for 24 hours, which were then treated with Cycloheximide. GAPDH was used as 
loading control. (D) Densitometrical analysis of (B) and (C). For evaluation of protein degradation, the signal 
intensities of SNX5 bands were normalized against the accordant GAPDH signals and SNX5 signal in (A) of the 
‘0 h’ sample was set as 100%. Densitometrical analysis was carried out in ImageJ processing program. 
CHX=Cycloheximide 
 
3.4.2. SNX5 inhibits MuRF2-auto-ubiquitination in in vitro ubiquitination 
assays 
In vitro ubiquitination assays were performed to investigate if MuRF2 ubiquitinates its 
putative target protein SNX5. For these experiments, MBP-MuRF1, -2 and -3, and SNX5-
recombinant proteins were expressed and purified, and the assays were performed in a cell 
free system. As negative controls either E1, E2 (UbcH5a), E3 (MuRF), or ubiquitin were not 
added to the reaction. SNX5 was used as a potential substrate to be ubiquitinated, but was left 
out of the reaction as a control and to test auto-ubiquitination of MuRF E3 ligases (Fig. 28, 
left blot). Samples were subjected to SDS-PAGE and analyzed by western blot using anti-
ubiquitin antibody (Fig. 28). Ubiquitination of SNX5 could not be detected. However, 
MuRF2 was found to auto-ubiquitinate. Auto-ubiquitination of MuRF2 was inhibited when 
SNX5 was added to the reaction, providing further evidence that MuRF2 interacts with SNX5 




and mediates its degradation (Fig. 28, red arrows). Auto-ubiquitination of MuRF1 and 
MuRF3 was not detected. 
 
Figure 28: SNX5 inhibition of MuRF2 auto-ubiquitination in in vitro ubiquitination assay. In vitro 
ubiquitination assays were performed with recombinant GST-E1, GST-UbcH5a (E2), MBP-MuRF1, MBP-
MuRF2, or MBP-MuRF3, ubiquitin, and either with (right) or without (left) recombinant SNX5 as substrate. 
Western blot analysis was performed and anti-ubiquitin antibody was used for detection. The high molecular 
weight multiubiquitin chains detected on the left blot (red arrow) represent the auto-ubiquitination of MuRF2, 
which was inhibited after adding the substrate SNX5 to the reaction (right blot, red arrow).  
3.4.3. MuRF2 degrades SNX5 in a UPS-dependent manner 
To investigate whether MuRF2-mediated SNX5 degradation is UPS-dependent, expression 
assays in the presence or absence of MG132 were carried out. First, MuRF2, MuRF3 and 
SNX5 were expressed separately in C2C12 cells for 24 hours. Cells were then treated with 
MG132 or vehicle for 6 hours before lysis. Protein expression was examined in western blot 
analysis. MG132 led to an increased MuRF2, MuRF3 and SNX5 protein content compared to 
controls (Fig. 29). Consistent with previous results (Fig. 26 and 27), co-expression of SNX5 
and MuRF2 resulted in a decrease in SNX5 protein, compared to its separate expression, 
indicative of its MuRF2-mediated degradation. This effect was reversed through proteasome 
inhibition by MG132, indicating that MuRF2-mediated SNX5-degradation occurs via the 
proteasome. When MuRF2, MuRF3 and SNX5 were overexpressed together, the MuRF2-
mediated SNX5-degradation was abolished, confirming the stabilizing effect of MuRF3 on 
SNX5 (Fig. 29).  




              
Figure 29: SNX5 is degraded by MuRF2 in a UPS-dependent manner. MuRF2-Myc(His)6 or MuRF3-
Myc(His)6 and SNX5-FLAG were overexpressed in C2C12 cells for 24 h either separately or in a co- or triple-
transfection. Cells were then incubated for another 6 h in MG132 (10µM) for proteasome inhibition or vehicle 
before they were lysed. Western blot analysis was carried out to detect overexpressed proteins. Specific 
antibodies against Myc-tag and FLAG-tag were used. GAPDH was used as loading control. 
 
Immunofluorescence staining was used to examine the effects of MG132 treatment on 
MuRF2 and SNX5 expression. SNX5-FLAG and MuRF2-Myc(His)6 were co-expressed in 
C2C12 cells. Cells were either fixed or treated with MG132 for 6 hours before they were also 
fixed and stained. As expected, cells which were not treated with MG132 showed almost no 
SNX5 expression, indicative of its rapid degradation by MuRF2 (Fig. 30, A). After MG132 
treatment, SNX5-expression was detectable, as its MuRF2-mediated UPS-dependent 
degradation was prevented (Fig. 30, B).  





Figure 30: MG132 rescues the depletion effect of MuRF2 overexpression on SNX5 in C2C12 cells. C2C12 
cells were co-transfected with SNX5-FLAG and MuRF2-Myc(His)6. Cells were fixed 24 h after transfection (A), 
or were incubated for another 6 h in MG132 before they were fixed (B). Cells were stained using specific 
primary antibodies against FLAG-tag and Myc-tag, and fluorophore - conjugated secondary antibodies 
(Alexa555, red and Alexa488, green). Nuclei were stained with DAPI. Immunofluorescence microscopy was 
performed using 63X objective on a Leica SPE confocal microscope. 
 
3.4.4. MuRF2 interacts with and ubiquitinates SNX5 in in vivo 
ubiquitination assays 
A physical interaction between MuRF2 and its substrate SNX5 in co-immunoprecipitation 
assays could not be shown thus far, presumably due to its rapid degradation. To stabilize 
ubiquitinated SNX5 and inhibit its UPS-mediated degradation, in vivo ubiquitination assays 
were carried out, in which MG132 was used. In addition, the deubiquitinase-inhibitor N-
Ethylmaleimide (NEM) was applied during cell lysis to prevent the cleavage of ubiquitin 
bound to SNX5 by deubiquitinating enzymes (DUBs). SNX5-FLAG was co-expressed with 
MuRF2-Myc(His)6 or MuRF3-Myc(His)6 in C2C12 cells for 24 h. Co-immunoprecipitation 
assays were performed after incubation with MG132 and application of NEM. As control 
cells were incubated in vehicle and NEM-free lysis buffer was used. Immunoprecipitates were 




subjected to SDS-PAGE and western blot analysis using anti-Myc antibody for the detection 
of MuRF2-Myc(His)6 and MuRF3-Myc(His)6. While MuRF3 interacted with SNX5, 
regardless of whether MG132 and NEM were used or not, MuRF2 only co-precipitated with 
SNX5 after MG132 treatment and NEM application. This indicates a physical interaction 
between MuRF2 and SNX5, which is detectable only when the degradation is inhibited. Also, 
auto-ubiquitination of MuRF2 was detected in the precipitate (Fig. 31). 
 
                        
Figure 31: MuRF2 is co-precipitated with SNX5 in in vivo ubiquitination assay. C2C12 cells were co-
transfected with MuRF2-Myc(His)6 or MuRF3-Myc(His)6 and SNX5-FLAG or empty FLAG-vector. Co-
immunoprecipitation assays were performed with or without MG132-incubation and application of NEM. Inputs 
(make up 5% of total cell lysates) were analyzed by Immunoblotting (IB), using anti-Myc and anti-FLAG 
antibodies, and are shown in the upper and middle panels, respectively. Immunoprecipitates (IP) were analyzed 
using anti-Myc antibody and are shown in the lower panel. MuRF3 was detected in SNX5 immunoprecipitates 
both with and without MG132 and NEM. MuRF2 was only co-precipitated with SNX5 after MG132 treatment 
and NEM application, and showed auto-ubiquitination (red arrow). NEM= N-Ethylmaleimide. 
 
Another in vivo ubiquitination assay was performed to investigate the interaction between 
MuRF2 and SNX5 in more detail. In addition to the previous assay, MG132 and NEM were 
also applied separately, and detection of co-precipitates was also carried out with specific 
anti-SNX5 antibody. SNX5-FLAG was co-expressed with MuRF2-Myc(His)6 in C2C12 cells 
for 24 h. Co-immunoprecipitation assays were performed after incubation with MG132 and 




application of NEM. As control cells were incubated in vehicle and NEM-free lysis buffer 
was used. Immunoprecipitates were subjected to SDS-PAGE and western blot analysis using 
anti-Myc or anti-SNX5 antibodies. When anti-Myc antibody was used for detection, the 
interaction between SNX5 and MuRF2 was detectable when only MG132 was used. 
However, more MuRF2 was co-precipitated with SNX5 when both MG132 and NEM were 
used. In contrast, MuRF2 was not detected in SNX5-precipitates when only NEM was 
applied. When detection of co-precipitates was carried out with specific anti-SNX5 antibody, 
and after longer exposure of western blots, ubiquitination of SNX5 was detectable, but only in 
co-immunoprecipitations where either MG132 or both MG132 and NEM were applied. These 
results provided further evidence that MuRF2 interacts with and ubiquitinates SNX5, 
mediating its UPS-dependent degradation (Fig. 32).  
 
                       
Figure 32: MuRF2 interacts with and ubiquitinates SNX5 in in vivo ubiquitination assay. C2C12 cells were 
co-transfected with MuRF2-Myc(His)6 and SNX5-FLAG or empty FLAG-vector. Co-immunoprecipitation 
assays were performed with or without MG132-incubation and application of NEM in cell lysis. Inputs (make up 
5% of total cell lysates) were analyzed by Immunoblotting (IB), using anti-Myc and anti-FLAG antibodies, and 
are shown in the two upper panels. Immunoprecipitates (IP) were analyzed using anti-Myc and anti-SNX5 
antibodies and are shown in the three lower panels. MuRF2 was co-precipitated with SNX5 after MG132 
treatment, regardless of NEM application. Ubiquitination of SNX5 was detectable after longer exposure. NEM= 
N-Ethylmaleimide. 




3.4.5. MuRF3 stabilizes SNX5 and prevents its MuRF2-mediated 
degradation 
This study showed that MuRF3 stabilized SNX5. To investigate this in more detail, an 
expression assay was performed, in which MuRF2-Myc(His)6 or MuRF3-Myc(His)6 and 
SNX5-FLAG were overexpressed in C2C12 cells for 24 h either separately or in co- or triple-
transfections. In triple-transfections, constant amounts of MuRF2 and SNX5 were 
overexpressed with three increasing amounts of MuRF3 expression plasmid. Cell lysates were 
subjected to SDS-PAGE and western blot analysis. Co-expression of MuRF2 with SNX5 led 
to a decrease in SNX5 expression. This effect was inhibited by increasing amounts of 
MuRF3, indicating that MuRF3 stabilizes SNX5 and prevents its MuRF2-mediated 
degradation. Interestingly, MuRF3 appeared to stabilize MuRF2 as well (Fig. 33).  
 
                  
Figure 33: MuRF3 stabilizes SNX5 and prevents its MuRF2-dependent degradation. MuRF2-Myc(His)6 or 
MuRF3-Myc(His)6 and SNX5-FLAG were overexpressed in C2C12 cells for 24 h either separately or in a co- or 
triple-transfection. Three different amounts of expression plasmid encoding for MuRF3-Myc(His)6 were 
transfected to examine its effect on SNX5 expression. Western blot analysis was carried out to detect 








3.5. SNX5 expression during skeletal muscle atrophy 
3.5.1. SNX5 expression in the denervation atrophy mouse model 
Because endogenous expression tests showed especially high SNX5 expression in muscle, a 
possible change in Snx5 mRNA expression and SNX5 protein content during skeletal muscle 
atrophy was investigated. Therefor, two different mouse atrophy models were used. In the 
first mouse model denervation-induced muscle atrophy was induced in adult male wild type 
mice by ligation of the left sciatic nerve, resulting in neurogenic atrophy of the lower 
hindlimb muscles. Mice were sacrificed 7, 14 and 21 days after surgery and muscle tissues 
were obtained. In addition, muscle tissues from non-treated mice were used as control. For 
further analyses of SNX5 expression only gastrocnemius-plantaris (GP) muscle was used. 
Deneravtion resulted in a significant loss of muscle weight, a reduction of myocyte cross 
sectional area, and increased Trim63 and Fbxo32 expression (these results were recently 
published on the same mice used in this study, Schmidt F. et al., 2014; Langhans C. et al., 
2014). Denervation resulted in a significant upregulation of Snx5 mRNA expression in the GP 
muscle 7 (5 fold, p<0.05), 14 (4.7 fold, n.s.) and 21 (4.5 fold, p<0.05) days after denervation. 
These results were consistent with western blot analysis, where an increase in SNX5 protein 
expression 7, 14 and 21 days after denervation was observed. SNX5 expression was increased 
during denervation-induced atrophy (Fig. 34).  
 
Figure 34: SNX5 expression in denervation-induced skeletal muscle atrophy. Skeletal muscle atrophy was 
induced in adult male mice by ligation of the left sciatic nerve. Operated (O) and sham (S) mice were sacrificed 
7, 14 and 21 days after surgery and muscle tissues were obtained. Muscle tissues from non-treated mice were 
used as controls (C). Western blot analysis (A) and qRT-PCR for Snx5 expression (B) were performed with only 
M. gastrocnemius-plantaris (GP). SNX5 expression was detected in western blots using specific anti-SNX5 
antibody. GAPDH was used as control. Data are presented as mean ± SEM. n=3. 
 




3.5.2. SNX5 expression in the starvation atrophy mouse model 
The second atrophy mouse model used was starvation. In starvation-induced muscle atrophy, 
adult male mice were food-deprived for 24 h and 48 h to induce muscle atrophy before they 
were sacrificed. Control mice were not exposed to starvation and were sacrificed after 0 h, 24 
h and 48 h. Muscle tissues were obtained for analyses. Only GP muscle was used for further 
analysis of SNX5 expression. Starvation resulted in a significant loss of muscle weight, a 
reduction of myocyte cross sectional area, and increased Trim63 and Fbxo32 expression 
(these results were recently published on the same mice used in this study, Schmidt F. et al., 
2014; Langhans C. et al., 2014). A small increase in Snx5 mRNA expression was observed 
after 24 h of starvation. However, no significant change in SNX5 protein content was 
observed (Fig. 35). 
 
Figure 35: SNX5 expression in starvation-induced skeletal muscle atrophy. Adult male mice were food-
deprived for 24 h and 48 h to induce muscle atrophy before they were sacrificed. Control mice were not exposed 
to starvation and were sacrificed after 0 h, 24 h and 48 h. Muscle tissues were obtained for analyses. Western 
blot analysis (A) and qRT-PCR for Snx5 expression (B) were performed with only M. gastrocnemius-plantaris 
(GP). SNX5 expression was detected in western blots using specific anti-SNX5 antibody. GAPDH was used as 
control. Quantitative real-time-PCR-analyses of Snx5 expression were carried out. Data are presented as mean ± 
SEM. n=3. 
 





Muscle specific E3 ligases, MuRF1, MuRF2 and MuRF3 have been implicated in several 
cellular functions such as the degradation of sarcomeric proteins (MuRF1 and MuRF3), 
indicating their importance in maintenance of skeletal and cardiac muscle structure and 
function (Fielitz J. et al., 2007 b), stabilization of microtubules (MuRF2 and MuRF3; Spencer 
J.A. et al., 2000, Pizon V. et al. 2002), and myocyte differentiation (MuRF2 and MuRF3; 
Spencer J.A. et al., 2000; Centner T. et al., 2001; Pizon V. et al. 2002). Nevertheless, the 
precise mode of action of these enzymes is still uncertain. In addition, very little is known 
about the E3 ligase function of MuRF2, for which no substrate proteins have been identified 
thus far. 
In this study, the aim was to identify and characterize interaction partners and target proteins 
of MuRF1, MuRF2 and MuRF3 for a better understanding of their functions. For the first 
time, MuRF2 and MuRF3 were linked to subcellular trafficking through interaction with and 
regulation of SNX5, which as a retromer subunit is a key player in the retrograde transport 
from endosomes to TGN (Wassmer T. et al., 2007). Also, SNX5 interacts with the muscle 
specific CHC22 and mediates an intermediate microtubule-dependent retrograde transport 
step, which is crucial for GLUT4 trafficking in human muscle. Disruption of GLUT4 
pathways has been indicated in patients of type 2 diabetes (Vassilopoulos S. et al., 2009; Esk 
C. et al., 2010).    
4.1. Using the SILAC-AP-MS approach for the identification of novel 
substrates and interaction partners for MuRF1, MuRF2, and MuRF3 
The quantitative mass spectrometry (MS)-based approach offers the unique potential to place 
proteins into a functional context while improving the understanding of the molecular 
processes in which they are involved. For an accurate quantification of proteins, SILAC 
labeling was combined with conventional protein affinity purification (AP) and MS-analysis 
(SILAC-AP-MS). This technique allowed the comparison between different cellular states, 
such as proliferating myoblasts with differentiated myotubes, and differentiated myotubes 
with atrophic myotubes. This approach also allowed an accurate detection of proteins with a 
significant change in abundance as a result of MuRF-overexpression, in myoblasts as well as 
during differentiation and atrophy. An increase in protein abundance indicated that the protein 
was likely to interact with MuRF or with another up-regulated protein in the same cell 
population. Conversely, the most likely explanation for decreased protein abundance was that 




this protein was a possible substrate of the overexpressed MuRF or it binded another 
downregulated protein.  
An analysis of MS data from the different assays showed that, as expected, a large number of 
muscle structural and cytoskeleton associated proteins were detected. In addition, many 
components of the UPS, such as proteasome subunits were also detected in the different 
screens. MuRF3 was detected as the most enriched protein in myoblasts overexpressing 
MuRF1 and MuRF2, and MuRF2 was also enriched in myoblasts overexpressing MuRF3, 
confirming the heterodimerization of MuRF-proteins. Interestingly, many proteins with a 
significant abundance difference in myoblasts overexpressing MuRF2 and MuRF3 were 
detected, which were found to be involved with intracellular transport, especially vesicle-
mediated transport. For example, in myoblasts overexpressing MuRF2, EEA1 and clathrin 
light chain B (CLCB) were detected displaying abundance enrichment. EEA1 participates in 
endocytosis and transport from EEs to LEs, and CLCB is a regulatory subunit of clathrin, the 
main structural component of coated pits essential for receptor-mediated endocytosis. Another 
protein which was detected in myoblasts overexpressing MuRF2 with a 1.9-fold enrichment 
was SNX8. Interestingly, SNX8 regulates endosome-to-TGN transport through a pathway that 
is distinct from that of the SNX1/SNX5-containing retromer complex (van Weering J.R. et 
al., 2012a; van Weering J.R. et al., 2012b). In myoblasts overexpressing MuRF3, SNX4 and 
the mammalian retromer subunit SNX5 were detected, both displaying a 2-fold abundance 
enrichment. SNX4 is involved in the endosomal recycling pathway and is associated with 
specific tubular elements which are spatially and functionally different from the SNX1/SNX5-
retromer complex. SNX4, SNX5 and SNX8 are all linked to microtubule-based motor 
function, and although they are all targeted to the early endosome, these three SNXs are 
involved in separate endosomal sorting events and define distinct membrane trafficking 
pathways (van Weering et al., 2012b; van Weering et al., 2012a; Hunt S.D. et al., 2013). 
In addition, several downregulated proteins involved in subcellular trafficking were detected, 
such as subunits of adapter protein 3 (AP3) complex, which plays a role in protein targeting to 
the lysosome, importin-7, importin-8 and importin alpha S2, which function in nuclear protein 
transport, and subunits of the endosomal sorting complex required for transport (ESCRT)-I 
and II, which are required for the sorting of endosomal cargo into multivesicular bodies 
(MVBs). 
 




4.2. SNX5 was identified as a novel interaction partner of MuRF3 
MS-data showed an almost 2-fold enrichment of SNX5 in myoblasts expressing MuRF3 
compared to the control, suggesting its putative interaction with MuRF3. SNX5 was of special 
interest because it mediates retrograde trafficking as a retromer subunit and regulates the 
degradation of membrane receptors like epidermal growth factor receptor (EGFR), thus 
regulating different signal transduction pathways (Wassmer T. et al., 2007; Sun Y et al., 
2013). Very little is known about the expression and function of SNX5 in muscle. In addition 
to its ubiquitous expression in all mouse organs tested in this study, with especially high 
expression in the pancreas, lung and spleen, SNX5 was strongly expressed in heart and 
skeletal muscle. Due to its essential role in subcellular trafficking and transport, and therefore 
in numerous secretion pathways, and its indispensable role in differentiation of alveolar 
epithelial type I cells in mice, its high expression in pancreas and lung was somewhat 
expected. It has been reported that disruption of the Snx5 gene in mice results in 40% 
perinatal lethality due to cyanosis and respiratory failure (Im S.K. et al., 2013). 
SNX5 exhibited a perinuclear and homogenous cytosolic staining pattern in C2C12 cells. A 
comparable subcellular distribution of SNX5 was also described for non-muscle cells 
(Teasdale R.D. et al., 2001; Sun Y. et al., 2013). Because subcellular trafficking is a dynamic 
process that takes place continuously, it was expected to observe retromer-carrying vesicles, 
and therefore SNX5, in cell periphery as well as in the perinuclear region, where TGN is 
localized. In addition, SNX5 colocalized with the early endosome marker EEA1 but not with 
the late endosome and lysosome marker LAMP1. These data indicate that SNX5 localizes to 
early endosomes but not to late endosomes and lysosomes in muscle cells. This is consistent 
with previous reports which showed the predominant localization of SNX5 to the membranes 
of early endosomes in human breast carcinoma and human epitheloid cervix carcinoma cells 
(Teasdale R.D. et al., 2001; Merino-Trigo A. et al., 2004; Sun Y. et al., 2013).  
4.3. SNX5 interacts physically and co-localizes with MuRF3 
Co-immunoprecipitation experiments were performed to examine a possible interaction of 
MuRF1, MuRF2 and MuRF3 with SNX5. MuRF3 co-immunoprecipitated with SNX5 
indicating they physically interact with each other. MuRF1 was also detected in the SNX5-
precipitate, suggesting a possible interaction between the two proteins. Nevertheless, putative 
interaction between MuRF1 and SNX5 could not be validated.  




Results of co-immunoprecipitation assays were supported by immonostaining experiments, 
which were carried out to investigate the co-localization of MuRF3 and SNX5. SNX5 was 
overexpressed in C2C12 cells and immunostaining showed the expected perinuclear and 
homogenous cytosolic staining pattern. MuRF3 was also overexpressed in C2C12 cells and 
exhibited its typical filament-like staining pattern. This MuRF3 staining pattern was described 
by Spencer et al. in 2000, when MuRF3 was reported to bind to and stabilize microtubules. In 
immunostaining experiments, they showed that MuRF3 co-localized with glutamylated 
microtubules and exhibited filament-like structures which radiated from the perinuclear 
region, the microtubule organizing center (MTOC), into the cell periphery (Spencer J.A. et 
al., 2000). Interestingly, when SNX5 was co-expressed with MuRF3, it changed its cellular 
distribution and co-localized with MuRF3, exhibiting the same microtubule-like staining 
pattern as MuRF3. Likewise, overexpressed MuRF3 also caused endogenous SNX5 to change 
its cellular localization to co-localize with MuRF3. These results provide further proof for the 
interaction between SNX5 and MuRF3.  
4.4. Identification of the interaction domains of SNX5 and MuRF3 
To identify the regions in SNX5 and MuRF3 which are responsible for their interaction, 
several deletion mutants in both proteins were generated. As a member of the SNX-BAR 
subfamily of SNXs, SNX5 has one C-terminal BAR domain in addition to its N-terminal PX 
domain. SNX5-BAR has been shown to be responsible for the interaction of SNX5 with 
different proteins, such as FANCA, for which the PX domain is not required (Otsuki T. et al., 
1999), CHC22 (Towler M.C. et al., 2004), or DOCK180 (an activator of small GTPases), 
which interacts with SNX5 through either one of the CCDs of SNX5-BAR (Hara S. et al, 
2008). In addition, the dimerization of SNX5 with SNX1 or SNX2 is mediated by the BAR 
domains of both SNXs, where either one of the three CC domains of SNX5-BAR is sufficient 
for their interaction. On the other hand, the PtdIns(3)P-binding SNX5-PX domain has been 
shown to associate with PtdIns(3)P-enriched elements of the endosomal pathway (Teasdale 
R.D. et al., 2001; Cullen P.J., 2008), and is the functional domain in regulation of EGFR 
pathway (Liu H. et al., 2006). Here, five different deletion mutant of SNX5 were generated; 
SNX5-PX lacked the BAR domain, SNX5-BAR lacked the PX domain, and SNX5∆aa206-
256, SNX5∆aa262-327 and SNX5∆aa344-397 had deletions in the first, second or third CCDs 
of the BAR domain, respectively. In co-immunoprecipitation assays and immunostaining 
experiments SNX5-PX did not co-immunoprecipitate or co-localize with MuRF3, indicating 
that it is not required for the interaction of SNX5 with MuRF3. SNX5-BAR, on the other 




hand, co-immunoprecipitated and co-localized with MuRF3, indicating that the BAR domain 
of SNX5 was responsible for its interaction with MuRF3. All three CCD deletion mutants of 
the BAR domain interacted with MuRF3, although SNX5∆aa206-256 and SNX5∆aa344-397 
(deletion of CCD1 and CCD3, respectively) showed a weaker interaction, indicating that the 
first and the third CCDs are more essential for SNX5 interaction with MuRF3. 
To determine the MuRF3-domain responsible for its interaction with SNX5, 14 different 
deletion mutants were generated, in which the different functionally important domains of 
MuRF3 were partially or completely deleted. Unfortunately, the expression of the small 
deletion mutants, such as MuRF3aa1-81, MuRF3aa82-117, MuRF3aa118-159, MuRF3aa160-
202, MuRF3aa203-277, as well as MuRF3aa278-267, was not possible in western blot 
analyses. Also, deletion mutants lacking the C-terminus of MuRF3 could not be detected 
either, suggesting the importance of an intact C-terminus for MuRF3 expression. 
Nevertheless, in a co-immunoprecipitation assay, deletion mutants including either one of the 
two MuRF3 coiled coil domains; MuRF3aa1-202, MuRF3aa1-277, MuRF3aa118-367, 
MuRF3aa160-367, MuRF3aa203-367, as well as MuRF3aa160-202, which only included the 
first coiled coil domain and none of the other domains, were all found to interact with SNX5. 
In addition, deletion mutant MuRF3aa1-159 interacted with SNX5 although it only contained 
an 18 aa residue of the first coiled coil domain, the RING finger domain and the MFC 
domain. On the other hand, deletion mutant MuRF3aa82-367 which contained both coiled 
coil domains did not interact with SNX5, which could be due to technical failure in this 
particular co-immunoprecipitation. These results suggested the coiled coil domains of MuRF3 
are responsible for mediating the interaction with SNX5. Previous studies showed that the 
coiled coil domains of MuRF-proteins mediate protein interactions. In a yeast two-hybrid 
system, MuRF1, 2 and 3 were shown to interact with each other through their coiled coil 
domains, which were sufficient for the interaction, to form heterodimers. On the other hand, 
for the binding of MuRF1 to titin a central 144 aa residue segment of MuRF1 was required, 
which included part of the conserved MuRF family domain, the B-box and only one coiled 
coil domain. The N-terminal RING-finger domain and the C-terminal acidic domain were not 
required for the interaction (Centner T. et al., 2001). In another study, the coiled coil domain 
of MuRF3 was shown to not only be necessary but also sufficient for its interaction with the 
glutamylated microtubules. However, amino acids 168-211 are required for optimal 
association, and the RING-finger domain is required for continuous binding along and 
stabilization of microtubules in vivo (Spencer J.A. et al., 2000).  




Three more deletion mutants of MuRF3 coiled coil domains were generated; MuRF3∆aa141-
186 with a deletion in the first CCD, MuRF3∆aa227-262 with a deletion in the second CCD, 
or MuRF3∆aa141-262 with deletions in both CCDs. Results of co-immunoprecipitation 
experiments showed a very weak interaction with SNX5 compared to the interaction between 
wild type MuRF3 and SNX5. Altogether, these results confirm that MuRF3 coiled coil 
domains mediate its interaction with SNX5. 
4.5. SNX5 and MuRF3 co-localize and associate with early endosomes and 
microtubules 
Although there have been conflicting reports about the subcellular localization of SNX5, it 
has predominantly been shown to localize to the membrane of EEs (Sun Y. et al., 2013; 
Teasdale R.D. et al., 2001; Merino-Trigo A. et al., 2004). This could also be shown in this 
study for endogenous and overexpressed SNX5. On the other hand, MuRF3 localized to 
microtubules and exhibited its typical microtubule-like staining pattern. To investigate the 
association of MuRF3 with EEs, LEs and lysosomes, its co-localization with EEA1 and 
LAMP1 was tested. Results showed that LAMP1, thus most LEs and lysosomes, was 
localized to the microtubule organizing center (MTOC) in the perinuclear region, from which 
the microtubules, as well as MuRF3, radiate into the cell periphery. On the other hand, EEA1 
co-localized with MuRF3, although partially, indicating that early endosomes, which are 
predominantly located in the cell periphery, were localized to microtubules and thus to 
MuRF3. This is consistent with previous studies which showed that EEs as well as LEs move 
along microtubules. EEs patrol the peripheral cytoplasm close to the plasma membrane 
through saltatory movement along microtubules. On the other hand, LEs are transported on 
microtubules in a bidirectional manner, with a net movement towards the MTOC in the 
perinuclear region of the cell, where most of the LEs and lysosomes localize (Huotari J. and 
Helenius A., 2011). Nevertheless, because subcellular trafficking is a dynamic and adaptable 
pathway, EEs, LEs, endolysosomes and lysosomes are continuously undergoing maturation 
and transformation. This makes it difficult and only partially useful for protein components, 
such as EEA1 and LAMP1, to be used as specific molecular markers, since most of them are 
only transiently associated with these organelles (Huotari J. and Helenius A., 2011). That’s 
why it was expected to have partial co-localization of MuRF3 with EEs and LEs. 
 
These results are also in line with a very interesting study by Kaisto et al., which is one of the 
very few studies investigating endocytic trafficking pathway in muscle. It showed the 
localization of the different compartments of the endocytic trafficking pathway in rat 




myofibers, which were isolated and exposed to endocytic tracers and labeled with antibodies 
against markers of the endocytic and exocytic pathways. Results showed that the recycling 
and the lysosome- directed pathways were distinct. Sarcolemmal coated-pits, which indicate 
endocytic activity, were concentrated at the I-bands and accordingly, EEs were distributed 
along the whole length of the myofibers and in a cross-striated fashion. Furthermore, 
recycling and LEs showed perinuclear and interfibrillar localization with a distribution pattern 
that followed the course of the microtubule network, indicating that LEs, as well as EEs, 
travel along microtubule tracks (Kaisto T. et al., 1999).  
In this study, a triple immunostaining experiment of MuRF3, SNX5 and EEA1 was 
performed. The localization of MuRF3 and SNX5 to EEs was tested. MuRF3 and SNX5 co-
localized and showed the microtubule-like staining pattern. EEA1 staining showed cytosolic, 
mostly peripheral distribution, partially along the microtubule-like structures. Results suggest 
that MuRF3 and SNX5 co-localized with each other and partially localized to EEs. This can 
be explained by the complexity of the spatial organization of the retromer-endosomal 
network. As a subunit of the retromer, SNX5 is localized to retromer-labeled EEs and 
recycling endosomal vesicles, which display a spatial organization defined not only by the 
presence of dispersed peripheral endosomes, but also an enrichment of recycling endosomal 
vesicles and tubules which cluster in the vicinity of the TGN, localized to the MTOC in the 
perinuclear region. From previous studies and live cell imaging experiments, it has become 
apparent that this steady-state is highly dynamic. In retromer-mediated retrograde trafficking 
pathways the retromer-labeled vesicular and tubular structures undergo a number of fission 
and fusion events as they move from the cell periphery along microtubules towards TGN in 
the perinuclear region. This steady-state distribution relies upon the interaction of retromer-
subunits SNX5 and SNX6 with p150glued component of dynactin, an activator of the minus-
end directed microtubule motor dynein, and the binding of SNX1 to the TGN-localized Rab6-
interacting protein 1 (Rab6IP1). By recruiting the dynein/dynactin motor complex, the SNX 
BAR retromer subcomplex coordinates cargo sorting and tubular-based carrier formation at 
the donor endosomal membrane with long-range minus-end-directed microtubule-based 
transport and carrier recognition at the recipient TGN membrane. Suppression of p150glued or 
Rab6IP1 or disruption of microtubules results in the generation of a new steady-state 
characterized by the peripheral dispersal of retromer-labeled vesicles and a correlated 
impairment in retromer-mediated sorting to TGN. Disruption of microtubules also causes the 
dispersal of LEs and lysosomes throughout the cytoplasm, as well as a delay in the maturation 
of endosomes and cargo degradation (Cullen P.J., 2008; Wassmer T. et al., 2009; Huotari J. 




and Helenius A., 2011). These reports as well as the results of this study indicate a functional 
association between SNX5 and the microtubule cytoskeleton, and suggest a role of MuRF3 in 
stabilizing this association.   
4.6. SNX5 is a target protein of MuRF2 
After repeatedly making the observation of a decrease in SNX5 expression once co-expressed 
with MuRF2, SNX5 was assumed to be a putative MuRF2 substrate. A first proof of this 
assumption was delivered when a decrease in SNX5 expression was observed when co-
expressed with increasing amounts of MuRF2. In contrast, increasing MuRF3 expression had 
no effect on SNX5, indicating that SNX5 is a target protein of MuRF2 and not MuRF3. 
Because the RING finger domain of ubiquitin E3 ligases is the functional domain responsible 
for their E3 ligase activity, the RING finger domain of MuRF2 was inactivated to examine the 
ability of an E3 ligase deficient MuRF2 to degrade SNX5. The RING finger domain of 
MuRF-proteins is a C3HC4-type zinc finger domain which contains one histidine and seven 
cysteine residues which are highly conserved and essential for the coordination of the two 
zinc cations and for maintaining the structural and functional integrity of the RING finger 
domain (Lorick K.L. et al., 1999; Joazeiro C.A. and Weissman A.M., 2000; Spencer J.A. et 
al., 2000). Two cysteine residues, Cys42 and Cys50, were altered into serines, generating the 
E3-ligase deficient MuRF2-[(C42S; C50S)]. In a further expression assay, increasing the 
expression of MuRF2-[(C42S; C50S)] did not cause a decrease in SNX5 expression which 
remained constant, providing additional evidence that SNX5 is a MuRF2 substrate. 
In Cycloheximide chase experiments, the putative MuRF2-mediated degradation of SNX5 
was investigated further. Co-expression with MuRF2 enhanced SNX5 degradation even 
without CHX treatment, as a decrease in SNX5 expression was observed in comparison with 
SNX5 expression when expressed alone, which is consistent with previous results. SNX5 
degradation was enhanced throughout the whole time course of the assay when co-expressed 
with MuRF2, until it was completely abolished after 6 hours of CHX treatment (0% 
remaining SNX5 in densitometrical analysis), confirming its MuRF2-mediated degradation. 
On the other hand, MuRF3 did not enhance SNX5 degradation, but rather stabilized SNX5 
expression. Although at time point 0 hours (no CHX treatment), only about 65% SNX5 was 
expressed in comparison with the control, SNX5 expression remained stable throughout the 
course of the experiment, with over 30% remaining SNX5 after 6 hours of CHX treatment.  




Further evidence of MuRF2-mediated degradation of SNX5 was provided by in vitro 
ubiquitination assays. These assays were performed to test possible MuRF2-mediated SNX5 
ubiquitination. As a control reaction and for testing whether MuRF E3 ligases auto-
ubiquitinate, the substrate SNX5 was taken out of the reaction. Because the UPS is highly 
regulated at multiple levels, E3 ligases as well as other components of the system can be 
regulated by ubiquitination and subsequent degradation, mediated by themselves (a process 
known as regulatory self- or auto-ubiquitination) or by heterologous ligases. Auto-
ubiquitination is a general characteristic of E3 ligases in vitro, and is often used to confirm 
that a certain protein is an active E3 ligase and to assess functionally significant interactions 
with specific E2 enzymes (Lorick K.L. et al., 1999). The result of ligase auto-ubiquitination is 
auto-regulation or targeting for self-destruction (Weissman A.M. et al., 2011). 
In these assays, the ubiquitination of SNX5 could not be detected by either one of the MuRF 
proteins, but MuRF2 was found to auto-ubiquitinate. Interestingly, this auto-ubiquitination of 
MuRF2 was inhibited when SNX5, the substrate, was added to the reaction. Inhibition of 
auto-ubiquitination by the substrate has not been described for MuRF E3 ligases thus far, but 
it has been reported for F-box proteins of the Skp1-Cullin-F-box protein (SCF) complex, 
which provide substrate specificity to the complex. It was observed that their degradation is 
mediated via an ‘autocatalytic’ mechanism within the complex (mediated by the RING finger 
components), and attenuated by their respective substrates. This regulation mechanism 
ensures that sufficient levels of F-box proteins are maintained to target high level of substrates 
when they occur. However, after substrate concentration decreases, the F-box protein 
becomes abundant, and therefore is targeted for proteasomal destruction, while preserving the 
other components of the SCF complex, allowing for a quick reassembly of the complex with 
different F-box proteins to adapt to changes in the desired specificity (Galan J.M. et al, 1999; 
Li Y. et al, 2004; de Bie P. and Ciechanover A., 2011). Although this auto-regulatory 
mechanism has not been reported for MuRF-proteins, the results of these in vitro 
ubiquitination assays strongly suggest that MuRF2 is regulated by auto-ubiquitination in vitro. 
In addition, these results confirm that MuRF2 has an E3 ligase activity, which mediates the 
degradation of SNX5.  
4.7. MuRF2 degrades SNX5 in a UPS-dependent manner 
Having shown that SNX5 is a MuRF2 target protein, it was important to clarify, if SNX5 
degradation occurs via the 26S-proteasome. In expression and immunostaining assays the 
proteasome inhibitor MG132 was applied with the assumption that if SNX5 degradation is 




MuRF2-mediated, then this degradation would be inhibited by MG132 treatment. Indeed, 
MG132 prevented MuRF2 mediated degradation of SNX5 indicating that SNX5 is degraded 
in a UPS-dependent manner and that MuRF2 contributes to this reaction. When MuRF2, 
MuRF3 and SNX5 were overexpressed together, the MuRF2-mediated SNX5-degradation 
was prevented by MuRF3, confirming the stabilizing effect of MuRF3 on SNX5. The fact that 
the amount of expressed MuRF-proteins increased after treatment with MG132 indicated that 
the degradation of MuRF-proteins is also UPS-dependent. Inhibition of MuRF2-mediated 
UPS-dependent degradation of SNX5 was also observed in immunostaining assays, in which 
MG132 was also used. After co-expression with MuRF2, SNX5 could not be detected without 
MG132 treatment, which confirms its rapid degradation by MuRF2. Nevertheless, after 
MG132 treatment, MuRF2-mediated UPS-dependent degradation of SNX5 was prevented and 
it could therefore be detected.  
A physical interaction between MuRF2 and its substrate SNX5 could not be shown in 
conventional co-immunoprecipitation assays. Presumably, the interaction occurs in a very 
short period of time, in which SNX5 is rapidly ubiquitinated and degraded, making it difficult 
to be detected. In in vivo ubiquitination assays, ubiquitinated SNX5 was stabilized and its 
UPS-mediated degradation and deubiquitination were inhibited by MG132 and the 
deubiquitinase-inhibitor N-Ethylmaleimide (NEM), respectively. Importantly, when UPS-
mediated degradation and deubiquitination were inhibited, a physical interaction between 
MuRF2 and SNX5 was detected in co-immunoprecipitation experiments. On the other hand, 
MuRF3 interacted with SNX5 regardless of whether MG132 and NEM were used or not, 
which is consistent with previous results. In addition, auto-ubiquitination of MuRF2 was 
detected in the precipitate, probably due to NEM application. These results were verified in a 
further in vivo ubiquitination assay, in which MG132 and NEM were also applied separately. 
The interaction of MuRF2 with SNX5 was shown when MG132 was used alone or together 
with NEM. The application of NEM alone was not sufficient for stabilizing SNX5 and for the 
detection of its interaction with MuRF2, which supports previous results. By using specific 
antibodies against SNX5 and at longer exposure in western blot analysis, ubiquitination of 
SNX5 was detectable when MG132 and NEM were applied, but also when only MG132 was 
used, which indicates that although DUBs in the cell are active, they are not active enough to 
significantly inhibit the ubiquitination of SNX5 by MuRF2. These results provide strong 
evidence that MuRF2 interacts with and ubiquitinates SNX5, thus mediating its UPS-
dependent degradation in vivo. 




4.8. MuRF3 stabilizes SNX5 and prevents its MuRF2-mediated 
degradation 
As already observed in expression assays and CHX-chase experiments, MuRF3 had a 
stabilizing effect on SNX5 expression. This observation was verified in further expression 
tests, in which increased amounts of MuRF3 were co-expressed with constant amounts of 
MuRF2 and SNX5. Results showed that MuRF2-mediated degradation of SNX5 was 
inhibited by MuRF3 in a dose dependent manner. These results confirm the stabilization of 
SNX5 by MuRF3 and inhibition of MuRF2 mediated degradation. Therefore, MuRF2 and 
MuRF3 function antagonistically in the regulation of SNX5. 
4.9. A possible regulatory role of MuRF2 and MuRF3 in SNX5-mediated 
trafficking pathways through microtubule stabilization 
 
Microtubules are dynamic structures that have many functions ranging from organelle and 
cargo transport to mitosis and myogenesis (Pizon V. et al., 2002). Over the past years, a 
growing body of evidence has suggested a role of microtubules and other non-contractile 
cytoskeletal components in muscle differentiation and maintenance. Furthermore, 
microtubules are required for proper contractile function of the muscle and their levels 
increase in cardiac hypertrophy (McElhinny A.S. et al., 2004). It has been reported that 
disruption of microtubule dynamics with depolymerizing or destabilizing agents inhibits 
skeletal myoblast fusion, differentiation, and normal myofibrillogenesis. Microtubule 
dynamics is reduced in the early stages of myogenic differentiation by transient formation of 
the stable glutamylated microtubules, which seem to be involved in the active transport of 
sarcomeric proteins to the sites of myofibrillogenesis, while the dynamic pool of tyrosinated 
tubulin is simultaneously reduced (Gundersen G. et al., 1989; Pizon V. et al., 2002). MuRF2 
was shown to be required for the integrity of stable glutamylated and acetylated microtubules, 
but not the dynamic tyrosinated microtubules. Through its transient association with stable 
glutamylated microtubules, myosin and titin during early myofibrillogenesis MuRF2 acts as 
an adaptor between the sarcomeric proteins and the microtubule network (Pizon V. et al., 
2002). Nevertheless, the molecular mechanisms responsible for regulating the stability of 
glutamylated microtubules have remained elusive. Because MuRF2 colocalizes with only a 
portion of cardiac microtubules and appears to be only transiently associated with skeletal 
myocyte glutamylated microtubules, it has been suggested that it may interact with 
microtubules via hetero-oligomerization with MuRF3 (McElhinny A.S. et al., 2004). 
Therefore, MuRF3, which associates with glutamylated microtubules throughout development 




regulating their dynamics (Centner et al., 2001; Spencer et al., 2000), was suggested to act as 
the primary stabilizer while MuRF2 plays an accessory role in microtubule stabilization 
(McElhinny A.S. et al., 2004).  
 
Stable microtubule arrays are not only required for normal muscle development and function, 
but are also essential for maintaining the integrity of intracellular trafficking-pathways. In this 
respect, their disruption causes a delay in the maturation of endosomes and cargo degradation, 
the dispersal of late endosomes and lysosomes throughout the cytoplasm, and the impairment 
of retromer-mediated retrograde transport to the TGN (Cullen P.J., 2008; Wassmer T. et al., 
2009; Huotari J. and Helenius A., 2011). GLUT4 transport pathway is a specialized 
trafficking pathway in skeletal muscle. In humans, 70–90% of insulin-stimulated glucose 
clearance depends on skeletal muscle and the GLUT4 pathway (Towler M.C. et al., 2004a). 
As a response to insulin or exercise, GLUT4 transporter is translocated from intracellular 
GLUT4 storage compartments (GSCs) to the plasma membrane to clear glucose from the 
bloodstream (Bryant N.J. et al., 2002; Hou J.C. et al., 2007; Huang S. et al., 2007). Disruption 
of GLUT4 membrane trafficking has been implicated in some forms of human type 2 diabetes 
(Garvey W.T. et al., 1998; Maianu L. et al., 2001). Previous reports regarding the role of an 
intact microtubule-network in insulin-dependent GLUT4 transport have been conflicting. 
Several studies have established microtubules as a major determinant for subcellular 
localization of GLUT4 by showing that GLUT4-containing vesicles associated with 
microtubules and that inhibition of the microtubule motor proteins dynein and kinesin as well 
as microtubule-depolymerization dispersed the perinuclear localized GLUT4 and partially 
inhibited insulin-stimulated glucose uptake and GLUT4 translocation to the cell surface 
(Emoto M. et al., 2001; Fletcher L.M. et al., 2000; Guilherme A. et al., 2000; Olson A.L. et 
al., 2000; Patki V. et al., 2000). On the other hand, other studies have failed to support a role 
of microtubules in insulin-induced GLUT4 translocation to the plasma membrane, and 
showed that microtubule disruption did not alter the initial rate of GLUT4 endocytosis 
(Shigematsu S. et al., 2002).  Nevertheless, it remains undisputed, that an intact microtubule-
network is essential for the correct retrograde recycling of GLUT4 transporter from early 
endosomes back to the perinuclear TGN after its initial internalization, an intermediate 
trafficking step critical for the subsequent transport of GLUT4 to GSCs (Shigematsu S. et al., 
2002). This particular intermediate stage of GLUT4 transport is mediated by the muscle 
specific CHC22, which is involved in the biogenesis of insulin-responsive GSCs in human 
muscle (Vassilopoulus S. et al., 2009). It occurs after the retrograde cargo exit from early 
endosomes, which is mediated by the ubiquitously expressed CHC17. CHC22 function 




requires retromer, which it recruits by specific binding to SNX5, facilitating the tubulation of 
GLUT4-containing recycling vesicles which move along microtubules towards TGN in the 
perinuclear region. It has also been shown to require dynein/dynactin motor activity on 
microtubules, thus an intact microtubule-network (Esk C. et al., 2010). The defective and 
expanded GSCs in some patients with type 2 diabetes exhibit high levels of CHC22, raising 
the possibility that CHC22 modulation of GLUT4 traffic might influence human tendency 
toward type-2 diabetes (Vassilopoulos S. et al., 2009). 
 
In addition to the GLUT4 trafficking pathway, other SNX5-mediated transport pathways have 
been shown to require a stable microtubule network. An example for such trafficking 
pathways is macropinocytosis, a pathway which mediates the endocytosis of solute molecules, 
nutrients and antigens, and is therefore important in functions associated with immune 
responses, and in which SNX5 plays an essential role in macropinosome-to-early-endosome 
trafficking (Lim J.P. et al., 2008; Wang J.T. et al., 2010; Lim J.P. et al., 2012). Upon EGF 
stimulation, SNX5 is sequestered to discrete subdomains of the macropinosomes. These 
subdomains are subsequently incorporated into highly dynamic SNX5-labeled tubular 
structures that depart from the macropinosome body and traffic to the perinuclear region of 
the cell, before fusing with early endosomal acceptor membranes. The extension and 
subsequent fission of these tubular structures is dependent upon intact microtubules. As a 
result of microtubule-destabilization using the agent nocodazole, SNX5-labeled 
microdomains were observed to coalesce and emerge from the macropinosome before 
collapsing back onto the surface of the structure (Kerr M.C. et al., 2006).  
 
While the role of MuRF2 and MuRF3 in stabilizing microtubules has been reported only in 
regard to muscle differentiation and contraction, in this study they have been linked for the 
first time with a trafficking protein, SNX5, which is directly associated with microtubules 
through its binding to the dynactin component p150glued, and functionally dependent on a 
stable microtubule network. The interaction between SNX5 and MuRF3, the MuRF2-
mediated degradation of SNX5 and the stabilizing effect which MuRF3 has on SNX5 
expression suggest a possible regulatory role of MuRF2 and MuRF3 in microtubule-
dependent subcellular trafficking pathways.  




4.10. SNX5 is up-regulated during denervation but not during starvation 
or in atrophied myotubes 
As already mentioned, SNX5 has been implicated in muscle membrane trafficking through its 
interaction with the muscle specific CHC22, whereas it does not interact with the ubiquitous 
CHC17 (Towler M.C. et al., 2004b). Moreover, its notably high expression in muscle tissue 
and the interaction with MuRF3 are further indications for its muscle specificity. Therefore, in 
this part of the study, SNX5 expression after induction of skeletal muscle atrophy was tested. 
Skeletal muscle atrophy accompanies many chronic illnesses, sepsis, myopathies and 
dystrophies (Thomas, D. R., 2007). It is characterized by a decrease in muscle mass, muscle 
strength and fatigue resistance, and has the clinical consequence of severe deterioration of 
life-quality of the patients (Fanzani A. et al., 2012; Bonaldo P. and Sandri M., 2013). 
Although in the past years a lot has been reported about the different signaling pathways 
triggering skeletal muscle atrophy, changes in subcellular trafficking pathways during muscle 
atrophy remain unknown. Therefore mRNA and protein expression of SNX5 was tested in 
two different atrophy mouse models, denervation and starvation, as well as atrophied C2C12 
myotubes. Denervation- and starvation- induced muscle atrophy was confirmed by a 
decreased muscle weight and an increased gene expression of Trim63 and Fbxo32, which are 
strongly induced in disuse atrophy (Bodine S.C. et al., 2001; Gomes M.D. et al., 2001). Snx5 
mRNA expression and SNX5 protein content were significantly increased 7, 14, and 21 days 
after denervation compared to the controls. A small increase in Snx5 mRNA expression was 
observed after 24 h but not after 48 h of starvation. Moreover, no significant change in SNX5 
protein content was observed during starvation-induced atrophy. Also, no change in SNX5 
protein content was observed in atrophied C2C12 myotubes after 24 h or 48 h of 
dexamethasone treatment. According to these results it was not possible to conclude with 
certainty that inducing atrophy had an effect on SNX5 expression.  
The up-regulation of SNX5 as a result of denervation can be explained by the fact that after 
nerve injury, cell intrinsic mechanisms of neuronal regeneration in the peripheral nervous 
system, such as long-distance retrograde signaling, are activated. This process depends on 
retrograde signaling from the axonal lesion site to cell body in order to provide accurate and 
timely information on the nature and extent of axonal damage, and to modulate and 
coordinate a regenerative response to the injury in the cell body. This is based on local axonal 
synthesis of critical carrier proteins, including importins and vimentin that link diverse 
signaling molecules, such as transcription factors, to the dynein/dynactin retrograde motor 




complex which moves toward the cell body along microtubules. The axonal signaling 
response to nerve injury induces alterations in cellular signaling, transcription, translation and 
post-translational modifications. For example, several kinases are activated in cell bodies in 
response to an injury event. Among these are the MAP kinases Erk1 and Erk2 and Jnk (Hanz 
S. and Fainzilber M., 2006; Rishal I. and Fainzilber M, 2010). As a protein which directly 
associates with the dynein/dynactin motor complex and contributes to retrograde minus-end 
transport pathways, SNX5 might be involved in axonal post-injury retrograde signaling. This 
could explain its upregulation in denervated muscle tissue, whereas no significant change in 
SNX5 expression was observed in mice after starvation, indicating that SNX5 upregulation 
was not due to induction of muscle atrophy but rather the denervation itself. This conclusion 
can be supported by the fact that SNX5 expression did not change in atrophied C2C12 
myotubes, and that SILAC-MS analyses investigating up- and down-regulation of proteins 
during differentiation and atrophy did not show any enrichment or decrease in SNX5 content 
during atrophy.  
 
Immobilization, aging and several inflammatory as well as other myopathies and dystrophies 
(e.g. critical illness myopathy) have been associated with disruption in GLUT4 pathway 
(Jensen E.B. et al., 2009; Hoshino S. et al., 2013; Weber-Carstens S. et al. 2013). Because 
SNX5 has been shown to play a role in GLUT4 translocation by binding to CHC22, it would 
be recommended to do further investigation regarding the role of SNX5 and also MuRF2 and 
MuRF3 in these conditions. Unfortunately, these mouse models and C2C12 mouse skeletal 
muscle cell line are not suitable because CHC22 only exists as a pseudogene in mice, which 
does not express the CHC22 protein (Vassilopoulos S. et al., 2009). Also, C2C12 muscle cell 
line does not contain insulin-responsive intracellular compartments and dexamethasone-
induced GLUT4 overexpression in C2C12 cells does not result in the formation of such 
compartments or lead to significant change in insulin-stimulated glucose transport (Tortorella 
L.L. and Pilch P.F., 2002).  
4.11.  Conclusions 
This study showed for the first time the association of the two muscle specific E3 ligases 
MuRF2 and MuRF3 with the mammalian retromer subunit SNX5, a protein involved with 
subcellular trafficking pathways. SNX5 was identified as a novel interaction partner of 
MuRF3. SNX5 interacted physically and via its BAR-domain with MuRF3. SNX5 and 
MuRF3 co-localized and associated with early endosomes. SNX5 was also identified as a 
substrate of MuRF2. MuRF2 interacted with and ubiquitinated SNX5 in vivo, mediating its 




degradation in a UPS-dependent manner. Interestingly, MuRF3 stabilized SNX5, inhibiting 
its MuRF2-mediated UPS-dependent degradation. SNX5 has been shown to directly associate 
with microtubules and to require an intact microtubule network for its function. The function 
of MuRF2 and MuRF3 as microtubule-stabilizers and the results of this study suggest a 
possible regulatory role of MuRF2 and MuRF3 in microtubule-dependent subcellular 
trafficking pathways. The better understanding of their regulatory function in specialized 
membrane trafficking pathways in muscle, such as GLUT4 pathway, may reveal new insights 
into diseases such as diabetes, and provide a better definition of processes critical for muscle 
development and repair.  
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Appendix-Figure 1: Distribution of significantly up- or down-regulated proteins during differentiation 
and atrophy of C2C12 cells overexpressing MuRF1. The significance of each protein was determined as the 
intensity vs. the ratio representing the abundance change during myocyte differentiation (A) or atrophy of 
myotubes (B). The legend refers to p-values from the Benjamini-Hochberg False Discovery Rate. Error rate was 
set to 0.05.  
A                                           B    
 
Appendix-Figure 2: Distribution of significantly up- or down-regulated proteins during differentiation 
and atrophy of C2C12 cells overexpressing MuRF2. The significance of each protein was determined as the 
intensity vs. the ratio representing the abundance change during myocyte differentiation (A) or atrophy of 
myotubes (B). The legend refers to p-values from the Benjamini-Hochberg False Discovery Rate. Error rate was 
set to 0.05. 
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Appendix-Figure 3: Distribution of significantly up- or down-regulated proteins during differentiation 
and atrophy of C2C12 cells overexpressing MuRF3. The significance of each protein was determined as the 
intensity vs. the ratio representing the abundance change during myocyte differentiation (A) or atrophy of 
myotubes (B). The legend refers to p-values from the Benjamini-Hochberg False Discovery Rate. Error rate was 
set to 0.05. 
 
 
Appendix-Table 1: Mass spectrometric data of proteins with a significant abundance difference during 
differentiation of myocytes overexpressing MuRF1. A total of 658 proteins were detected in this screen, of 
which 78 were proteins whose abundance has significantly changed as a result of MuRF1-overexpression, which 
make approx. 11.8%. 51 proteins were significantly up-regulated and 27 proteins were significantly down-
regulated. Significance was set to p-value < 0.05. 
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Appendix-Table 2: Mass spectrometric data of proteins with a significant abundance difference during 
atrophy of myotubes overexpressing MuRF1. A total of 657 proteins were detected in this screen, of which 95 
were proteins whose abundance has significantly changed as a result of MuRF1-overexpression, which make 
approx. 14.5%. 64 proteins were significantly up-regulated and 31 proteins were significantly down-regulated.  
Significance was set to p-value < 0.05. 
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Appendix-Table 3: Mass spectrometric data of proteins with a significant abundance difference during 
differentiation of myocytes overexpressing MuRF2. A total of 691 proteins were detected in this screen, of 
which 88 were proteins whose abundance has significantly changed as a result of MuRF2-overexpression, which 
make approx. 12.7%. 45 proteins were significantly up-regulated and 43 proteins were significantly down-
regulated. Significance was set to p-value < 0.05. 
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Appendix-Table 4: Mass spectrometric data of proteins with a significant abundance difference during 
atrophy of myotubes overexpressing MuRF2. A total of 690 proteins were detected in this screen, of which 81 
were proteins whose abundance has significantly changed as a result of MuRF2-overexpression, which make 
approx. 11.7%. 35 proteins were significantly up-regulated and 46 proteins were significantly down-regulated. 
Significance was set to p-value < 0.05. 
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Appendix-Table 5: Mass spectrometric data of proteins with a significant abundance difference during 
differentiation of myocytes overexpressing MuRF3. A total of 606 proteins were detected in this screen, of 
which 61were proteins whose abundance has significantly changed as a result of MuRF3-overexpression, which 
make approx. 10%. 37 proteins were significantly up-regulated and 24 proteins were significantly down-
regulated. Significance was set to p-value < 0.05. 
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Appendix-Table 6: Mass spectrometric data of proteins with a significant abundance difference during 
atrophy of myotubes overexpressing MuRF3. A total of 605 proteins were detected in this screen, of which 74 
were proteins whose abundance has significantly changed as a result of MuRF3-overexpression, which make 
approx. 12.2%. 39 proteins were significantly up-regulated and 35 proteins were significantly down-regulated. 
Significance was set to p-value < 0.05. 
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ADP     Adenosine diphosphate  
AP    Affinity purification  
APS   Ammonium persulfate 
ARR    Acidic rich region 
ATP   Adenosine triphosphate 
BAR    Bin/Amphiphysin/Rvs domain 
BMI   Body mass index 
BSA   Bovine serum albumin 
C2C12   Mouse myoblast cell line 
CCD    Coiled coil domain 
cDNA   Complementary DNA 
CHC    Clathrin heavy chain 
CHF    Chronic heart failure 
CHX    Cycloheximide  
CI-MPR   Cation-independent mannose 6-phosphate receptor 
CKD    Chronic kidney disease  
CLC    Clathrin light chain 
COPD    Chronic obstructive pulmonary disease  
COS7   African green monkey kidney cell line 
CSC    Cargo selective complex  
DCTN1   Dynactin subunit 1 
DMEM  Dulbecco’s modified eagle medium 
DMSO   Di-Methyl-Sulfoxide  
DANN   Desoxyribonucleic acid  
DUBs    Deubiquitinating enzymes  
E.coli   Escherichia coli 
ECM    Extracellular matrix 
ECV    Endosomal carrier vesicle 
EDL    M. Extensor digitorum longus 
EDTA   Ethylenediaminetetraacetic acid 
EE    Early endosome 
EEA1   Early endosome antigen 1 
EGFR    Epidermal growth factor receptor 
FANCA   Fanconi anemia complementation group A protein  
FBS   Fetal bovine serum 
FHL2   Four-and-a-half LIM domain protein 2  
GAPDH   Glyceraldehyde 3-phosphate dehydrogenase  
GLUT4   Glucose transporter type 4  
GP    M. Gastrocnemius-plantaris 
GSC    GLUT4 storage compartment 
GST   Glutathione S-transferase 
HDAC5   Histone Deacetylase 5 
HECT   Homologous to E6 associated protein C- terminus  
HEK293  Human embryonic kidney 293 cell line 
ICC    Immunocytochemistry 
IGF2R   Insulin-like growth factor II receptor 
ILV    Intraluminal vesicle 




IPTG    Isopropyl β-D-1-Thiogalactopyranoside  
LAMP1  Lysosomal-associated membrane protein 1 
LE   Late endosome 
MAFbx  Muscle atrophy F-box 
MB    Myoblast 
MBP    Maltose binding protein 
MFC    MuRF-family conserved domain  
MHC   Myosin heavy chain  
Mib1   Mind bomb-1 
Mm   Mus musculus 
mRNA   Messenger RNA 
MS    Mass spectrometry 
MT   Myotubue 
MTA    Atrophied myotube 
MTJs    Myotendinous junctions  
MTOC   Microtubule organizing center  
MuRF    Muscle RING-finger  
MVB    Multivesicular body 
NEM    N-Ethylmaleimide  
PBS   Phosphate buffered saline 
PCR    Polymerase chain reaction 
PEI    Polyethylenimine  
PKD2    Protein kinase D2 
PMSF    Phenylmethanesulfonyl fluoride  
PX    Phox-homology 
qRT-PCR  Quantitative real - time PCR  
RBCC   RING-B-box-coiled-coil   
RE   Recycling endosome 
RIPA   Radioimmunoprecipitation assay 
RING   Really interesting new gene 
RNA   Ribonucleic acid 
RT   Room temperature  
SCF   Skp-Cullin-F-box 
SDS   Sodium dodecyl sulphate 
SDS-PAGE  SDS polyacrylamide gel electrophoresis 
SILAC   Stable Isotope Labeling by Amino acids in Cell culture 
SNX    Sorting nexin 
SOC   Super optimal broth 
Sol   M. Soleus 
TA   M. Tibialis-anterior 
TAE   Tris-acetate-EDTA 
TCEP    tris(2-carboxyethyl) phosphine  
TGN    trans-Golgi network  
TRIM    Tripartite motif containing 
UPS   Ubiquitin proteasome system 
Vps   Vacuolar protein sorting 
WB    Western blot 
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